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Abstract
While cannabidiol (CBD) has been documented to elicit anxiolytic effects, only recently
have studies demonstrated the anxiolytic efficacy of the aromatic monoterpene, linalool. Past
research involving phytocannabinoid-phytocannabinoid formulations has shown that CBD may
yield superior anxiolytic efficacy when administered alongside other cannabis compounds, with
this phenomenon termed the “Entourage Effect” (EE); however, this EE has not been
investigated in phytocannabinoid-terpene formulations. Furthermore, investigations involving
intra-cranial CBD administration have shown the nucleus accumbens shell, known for affective
processing, to be a therapeutic target of interest. Thus, using treatment interventions in
behavioral and molecular assays, this thesis investigated the possibility of EE-potentiated
anxiolysis within linalool-CBD formulations through olfactory and intra-NAcSh routes of
concurrent acute administration, focusing on GABAAR and ERK signaling mechanisms
previously shown to be mediated by linalool and CBD. Altogether, findings ultimately suggest
that linalool-CBD formulations elicit EE-potentiated anxiolysis through GABAAR- and ERKdependent mechanisms capable of reversing chronic stress-induced anxiety.
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Cannabidiol, CBD, THC, phytocannabinoid, nucleus accumbens shell, mesocorticolimbic
pathway, entourage effect, monoterpene, terpene, linalool, anxiety, anxiolysis, GABAAR, ERK,
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Summary for Lay Audience
Commonly referred to as cannabis, the plant species Cannabis sativa contains two major
substances, cannabidiol and tetrahydrocannabinol (THC), both of which modulate emotional
processing. Although these substances are collectively termed “phytocannabinoids”, they yield
contrasting psycho-modulatory effects. While THC has been shown to yield psychoactive
symptoms, CBD has been demonstrated to reverse these symptoms when co- or postadministered, and also elicit anti-anxiety effects. Interestingly, developments in cannabis
research have documented that when administered in conjunction, THC and CBD may yield
greater anti-anxiety effects than those achieved alone with CBD plant extracts. This phenomenon
of increased anti-anxiety effects following the combination of cannabis compounds has been
termed the “Entourage Effect” (EE). Furthermore, studies demonstrated that administrations of
these compounds into specific brain structures within a circuit known as the mesolimbocortical
(MCL) pathway are especially effective in generating mood-altering effects. Within this MCL
pathway, the nucleus accumbens brain structure—in particular its “shell” sub-region (NAcSh)—
has shown to be a therapeutic target of interest, given that past studies employing intra-NAcSh
administrations of these cannabis compounds reported significant mood-altering results.
Importantly however, combinations involving terpenes (aromatic substances) found in cannabis
have yet to be explored despite their anxiolytic potential, highlighting an area of interest in the
investigation of the Entourage Effect.
Thus, this thesis sought to determine whether an EE existed in combined linalool
(anxiolytic terpene) and CBD treatments, using olfactory and intra-NAcSh routes to respectively
administer these compounds in rat models. Utilizing behavioral tests followed by molecular
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analyses of biomarkers of interest, the findings of this thesis demonstrated that there exists EEpotentiated anti-anxiety effects following concurrent administration of odorous linalool and
intra-NAcSh CBD. In addition, through incorporation of protein modulators and models of
chronic stress, the observed EE was found to successfully reverse chronic stress-induced anxiety
and elicit anti-anxiety effects through specific protein modulations. Ultimately, these findings
highlight the therapeutic potential of cannabis as a natural alternative to conventional
medications used to treat anxiety symptoms and disorders. With safe use profiles, CBD and
linalool may serve as an adjunct—or even replacement—for these conventional medications
riddled with unwanted and potentially dangerous, side-effects.
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1. Introduction
Cannabis sativa, commonly referred to as marijuana or simply cannabis, is one of the
most cultivated and consumed psychoactive substances in the world. According to the World
Health Organization (WHO), there exists an estimated 147 million annual users of cannabis,
which equates to roughly 2.5% of the world population, overshadowing the annual prevalence
usage of other drugs such as cocaine (0.2%) and opiates (0.2%). Yielding a rich history
consisting of both positive and negative affective experiences following its ingestion or
inhalation, cannabis has begun to garner serious interest in the scientific field due to its medicinal
properties and potential for pharmacotherapeutic applications (Callaway, 2004; Izzo et al, 2009;
Pertwee, 2008).
Currently, over 500 chemical substances and 100 phytocannabinoids have been
successfully isolated and identified from Cannabis sativa, including cannabidiol (CBD) and Δ9tetrahydrocannabinol (THC). THC is the primary psychoactive compound in cannabis and is
believed to be responsible for the negative side-effects of cannabis use, including episodes of
anxiety, psychosis and cognitive deficits, especially following chronic adolescent exposure. In
contrast, research into the psychotropic effects of CBD has shown quite the opposite (D’Souza
et al, 2005). Indeed, as the predominant non-psychotropic phytocannabinoid found within
Cannabis sativa, clinical and pre-clinical evidence has shown that CBD may possess many
therapeutic effects potentially applicable in the clinical setting (Crippa et al., 2018; Millar et al.,
2019). For example, considerable evidence has suggested that it may not only be effective in
attenuating the psychoactive effects elicited by THC, but also effective alone in reducing both
depression and anxiety symptoms in animal models (Boggs et al, 2017; Fogaça et al, 2014;
Murkar et al, 2019). While the exact pharmacological mechanisms through which CBD produces
1

its purported therapeutic effects remain unclear, the potential for pharmacotherapeutic effects of
CBD for a range of neuropsychiatric symptoms, including anxiety, depression and schizophrenia,
is receiving considerable pre-clinical and clinical research focus (Campos et al, 2012; Pertwee,
2008; Petrocellis and Marzo, 2009).
Psychoactive effects, however, have also been discovered in a lesser studied group of
compounds within cannabis known as the ‘terpenes’. Often referred to as essential oil
components, terpenes are the substances found within cannabis which provide the plant with its
distinctive aromatic profile, with at least 20,000 characterized and 200 reported to be contained
in the plant (Russo, 2011). Commonly found terpenoids in both cannabis and other plants include
limonene, α-pinene, β-myrcene, linalool, β-caryophyllene, nerolidol and phytol amongst others.
Aside from their distinct aroma, these terpenes have also been documented in animal models to
elicit a variety of physiological effects upon administration (via inhalation or ingestion),
including anti-anxiety, analgesic and anti-convulsant effects (Elisabetsky et al., 1995; Peana et
al., 2006; Russo, 2001). While terpene yields are often less than 1% in cannabis assays,
individual terpenoid concentrations as small as 0.05% have been deemed to be of
pharmacological significance in altering brain activity levels (Adams and Taylor, 2010).
Given that the scientific field regarding cannabis is still relatively young and many
mechanisms of action remain unclear, there exists a need to pursue further research in order to
both examine the properties of CBD and terpenes as well as elucidate their underlying
mechanisms. More importantly, recent research has highlighted the potential for
phytocannabinoid-terpenoid therapeutic interactions, dubbed the “Entourage Effect”, especially
in regard to anti-anxiety effects (Russo, 2011). The entourage effect refers to the concept that
specific compounds within cannabis, may functionally interact with each other (thus forming an

2

“entourage” or combined group effect) to synergize or potentiate the pharmacotherapeutic
potential of cannabis-derived formulations—particularly in a manner whereby the novel
combinatorial formulation achieves a superior psychotropic effect compared to either individual
treatment administration alone. For example, do specific terpenes interact with either THC or
CBD to modulate or potentiate there pharmacological and/or therapeutic properties? With this
important concept in mind, the subsequent literature overview seeks to illustrate the importance
of pursuing such alternative anti-anxiety medications and the mechanisms of action which
underlie phytocannabinoid and monoterpene therapeutic effects, with a focus on exploring the
potential for the presence of the Entourage Effect in co-administration of CBD and the specific
mono-terpene, linalool.

1.1 Overview of Anxiety and Anxiety Disorders
1.1.1 Defining Anxiety and Anxiety Disorders
Anxiety is an emotion experienced commonly throughout an individual’s life, often
characterized by worried thoughts, feelings of tension and physiological changes such as
increased blood pressure (Kazdin, 2000). The presentation of anxiety, according to the theory of
cognitive appraisal proposed by Lazarus and Folkman (1984), often stems from threat appraisals
generated by individuals in their perception of a stressful situation, or stressor. In responding to
these threats, strategies such as emotion-, problem- and meaning-based coping are often utilized;
consequently, by addressing these external stressors, internal states of anxiety which developed
in response to stressors can be relieved. However, while stress is often acute in nature and
subsides following removal of the originating stressor, anxiety can continue to persist even after
the external stressor is eliminated. Furthermore, while feeling anxious or experiencing anxiety
may be commonplace, increased severity of these emotions, such as frequency and deleterious
3

impacts to daily functioning, may be indicative of a chronic mental health disorder.
According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
(DSM-V) established by the American Psychiatric Association, a key element in the diagnosis of
an anxiety disorder in comparison to normal states of anxiety, involves clinical presentations
wherein the individual’s mental condition is severely impairing their functioning in one or more
activities of daily living; these include but are not limited to, social and occupational functioning
across multiple settings. This key requirement is shared amongst the diagnoses of the eight
principal anxiety disorders currently listed in the DSM-V: separation anxiety disorder, selective
mutism, specific phobia, social anxiety disorder (social phobia), panic disorder, agoraphobia,
generalized anxiety disorder and substance/medication-induced anxiety disorder. Unlike
individuals experiencing anxiety whose mental condition may improve following therapeutic
interventions and the development of effective coping strategies, many individuals diagnosed
with anxiety disorders require specialized treatment to adequately manage their conditions and/or
improve their long-term mental health outcomes.
1.1.2 Prevalence of Anxiety Disorders and Implications
According to a recent systematic review conducted by the World Health Organization,
the global age-standardized prevalence of any anxiety disorder (including post-traumatic stress
disorder) is approximately 21.7%. Furthermore, findings suggest that in conflict settings, the
prevalence of anxiety increases with age, with prevalence rates over 30% in individuals over 40
years of age (Charlson et al., 2019). When assessing the lifetime prevalence of anxiety disorders
based off of large population-based surveys, the prevalence rate was found to be as high as
33.7% (Bandelow et al., 2015). These rates are alarming in light of the fact that the Anxiety and
Depression Association of America reported that those with anxiety disorders are three-to-five
4

times more likely to require a clinical treatment and six times more likely to be hospitalized due
to development of a co-morbid psychiatric disorder than those without anxiety disorders. Given
these findings and coupled with the fact that the United Nations projects the global population to
rise to 8.5 billion by 2030, there exists an urgent need to address the scaling and efficacy of
treatments for this increasing number of individuals with mental health illnesses.
1.1.3 Conventional Treatments for Anxiety Disorders
The primary options for treating anxiety disorders include psychotherapy-based
interventions (such as cognitive-behavioural therapy) and conventional anti-anxiety medications
(including benzodiazepines, which potently modulate GABAergic transmission, and SSRIs
which modulate serotonergic transmission). Previous research has indicated optimal health
outcomes after undergoing individual cognitive behavioral therapy (large effect size of 1.30,
n=93), which can range from 5 to 20 weekly sessions (30 to 60 minutes) to achieve desired
health outcomes (Bandelow et al., 2015; National Health Service). Although Bandelow and
authors found that medications such as benzodiazepines (ES: 2.15; n = 42) and selective
serotonin reuptake inhibitors (ES: 2.09; n = 62) were more effective than cognitive behavioral
therapy (CBT), the issues of potential side effects and unwanted drug interactions potentially
outweighed the effectiveness of the treatments when considering patient safety and longevity of
treatment effects. However, a 2-year follow-up meta-analyses demonstrated that through 93
studies with 185 study arms, the enduring efficacy of both drug medication and CBT treatment
persisted with relatively equal efficiency (Bandelow et al., 2018). When combined with the fact
that relapse rates between drug treatments (8-56%) and CBT (48%) for anxiety disorders was
relatively comparable, the distinction between treatment advantage becomes minimal. Other
factors, such as ease of access, drug costs, as well as patient adherence, become influential
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factors in determining treatment type pursuance and long-term efficacy (Bandelow et al., 2008;
Donovan et al., 2010; Durham et al., 2005).
Frontline anxiety medications such as SSRIs and benzodiazepines, despite their
convenience advantages when compared to continual weekly sessions of psychotherapy, suffer
from multiple drawbacks, including potential ineffectiveness and chronic side-effects, such as
drug dependence and withdrawal. In a recent study by Kagan et al. (2020) which conducted a 3to-12 year follow-up after initial treatment in the child/adolescent multimodal extended longterm study (CAMELS Trial), the 40.6% of [total] 318 patients who chose to discontinue anxiety
medication use following the trial reported primary concerns of perceived ineffectiveness
(31.8%) and side effects (25.5%). To compound issues further, a study conducted by Read and
Williams (2018) found that 61% of patients (n=1431) reported experiencing at least 10 adverse
effects, including blunting of affect (71%), sexual dysfunction (66%), suicidality (50%),
withdrawal symptoms (59%) and addiction concerns (40%). The latter two adverse effects of
withdrawal and addiction are of vital concern when addressing the tranquilizer-class anxiety
medications, the benzodiazepine family. Despite their acute efficacy, studies suggest that usage
of over four months, higher dosages, immediate drug cessation and utilization of short-acting
benzodiazepines such as alprazolam, can result in the development of serious withdrawal
syndromes (Owen and Tyrer, 1983). Reported withdrawal symptoms include epileptic seizures,
tachycardia, gastrointestinal dysfunction, drug tolerance and locomotor abnormalities, often
resulting in a transition to higher and higher doses of benzodiazepines (Franck et al., 2004).
Long-term problems with cognitive functioning among patients even after six months following
drug cessation was reported by Barker (2004). In summary, these multiple issues of both short
and long-term side-effects associated with most current anti-anxiety medications, raises
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substantial concerns about their viability as the primary go-to treatment of choice for anxiety
treatments. More importantly, they underscore the importance in finding alternative
pharmacotherapies for the treatment of anxiety disorders that display fewer side-effects, better
patient tolerance and long-term safety profiles.

1.2 The Mesocorticolimbic Pathway
Central to an understanding of the mechanisms underlying the presentation of anxiety
symptoms is an investigation of the mesocorticolimbic (MCL) pathway—comprised of the
mesocortical and mesolimbic neural pathways, it is critically involved in a host of cognitive and
affective functions including learning, emotion, memory and motivated behaviours related to
reward learning (Helbing et al., 2016; Yamaguchi et al., 2011). It includes the dopaminergic
(A10) neurons which project from the ventral tegmental area (VTA) to the prefrontal cortex
(PFC), nucleus accumbens (NAc) and olfactory tubercle, with the combination of the latter two
structures referred to as the ventral striatum (Ikemoto, 2010). Notably however, the mesolimbic
pathway is reciprocal in nature, with GABAergic projections from the nucleus accumbens
extending into regions such as the VTA and regulating its activity in turn (Yang et al., 2018).
While the mesolimbic pathway consists of the VTA and ventral striatum, its impact on cognitive
functioning revolves around connections with other brain structures. Connections to the
amygdala and hippocampus ultimately allow for the development of fear learning and memory
formation, while connections with the prefrontal cortex and anterior cingulate cortex allow for
mediation of emotional regulation and executive functioning (Everitt and Robins, 2005).
1.2.1 Nucleus Accumbens
The Nucleus Accumbens (NAc) is a site of convergence for many excitatory afferent
connections including the VTA, cerebral cortex and thalamus, allowing for subsequent
7

regulation of behavioural responses towards reward and conditioned learning and memory
(Nicola et al, 2000; Wise, 2004; Zahm, 2000). Structurally, the NAc is comprised of two major
divisions: the core (NAcc) and the shell (NAcSh). Both divisions consist of mostly medium
spiny neurons (MSN) which have been found to have relatively low baseline firing rates,
suggesting these neurons are primarily GABAergic in nature (Castro and Bruchas, 2019). Highly
regulated through dopamine innervation, the MSNs within the NAc have been identified to
contain multiple dopamine receptor variations including D1 and D2 subtypes. These subtypes
have been found to partially delineate NAc efferent projections referred as direct (primarily D1;
targets: substantia nigra and VTA) or indirect (primarily D2; targets: pallidal and hypothalamic
structures) pathways (Castro and Bruchas, 2019).
On a systems-level, the NAc has also been implicated by studies as being critically
important brain region in the management of anxiety-related behaviors (Kalin et al., 2005; Lago
et al., 2017; Levita et al., 2012). As documented by Levita et al (2012) and Lago et al. (2017),
the involvement of the NAc in modulating motivation may not only be limited to risk/reward
responses, but also the motivation to avoid danger; as a result, aberrant NAc activity states result
in impaired risk avoidance management that underlie the maladaptive avoidance behaviors in the
vast majority of anxiety disorders. These interpretations compliment the findings made by Kalin
et al. (2005) who utilized PET scanning and demonstrated in rhesus monkey models that
increased NAc metabolic activity is positively correlated with excessive freezing time in the
human intruder paradigm—effectively emphasizing the importance of the NAc in modulating
perceived anxiety.
Furthermore, developments in the field of natural medications have yielded interesting
findings implicating the NAc as a region of interest for therapeutic interventions (Bhattacharyya
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et al., 2010). Through the use of functional mangetic resonance imaging (fMRI), Bhattacharyya
and authors showed that oral administrations of the phytocannabinoid, cannabidiol (derived from
the plant species Cannabis sativa), were able to reverse aberrant NAc activity and psychotic
symptoms induced by exposure to the psychoactive phytocannabinoid, Δ-9Tetrahydrocannabinol. Given that abnormal NAc activity has been linked to increased anxiety
symptoms (Kalin et al., 2005) and that severe anxiety can lead to the presentation of psychotic
symptoms, this collection of aforementioned studies highlights the therapeutic potential for the
development of treatments targeting NAc activity in the management of mood/anxiety disorders.
1.2.2 Prefrontal Cortex
Many studies have demonstrated that the prefrontal cortex (PFC) is instrumental in
modulating neuronal activity underlying anxiety and depression (Hare and Duman., 2020;
Ironside et al., 2019). Comprised of numerous subdivisions including the prelimbic, ventral
orbital, ventrolateral orbital and dorsolateral orbital regions, the PFC sends glutamatergic and
GABAergic neurons to associated brain regions to elicit downstream effects (Bedwell et al.,
2015; Lee et al., 2014; Wanchoo et al., 2009). While the exact mechanisms of action through
which the PFC exerts its systems-level effects is still unclear, the PFC has been found to be
directly involved in inhibiting aversive memories developed in fear conditioning paradigms, with
inactivation measures such as lesions of the PFC leading to decreased extinction while PFC
electrical stimulation led to increased extinction of conditioned responses (Ledoux, 2000;
Maroun et al., 2012; Morgan et al., 1993; Muller et al., 1997).
While the PFC has been implicated in the processing of emotions, it is arguably best
known for its role in cognitive functioning and executive decision-making. A primary area of
focus has been its direct and indirect involvement in establishing and maintaining working
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memory, as well as its influence on the motor cortices in carrying out locomotor activity
(Funahashi, 2017; Lara and Wallis, 2015; Schulz et al., 2019). In light of these various integral
roles that the PFC is involved in, as well as the fact that it has been implicated in emotional
processing, the PFC presents a significant target of interest in which anxiety—and anxietyrelated cognitive changes—can be studied using electrophysiology or drug treatment protocols to
elucidate potential mechanisms and intra- or inter-PFC functional connections correlating with
observed behavioral phenomena. In fact, recent research in our laboratory has shown that the
cannabidiol can potently modulate cognitive and affective functions in the PFC (Szkudlarek et
al., 2019). Specifically, Szkudlarek and authors had demonstrated that acute treatment of intracranial CBD infusions into the PFC region was capable in reversing symptoms of cognitive
changes that stemmed from aberrant PFC states and THC administration via 5-HT1AR signaling
mechanisms, highlighting the potential for therapeutic interventions targeting the PFC region in
the management of mood/anxiety disorders.
1.2.3 Functional Connections between the PFC, NAc and Associated Brain Regions
While the two mesocorticolimbic brain regions of the NAc and PFC have been shown to
play important roles in affective processing as described in previous sections, a full
understanding of the mechanistic intricacies of the mesocorticolimbic pathway involves the
study of the relationship between PFC and NAc—more specifically, the various connections
between the two brain regions which modulate each other’s activity states. The NAc in particular
has been found to receive both glutamatergic and GABAergic projections from the PFC (Lee et
al., 2014; Russo and Nestler, 2013; Torregrossa et al., 2008; Wanchoo et al., 2009). While
increased activity from PFC glutamatergic projections to the NAc was determined to be
antidepressant in nature (Russo and Nestler, 2013), optogenic stimulation of GABAergic
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projections from the PFC to the NAc was found to result in increased avoidance behavior by
rodent subjects (Lee et al., 2014). Conversely, the NAc is able to indirectly modulate the activity
of the PFC through efferent GABAergic projections to the VTA, which in turn regulate
dopaminergic release from the VTA to the PFC, effectively modulating PFC neuronal activity
(Buchta et al., 2017; Ellwood et al., 2017; Norris et al., 2016; Yang et al., 2018). Collectively,
these studies demonstrate the integrative nature in which the NAc and PFC function as a system
rather than standalone structures on a molecular level within the mesolimbocortical pathway.
As mentioned above, associated brain structures such as the VTA play an important role
in facilitating affective processing within the MCL pathway. Interestingly, in addition to
projections to the PFC, the VTA has been documented to reciprocally modulate the NAc through
VTA-NAc dopaminergic projections (Groenewegen and Russchen, 1984; Heimer et al, 1991;
Nauta et al, 1978; Sesack et al., 2009; Somogyi et al, 1981; Zahm and Heimer, 1993). This is
particularly important to note as behavioral studies have documented impaired VTA-NAc
circuitry to be responsible for anxiety-related social behavior dysfunction and avoidance (Russo
and Nestler, 2013; Van der Kooij et al., 2018), suggesting that the VTA is capable of modulating
both PFC and NAc activity states during affective processing.
Furthermore, within the mesolimbocortical pathway, the discovery of PFC-amygdala
connections has led to studies documenting the important role of the PFC in regulating amygdala
activity, with complete extinction of conditioned aversive responses being achieved in
conjunction with increased fMRI activity of the PFC region and decreased activity in the
amygdala (Ironside et al., 2019; Pitman et al., 2012). In addition to these findings highlighting
brain activity alteration in response to PFC activation/inactivation, it is worth noting that
individuals diagnosed with depression and those with an anxiety disorder (including PTSD) have
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been found to exhibit hyperactive amygdala activity that is hypothesized to be due to reduced
inhibition from the PFC (Etkin et al., 2010; Hamilton et al., 2012; Maroun et al., 2012; Rauch et
al., 2000). Interestingly, while this top-down regulation from the PFC to amygdala predominates
the literature surrounding the two regions’ connections, GABAergic projections from the
amygdala to the PFC presents the notion that the PFC-amygdala connections are reciprocal,
rather than unidirectional in nature—adding an element of complexity to determining the
individual functionality of each region (Seo et al., 2016).
Taken together, these studies documenting the various functional connections between
these mesolimbocortical brain regions suggests clearly that not only do the PFC and NAc play a
role in affective processing, but that these regions are influenced by associated brain structures
such as the VTA and amygdala—emphasizing the fact that the affective processing abilities of
the PFC and NAc are not only modulated by one another, but also by other brain regions within
the MCL circuit that should be considered within a comprehensive analysis of MCL affective
processing.
1.2.4 The Role of the Mesocortiolimbic Pathway and Receptor Targets in Anxiety Disorders
Due to its integral role in emotion and cognitive processing as previously described, the
mesocorticolimbic (MCL) pathway has been implicated in many studies not only assessing
reward and motivation learning, but also anxiety disorders as well. A study conducted by
Burkhouse et al. (2020) found that the NAc played a critical role during treatment recovery from
anxiety disorders, as greater bilateral NAc volumes correlated with significantly greater
reductions in anxiety symptoms pre-to-post SSRI and CBT treatment. In conjunction with
findings that suggest NAc plays a key role in the communicative circuit between the amygdala
and the prefrontal cortex (Mannella et al., 2013), growing evidence suggests NAc may be a key
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target in anxiety disorder treatment and in the broader MCL pathway.
As a vital component of the cortical aspect of the MCL pathway, the PFC has been
implicated in a host of cognitive and affective functioning roles, including its top-down
inhibition of the amygdala by the PFC, yielding in turn a distinct profile of increased PFC
regulatory control being linked to decreases in perceived anxiety levels as mentioned earlier
(Ledoux, 2000; Maroun et al., 2012; Morgan et al., 1993; Muller et al., 1997). When considered
in conjunction with the findings that decreased PFC volumes have been correlated to increased
measures of both anxiety and depression (Madonna et al., 2019; Mohlman et al., 2009) and that
patients with anxiety and/or depressive disorders have been found to possess circuit
abnormalities in amygdala and hippocampal regions—two associated brain regions within the
mesocorticolimbic pathway essential in fear memory acquisition and recall—the PFC presents
itself as a viable target in the treatment of anxiety, depression or comorbid diagnoses of these
two mood disorders (Etkin et al., 2010; Godsil, 2013; Hamilton et al., 2012; Maroun et al., 2012;
Rauch et al., 2000).
Expanding upon the VTA-NAc circuitry analysis discussed in section 1.2.3, recent
studies examining the VTA have demonstrated the significance of its activity in the presentation
of anxiety symptoms. A study conducted by Cha et al. (2014) utilized fMRI to measure the brain
activity of participants while undergoing fear generalization tasks, with findings indicating that
participants with generalized anxiety disorder (GAD) exhibited heightened VTA activity
compared to non-GAD subjects in response to generalized stimuli. VTA hyperactivity was also
shown to correlate to manic states in mouse models, characterized by increased dopaminergic
activity and resulting locomotor abnormalities (Coque et al., 2011). When considering the
DAergic projections from the VTA to the NAc as well as its connections to cortical regions, the
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VTA ultimately presents a vital area of interest along with the NAc in the management of
anxiety disorders.
Correlations between behavioral and molecular analyses highlight GABA and 5-HT
receptors and their associated downstream molecular pathways, as being essential targets when
assessing models of anxiety and anxiety symptoms. Using proton magnetic resonance
spectroscopy, Strasser et al. (2019) had demonstrated that there existed a significant negative
correlation between subjects’ perceived situational stress and NAc GABA levels. This data
signifying the importance of NAc GABA levels in regulating anxiety is supported by Lopes et al.
(2012), who found that GABA-inhibition within the NAcSh increased anxiety symptoms in the
context of rodent feeding behaviour. In a similar manner, increasing evidence points towards
decreased intra-PFC GABA levels contributing towards the establishment and maintenance of
anxiety and depression disorders (Ghosal et al., 2017), suggesting that internal imbalances in
inhibitory control within these brain regions can lead to significant systems-level mood
dysfunction. Interestingly, the application of GABAAR antagonists in the VTA has been found to
be crucial in reversing drug-induced behavioral changes following their microinfusion
administrations into the NAcSh and VTA (Blacktop et al, 2016; Norris et al, 2016)—
highlighting the importance of GABAergic transmission between the NAcSh and VTA as well as
within VTA local circuitry. Overall, these studies suggest that both GABA levels and
GABAergic transmission within the mesocorticolimbic pathway are vital in the management of
anxiety, as indicative of the effectiveness of benzodiazepine as a frontline anxiety medication.
Existing evidence suggests that dysregulation of serotonergic transmission also plays a
significant role in the development of anxiety disorders, with decreases in 5-HT levels and
serotonergic transmission being associated with increased anxiety (Gartside et al., 1995). In
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particular, abnormal 5-HT1AR activity has been implicated in both the development and
treatment (SSRIs) of anxiety disorders (Akimova et al., 2009; Gordon and Hen, 2004; Lesch and
Gutknecht, 2004; Strobel et al., 2003). Within the PFC, 5-HT1ARs have been found located on
pyramidal glutamatergic neurons as well as interneurons that act on these pyramidal cells;
analysis conducted by Albert et al. (2014) have demonstrated anxiety symptoms to present
during low and high levels of 5-HT, presenting an interesting notion of non-directional
imbalance of 5-HT levels being the etiology of intra-PFC mood dysfunction. In addition to the
presence of HT1AR and its autoreceptor activity within the PFC and raphe nuclei (Garcia-Garcia
et al., 2014), HT1AR have been found localized on GABAergic interneurons within the NAcSh
(Van Bockstaele et al., 1996). This in turn suggests that serotonergic afferent projections to the
NAcSh may directly inhibit these interneurons, allowing for downstream increased activity of
striatal projections and modulation of anxiety-processing brain structures.
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1.2.5 Overview of Notable Molecular Biomarkers in Anxiety Disorders
In terms of downstream molecular signaling pathways associated with anxiety disorders,
abnormal levels of intracellular biomarkers such as GSK3β, Akt, ERK and JNK proteins have
been associated with anxiety symptoms and mood disorders (Crofton et al., 2017; Engeli et al.,
2014; Jope et al., 2006; Willock et al., 2016). While the activity of these proteins have been
correlated with presentations of anxiety symptoms which may appear phenotypically similar, the
generation of these symptoms through the regulation of specific signaling pathways and
downstream effectors documented in the literature is relatively unique between the proteins.
GSK3β, otherwise known as glycogen synthase kinase-3β, is a constitutively active
protein whose downregulation has been shown to be correlated with potential anxiolytic effects
(Crofton et al., 2017; Mines et al., 2010). Specifically, assessing the function of GSK3β within
the NAcSh, Crofton et al. (2017) demonstrated that GSK3β-knockdown in rat models
effectively decreased anxiety-like behavior through a potential suppressing mechanism on
tonally active interneurons (TANs). In another study, Mines et al. (2010) found that inhibition of
GSK3 in Fmr1 knockout mice decreased displays of anxiety during social interaction. As a
downstream target of both the Wnt and PI3K-Akt pathways, GSK-3β is readily inhibited through
phosphorylation of its Serine-9 residue within the N-terminus domain (Sani et al., 2012).
Akt, often referred to as Protein Kinase B, is a member of the PI3K-Akt pathway
involved in various cell activities including survival and proliferation (Qiao et al., 2018).
Phosphorylation at the Serine-473 and Threonine-308 residues in the activation loop of the
enzyme activates Akt, resulting in the activation of many downstream targets including the
inhibition of GSK3β (Bellacosa et al., 1998; Cross et al., 1995). Knockdown and polymorphism
analysis of Akt within animal and human subjects demonstrated that alterations of Akt ultimately
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resulted in increased susceptibility to chronic stress as well as heightened displays of trait
anxiety, suggesting that Akt signaling plays a critical role in mood/anxiety regulation (Engeli et
al., 2014; Willock et al., 2016).
Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated protein
kinase (MAPK) pathway responsible for a host of cellular roles, including but not limited to
mitogen signaling in cell cycle progression and integration of stress signals (Einat et al., 2003;
Zamora-Martinez et al., 2014). Often activated in response to cell stress, increased concentration
of phosphorylated ERK (p-ERK) has been associated with increased symptoms of anxiety and
depression, as well as overall mood dysregulation in various brain regions including the frontal
cortex and hippocampus (Ailing et al., 2008; Einat et al., 2003; Hudson et al., 2019).
JNK, also referred to as c-Jun N-terminal kinase, is also a member of the MAPK family
pathway along with ERK; as such, its phosphorylated activation occurs primarily in response to
perceived cell stress (Zeke et al., 2016). While the primary active isoform, JNK1, is known for
its role in regulating neuronal differentiation and maturation, studies have also implicated JNK1
in facilitating the development of symptoms reflective of anxious and depressive states (Hollos
et al., 2018; Mohammad et al., 2018). Interestingly, a proposed mechanism through which JNK1
elicits its effects within the hippocampus is through the prioritization of immature granule cell
neurogenesis. These immature cells have been observed to negatively regulate mature dentate
granule cell populations through recruitment of synapsing GABAergic inhibitory neurons,
resulting in overall decreased hippocampal neuronal activity and abnormal communication with
connected brain regions (Marín-Burgin et al., 2012).
While individual analyses of these protein biomarkers have yielded promise in providing
potential mechanisms to address in regard to anxiety disorder and treatment, it should be noted
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that these proteins ultimately work in conjunction with one another through both direct
interactions (e.g. the inhibition of GSK3β by Akt) as well as indirect downstream targets.
Furthermore, depending on the brain region being influenced, the resulting activation or
inactivation of these enzymes may yield varying behavioral outcomes.

1.3 Cannabis: An Alternative Treatment for Anxiety Disorders
1.3.1 Effects of Cannabis on Mental Health
Despite recorded usage as a medicinal plant for the past millennia, the effects and
underlying mechanisms of cannabis have still yet to be fully uncovered (Mechoulam, 1986;
Russo, 2007; 2008). Indeed, while cannabis’s effects have been primarily attributed to key
natural constituents such as tetrohydrocannabinol (THC) (Gaoni and Mechoulam, 1966),
naturally occurring endocannabinoids such as anandamide (AEA) (Devane et al., 1992) and 2arachidonoylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995), as well as
cannabidiol (CBD) and other such phytocannabinoids, the overall physiological effects that the
plant Cannabis sativa yields as a whole has yet to be conclusively defined.
Nonetheless, clinical and pre-clinical cannabis research has demonstrated the potential
therapeutic use of cannabinoid formulations including administration of plant extracts in the
treatment of movement disorders, psychiatric disorders, Alzheimers disease, epilepsy, pain and
multiple sclerosis (Montero-Olease et al., 2020). A defining milestone in the development of
cannabis-related therapeutic formulations include the United Kingdom’s approval of Nabiximols
(CBD-THC extract) in treating pain and spasticity in multiple sclerosis following a clinical study
conducted by Novotna et al. (2011). Although whole-plant extracts have yet to be approved by
North American regulatory agencies in the treatment of health conditions, cannabis-derived and
related products such as the FDA-approved drugs Epidiolex (purified CBD extract treating
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syndrome-specific seizures) and Dronabinol (synthetic THC used as an appetite stimulant,
antiemetic and sleep apnea remedy) highlight the therapeutic potential of cannabis-related
products.
1.3.2 Properties and Mechanisms of Action of Cannabidiol
Cannabidiol is a major phytocannabinoid within Cannabis sativa whose psychotropic
effects have largely been attributed to its regulatory role in the reduction of psychoactive
symptoms associated with THC. Within the endocannabinoid system, it has been demonstrated
that while cannabidiol possesses low affinity towards the endocannabinoid receptors CB1 and
CB2 which THC interacts with, CBD is capable of antagonizing the effects of CB1 and CB2
receptor agonists (Pertwee et al., 2002; Thomas et al., 2007). In addition, more recent studies
have suggested that CBD can act as a negative allosteric modulator for both CB receptors,
supporting the role of CBD as an inverse agonist for both THC and 2-AG receptor interactions
within the endocannabinoid system (Laprairie et al., 2015; Martínez-Pinilla et al., 2017; Morales
et al., 2016). Furthermore, a pre-clinical study by Hudson et al. (2019) discovered a potential
mechanism of action for THC/CBD interactions, demonstrating that increased anxiety-salience
observed following intra-ventral hippocampal infusions of THC was due to modulation of
extracellular signal-regulated kinase phosphorylation (p-ERK1/2). Subsequently, CBD-THC
coadministrations were found to reverse these observed changes through downregulation of pERK1/2 activity, providing further evidence for this pathway mechanism. Interestingly however,
CBD has also been found to indirectly augment CB receptor activity, potentiating the effects of
the CB receptor agonist anandamide (AEA) through its competitive interference in transport
protein binding, with clinical trials suggesting the subsequent elevation of AEA levels to be
inversely correlated with the presentation of psychotic symptoms in schizophrenia or
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schizophreniform patients (Leweke et al., 2012).
Aside from endocannabinoid receptors, CBD acts on several anxiety-related receptor
targets within the mesolimbic pathway, including 5-HT and GABA receptors. The effect of CBD
on 5-HT1A receptor activation in particular, is well documented, with both behavioral and
molecular studies demonstrating its role as an agonist at this subtype (Linge et al., 2016; Norris
et al., 2016; Pelz et al., 2017; Resstel et al., 2009; Russo et al., 2005). In terms of the mesolimbic
pathway, Norris et al. (2016) reported that administration of a 5-HT1A antagonist, NAD299, into
the NAcSh was effective in reversing the anxiolytic effects elicited by CBD within an olfactory
fear memory paradigm—suggesting 5-HT1A auto-receptor activation to be potentially integral to
the regulation of NAcSh GABA neurons and overall fear memory formation.
The interaction between CBD and GABA receptors is rather distinct between the two
receptor subtypes, GABAA and GABAB. While current evidence suggests that CBD does not act
through GABAB receptor activation (Lopes et al., 2012; Straiker et al., 2018), there exists
multiple studies which demonstrate its effects on the GABAA receptor, where can act as a
positive allosteric modulator (Bakas et al., 2017; Lopes et al., 2012; Morano et al., 2016; Ruffolo
et al., 2018). In addition, given that both in-vitro and in-vivo studies (Mallet et al., 2005; Tepper
et al., 2008) have shown GABAAR activation to inhibit GABA interneurons within the ventral
striatum—and more importantly, the subsequent increase in firing activity by NAc projection
neurons following such interneuron inhibition—there may exist a potential GABAAR-mediated
pathway of modulation in regards to the ability of the NAcSh to inhibit downstream VTA
DAergic activity and consequently modulate emotional states.
These mechanisms of action may shed light on the reported therapeutic properties of
cannabidiol, including anticonvulsive, anxiolytic, antipsychotic, anti-inflammatory and anti20

nausea effects (Mechoulam et al., 2002). Furthermore, despite its relatively poor bioavailability
through oral ingestion, pharmacological significance for both CBD and its metabolites has been
found in-vivo (Ujváry et al., 2016); in fact, Bergamaschi et al. (2011) demonstrated that a single
600mg oral dose of CBD was effective in significantly reducing anxiety symptoms of social
anxiety disorder (SAD) patients. With consideration of its relatively safe profile as a nonpsychoactive phytocannabinoid, CBD may ultimately constitute a natural alternative in place of
or assisting conventional medications in the treatment of neuropsychiatric conditions, especially
anxiety disorders, given CBD’s ability to influence the activity of 5-HT and GABAA receptors
that play a key role in the pathophysiology of such disorders.
1.3.3 Properties and Mechanisms of Action of the Mono-Terpene, Linalool
Linalool is an odorous, acyclic monoterpene found within many plants including
Lavandula angustifolia (Lavender) and Cannabis sativa (Milanos et al., 2017). As a component
of various essential oils, the use of linalool includes not only its incorporation in the perfume
industry but also in the treatment of various pathological conditions. For example, numerous
studies have reported that exposure to linalool can produce various effects, including but not
limited to cardiovascular effects (Anjos et al., 2013), anti-inflammatory effects (Huo et al., 2013)
and anxiolytic effects (Bradley et al., 2007; Harada et al., 2018; Linck et al., 2010).
Despite differing modes of administration (intraperitoneal, oral, odorous), various studies
have proposed that the underlying mechanisms of action for the physiological effects of linalool
and Lavandula angustifolia (which primarily consists of linalool and linalool metabolites)
involve the activation of GABAA and 5-HT1A receptors (Harada et al., 2018; Kessler et al., 2012,
2014; Malcolm and Tallian, 2018; Milanos et al., 2017), as well as competitive inhibition of
NMDA receptors (Brum et al., 2001; Elisabetsky et al., 1995, 1999). In addition, in-vitro studies
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have demonstrated that linalool administration to SH-SY5Y neuronal cells significantly
decreases expression of adenylate cyclase I, p-ERK and PKA, all of which are associated with
anxiety-related phenotypes, highlighting another potential mechanism manner in which linalool
may exert its psychotropic effects (Caputo et al., 2016; 2017; 2018).
Of particular interest for clinical applications is the non-invasive, olfactory route of
linalool administration. While a major aspect of the odorous effects of linalool were originally
thought to involve the inhalation and subsequent dissolving of linalool into the bloodstream,
Harada et al. (2018) have shown that linalool exposure in anosmic mouse models produces
anxiolytic effects via functional olfactory pathways. Given that the olfactory nervous system
connects to brain regions associated with memory, emotions and arousal such as the entorhinal
cortex and amygdala (Christen-Zaech et al., 2003), activation of these systems presents a
plausible explanation for anxiety symptom reduction following olfactory linalool administration.
Similar to CBD, given the relative safe profile of linalool and its metabolites (Malcolm et
al., 2018) as well as its documented anxiolytic effects exhibited in both animal and human
studies following non-invasive odor administration (Harada et al., 2018; Linck et al., 2010;
Takahashi et al., 2011; Zhang et al., 2016), there is potential usage for linalool as an anxiolytic
compound or in co-administration with conventional anti-anxiety medications or anxiolytic
cannabinoids, such as CBD.
1.3.4 The Entourage Effect
The Entourage Effect refers to the proposed mechanism by which combinations of
separate phytocannabinoid extracts might yield psychoactive effects that are more potent than
their individual administration (Ben-Shabat et al., 1998; Mechoulam et al., 1999; Russo, 2011).
Wagner and Ulrich-Merzenich (2009) have proposed that the potential mechanisms through
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which the Entourage Effect might be observed include multi-target receptor effects, increased
pharmacokinetic efficiency, improved bactericidal effects as well as modulation of adverse
events—with the latter being well established in the case of CBD’s ability to attenuate THCinduced psychosis (Davies and Bhattacharyya, 2019; Hahn, 2018).
Moreover, studies have demonstrated that whole-plant extracts of Cannabis sativa have
yielded greater therapeutic effectiveness in comparison to pure component administrations. For
example, Johnson et al. (2010) observed in a randomized controlled trial of advanced cancer
patients that while treatment with pure-THC extract did not yield significant anti-nociceptive
effects compared to placebo, patients taking CBD:THC combined extracts reported significantly
less pain compared to placebo-treated patients. In the context of animal studies, Gallily et al.
(2015) reported that while increasing dosage administrations of pure-CBD extracts in mouse
models yielded a biphasic effect on the mediation of inflammation, the dose-response curve
observed following whole-plant extract treatment resulted in a starkly linear correlation between
increased dosage and decreased presence of inflammatory cytokines.
While the therapeutic effects of linalool are well documented as previously described,
research specifically examining the existence of a potential Entourage Effect involving linaloolcannabinoid combinations is relatively scarce. Interestingly however, Takahashi et al. (2011)
discovered that there existed significant differences in anxiolytic efficiencies between Lavandula
plant species depending on their percentage composition of linalool (LO) and linalool acetate
(LA). While correlational analysis indicates lack of significant correlation between linalool vs.
anxiolysis (r = +0.54) and linalool acetate vs. anxiolysis (r = +0.72), there was a significant
correlation (P < 0.05) between combined LO + LA odorous treatment and anxiolytic efficiency
(r = +0.82). This study suggests the mechanistic potential for interaction dynamics between
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linalool and other cannabis compounds in achieving anxiolytic outcomes.
As it currently stands in the literature surrounding cannabis research, there exists a lack
of studies documenting the potential for Entourage Effects between the monoterpenes and
phytocannabinoids (Russo, 2011). However, given previously described similarities in both
receptor targets (GABAAR, 5-HT1AR, p-ERK downregulation), common modulation of neuronal
pathways and anxiolytic outcomes between linalool and CBD, there exists an interesting
possibility for the existence of an Entourage Effect between the two compounds. This
exploration forms the foundation for my research project and thesis.

1.4 Research Aims and Hypothesis
The overarching hypothesis of my thesis is that combinations of CBD with linalool yield
greater reductions in anxiety-related behaviors and anxiety-related molecular biomarkers
compared to individual administrations of either treatment due to an Entourage Effect between
the two compounds.
In have addressed this general research question with the following specific
experimental aims:
Aim 1: Determine if CBD-linalool co-administration in the NAcSh on anxiolytic
measures of spatial cognitive functioning, emotional memory formation and processing within
the baseline cohort exhibit an Entourage Effect by potentiating the behavioural anti-anxiety
effects of either compound alone.
Aim 2: Characterize the pharmacological mechanisms associated with any potential
linalool-CBD entourage effects by determining the potential roles of the anxiety-related
biomarkers GABAA or ERK-1-2 signalling pathways in these effects. Subsequently, characterize
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the localized molecular signaling effects of CBD, linalool or their combination, on anxiolytic
actions directly in the NAcSh in baseline cohorts.
Aim 3: Determine whether the anxiolytic effects elicited by linalool-CBD combinations
are able to reverse anxiety symptoms induced by exposure to chronic unpredictable stress within
the chronic stress cohort.

2. Methods
2.1 Animals and Housing
Adult male Sprague-Dawley rats (300-400 grams) were acquired from Charles River
Laboratories (Quebec, Canada) and used in accordance with guidelines outlined by the Canadian
Council for Animal Care (CCAC) and University of Western Ontario Animal Care Committee
(AUS protocol 2018-053). Upon arrival, rats were paired and housed together under controlled
conditions (constant temperature and humidity, food and water provided ad libitum, 12-hour
light/dark cycle) monitored by both ACVS and laboratory technicians in the designated animal
care facility at Western University. Rat housing specifications include a plexiglass rectangular
box filled with approved corn bedding and environmentally enriched objects (such as wood
chewing blocks, and paper nesting material).

2.2 Surgical Procedures
Surgical procedures for adult male Sprague-Dawley rats were initiated after at least 7
days following their arrival to the animal care facility at Western University. Rat subjects
designated for surgery were anesthetized with a 2 : 1 mixture ratio of Ketamine (80 mg/kg;
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Vetoquinol) and Xylazine (6 mg/kg; Bayer) via intraperitoneal injection. Following confirmation
of the lack of a pain reflex response, subjects were then treated with meloxicam (1 mg/kg) to
further decrease any pain perception as well as inflammation; in addition, a second dosage was
administered during the first day post-surgery. Rats were positioned in stereotaxic apparatus for
cannula implantation, with a warm heat pad positioned below a disposable urine pad to maintain
constant body temperature; to this end, the subject’s temperature was taken both pre- and postsurgery. Following surgical preparation, eight-millimeter stainless steel guide cannulas (22 G;
Plastics1) were implanted into the NAcSh bilaterally at a 12° angle using these stereotaxic
coordinate positions at a 12° angle (mm from bregma): anterior-posterior (AP) ± 1.8, lateral
(LAT) ± 2.6, and ventral (V) – 7.4 from the subject’s dural surface. All coordinates were
acquired from the Rat Brain Atlas created by Paxinos and Watson (2005). Guide cannulas were then
secured in place through the use of miniature screws attached to the skull and dental acrylic cement.
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2.3 Drug Preparation and Administration
Linalool (97%; Acros Organics), CBD, EPA (eicosapentanoic acid, ERK activator) and
Flumazenil (Tocris) were utilized in this study. Regarding intra-cranial drug infusions, vehicle
solutions comprised of dimethyl sulfoxide (DMSO), cremophor and 0.9% pH 7.4 saline (1:1:18).
CBD-only, EPA-only and Flumazenil-only drug solutions were created from dissolving the
respective drugs in the DMSO-Cremomophor-Saline solvent (referred to in brief as the “PBS
solution”), with a mixture ratio of 1:1:18 to 5:5:30. Combination administrations, namely the
CBD-EPA and CBD-Flumazenil treatment mixtures, were created using the 1:1:18 and 5:5:30
ratio compositions respectively. Nitrogen gas was used to evaporate the ethanol solvent from the
original EPA stock solution. Target concentrations of drugs within each mixture were as follows:
5 ng/0.5µL CBD (sub-threshold dosage; Norris et al., 2016), 1 mM EPA (effective dosage in
attenuating CBD-THC anxiolytic effects; Hudson et al., 2019) 5 μg/µL flumazenil (effective
dose from an aggregate of studies; Da Cunha et al., 1999, Dos Reis and Canto-de-Souza, 2008,
Herzog et al., 1996, Jardim et al., 2001).
To prepare for odorous drug administration, the day prior to beginning behavioral testing,
rat subjects were placed within a transparent, rectangular plexiglass cage with a filter top (to
prevent odours from entering or leaving the cage) and four spice jars (one in each corner, secured
by Velcro adhesive). The spice jars each contained a small weigh boat which contained distilled
water (2000 μL); this cage apparatus would serve as the medium for the odorous drug delivery.
Rat subjects were allowed to habituate to this novel environment for 30 minutes before being
placed back into their housing cages. On test day, subjects were placed within the same odorexposure box for a 30-minute exposure session; however, based on their treatment group
designations, they would be exposed to either distilled water (2000 μL) or linalool (200 µL or
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2000 µL). Subjects exposed to distilled water—and thus essentially air—were labelled with the
term “VAir”, while those exposed to linalool were given the prefix “L200-” or “L2000”
depending on whether they were exposed to 200 μL or 2000 μL (per spice jar) respectively.
Immediately following this odor treatment session, intracranial drug deliveries were
conducted. Intra-NAcSh microinfusions were conducted using microinjectors attached to a
Hamilton syringe, performed over a 1-minute time period. Microinjectors were kept in place for
an additional 1-minute time period following infusion to allow for maximum diffusion from the
injector tips. Subjects treated with PBS solutions were designated with the term “VPBS”, while
those given bilateral administration of 5 ng/0.5μL CBD were labelled with the term “-CBD.”
Following this, animal subjects were then immediately exposed to designated test procedures.
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2.4 Chronic Unpredictable Stress Protocol
The Chronic Unpredictable Stress (CUS) Protocol was a protocol designed by previous
lab member Dr. Justine Renard to simulate the acquirement of chronic stress in designated rat
subjects. The protocol involved 14 consecutive days of unpredictable stress activities, including
supra-threshold footshocks (0.6 mA), food and water deprivation, wet bedding, the tilting of rat
plexiglass home cages at a 45° angle, and sudden light deprivation. Following the 14-day
protocol, food, water, and housing conditions returned to previous controlled conditions and
animal behavioral testing began immediately. Subjects exposed to the CUS protocol were
labelled with the prefix “CUS-” to specify their chronically stressed nature; these subjects were
then compared with treatment group interventions to determine whether these interventions were
effective in reversing chronic-stress induced cognitive changes acquired from exposure to the
CUS protocol.
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2.5 Experimental Cohorts and Treatment Group Designations
Aside from the aforementioned baseline and chronic stress cohorts (the latter employing
the CUS protocol to induce chronic stress within subjects), separate experimental cohorts
received intra-NAcSh flumazenil and EPA administration to test whether GABAAR and/or ERK
activity were potentially correlated with behavioral effects associated with CBD-Linalool
administration. The final group designation summary is illustrated in the table below.
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2.5 Behavioral Testing
2.5.1 Open Field Test.
This task is a sensorimotor test which measured overall locomotor activity and
thigmotaxis of rat subjects. The test apparatus consists of a transparent plexiglass box that
assesses various motor movements using a grid system of laser interference detection (San Diego
Instruments). Center and total distance travelled (in cm) by rat test subjects were recorded during
30-minute test sessions for data analyses, with the first 5 minutes of behavioral observations
being assessed for locomotor and thigmotaxic measures.
2.5.2 Light Dark Box Test.
This task measured the bright-space anxiety exhibited by rats, based upon the rats’
instinctive tendency to avoid bright-lit environments. The test apparatus comprised of a twocompartment non-transparent plexiglass box (50 x 25 x 37 cm), with a white-coloured,
uncovered compartment and a black-coloured, lidded compartment. A 10 by 10 cm open
doorway separated these different compartments, allowing rat subjects to easily traverse between
the two compartments. The white-coloured compartment was brightly lit by an overhead lamp
located approximately 125 cm above the floor of this respective compartment. To begin the
experimental session, the rat was placed in the white-coloured compartment with its back facing
the open doorway. Rats were then observed for a total of 5 minutes, with measurements such as
total time spent in the light, risk assessment, latency to first compartmental and second
compartmental transitions, as well as total number of transitions during the test session.
Transitions between compartments were deemed complete when all four feet of the rat were
placed in the new compartment. Risk assessment measures included times when the rat was in
the dark compartment and placed at a minimum its nose into the light compartment, with the
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maximum inclusion criteria being three of four paws in the light compartment. Test sessions
were recorded and analyzed offline (Behaview software; www.pmbogusz.net).

2.5.3 Social Motivation and Recognition
The Social Motivation and Recognition test, otherwise known as the Three-Chamber
Sociability and Social Memory test, is a three-stage test used to assess the degree of sociability
and social recognition memory, as described by Loureiro et al. (2015). The first stage of
habituation was a 13-minute session whereby the subject could explore the test apparatus and
become familiar with the environment. The next day, within a span of 24 hours, the subject was
placed again within the center chamber for a 5-minute session with the chamber gates down.
After this 5-minute session, the second stage of social motivation and third stage of social
recognition were conducted in successive order. The second stage involved placing an empty
small wired cage and another one filled with a stranger male rat within the left and right
chambers; chamber gates were then lifted, and the test subject’s time spent interacting with each
cage was recorded for 8 minutes. Immediately after the second stage, a novel male rat was
introduced into the empty wired cage, rendering the cage already with a rat from the first stage
the “familiar rat”; the subject’s total interaction time with each cage was then recorded for
another 8-minute session. Throughout the testing protocol, the empty wired cage and stranger rat
wired cage in the second stage of the test were counterbalanced between the left and right
chambers of the test apparatus. Subjects’ recorded interaction times with the cages during the
task was analyzed offline (Behaview software; www.pmbogusz.net).
2.5.4 Elevated Plus Maze
This task involved a black acrylic maze apparatus with four arms (10 x 50 cm), extending
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from a 10 x 10 cm base platform elevated 50 cm above the floor. Two opposite arms were
shielded with 40 cm-high walls, while the remaining two opposing arms were unshielded except
for a 1 cm-high ledge that served to prevent subjects from falling off the platform while
exploring. The elevated plus maze task measures open-space anxiety, with primary outcomes
including total time spent in open arms, risk assessment (total time spent by the subject placing
at a minimum its nose, or at a maximum three of its paws in the open arm area) and total number
of arm transitions. Rat subjects were placed on the center platform facing an open arm and
allowed to explore the maze apparatus for 10 minutes. Exploration behavior was recorded and
analyzed offline (Behaview software; www.pmbogusz.net).
2.5.5 Context-Dependent Fear Conditioning
As an associative learning and memory task, context-dependent fear conditioning
measures the degree of freezing behavior exhibited by rats following the formation or recall of a
previously acquired associative fear-memory between a footshock stimulus and a specific
sensory or contextual cue. Using the same test apparatus described previously (Norris et al.
2016), the task involved two stages: conditioning and testing. Conditioning (Stage 1) involved
pairing contextual stimuli (in the form of a black-and-white striped walled, lidless box) to suprathreshold footshocks (0.8 mA, 1 second in duration, 10 total administered at randomized
intervals over a 25 minute session) delivered via a metallic grid shock floor located at the base of
the box enclosure. The next day, within 24 hours, rat subjects were re-introduced to the same test
environment (Stage 2) and their subsequent freezing behavior recorded. Treatment effects for the
acquisition phase of fear memory was assessed by administering treatment immediately prior to
the conditioning phase; in contrast, to examine the effects of drug interventions to modulate the
recall of fear memory formation was tested by administering treatment immediately prior to the
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testing (recall) phase of the procedure. Recorded data was then analyzed in an offline manner
(Behaview software; www.pmbogusz.net).
2.5.6. Spontaneous Alternation
This test assesses the rats’ spatial working memory and examines the ability of the rat to
hold short term memory (i.e. having just visited a specific maze arm) during the performance of
the task. Normally, healthy rats will alternate between the test arms but will continue to re-enter
the just experienced arms when there is a working memory deficit. A Y-maze (black acrylic, 3
arms separated by angles of 120˚ from one another; each arm length was 50 cm with a wall
height of 40 cm) was placed on the floor and rats were placed at the end of a designated starting
arm facing the wall. Subjects were then allowed to explore the maze apparatus and alternate
between arms during a 15-minute session. A successful arm entry was classified as all four paws
of the rat had either entered or left an arm, and a successful set of alternations was defined by
three consecutive entries into unique arms (e.g. entry into arm A, then B, then C). Subjects’
exploratory behaviors were recorded and analyzed offline (Behaview software;
www.pmbogusz.net).
2.5.7 Novel Object Recognition
The novel object recognition test examines a rat’s ability to discern between novel and
familiar objects, representative of short or long-term memory (depending on the retention
interval). Healthy rats will recall an object previously encountered, preferring the choice of a
novel object when given a choice to explore a recently encountered vs. novel object in the test
chamber. This ability is impaired during memory impairments, whereby rats will show deficits in
discerning between the previously encountered vs. novel object during the object exploration
test. The test apparatus comprised of an 80 x 80 cm lidless box (black acrylic). Subjects were
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exposed to the box for a 20-minute session one day prior to the actual test to allow them to
habituate to this novel environment. Testing day consisted of two stages, each 3 minutes in
length. During the first stage, subjects were placed in the test box that contained two identical
objects in two corners (15 cm away from each box wall, with both corners being shared by a
single side). Following the 3-minute session, subjects were returned to their housing cages. One
hour later, subjects were re-introduced to the box with one of the former objects replaced at the
same previous corner location. Designations for novel-familiar object alternations were
counterbalanced between subjects. The time subjects spent sniffing the object (deemed as
exploratory behavior) was recorded and analyzed offline (Behaview software;
www.pmbogusz.net).
2.5.8 Testing Timelines
Shown below are the different test cohorts and their associated behavioral assays,
organized in a chronological manner and beginning from day 1 of testing or protocol exposure:
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2.6 Molecular Analyses
At the end of experimental tests prior to euthanasia, rats were given one last drug and
odour administration (as previously described) based upon their respective treatment group
designations during behavioral testing. Subjects were then injected intra-peritoneally with an
overdose of sodium pentobarbital (240 mg/kg, i.p., EuthanylTM) and decapitated. Brains were
extracted and then flash frozen at –80°C. Coronal sections (99 µm) of the brains containing the
PFC, and NAcSh were sliced using a cryostat and mounted on glass slides; bilateral
microdissections were then taken from the specified brain regions (NAcSh microdissections
were taken from around the infusion site to avoid any regions with active gliosis). Tissue
samples were homogenized using a Dounce homogenizer and proteins were then isolated using
lysis buffer containing phosphatase and protease inhibitors. Protein quantification was conducted
using the bicinchoninic acid (BCA) assay.
The western blotting procedure was conducted in the same manner as previously
described by Lyons et al. (2013), with protein samples being denatured in Laemmli buffer and
diluted to ensure all concentrations were equal and each well loaded with 25 µg of protein.
Samples underwent SDS polyacrylamide gel electrophoresis (SDS-PAGE) at 125V for 1.5 hours
in 10% acrylamide gels, followed by transference to nitrocellulose membranes using the TransBlot Turbo Transfer System (Bio-Rad) at 2.5A for 10 minutes. After blocking with 2.5% bovine
serum albumin (BSA) in TBS-T for one hour, membranes were then placed in blocking solution
containing the following primary antibodies with their respective host species and dilutions as
follows: α-tubulin (mouse; 1:10,000; Sigma-Aldrich), phosphorylated GSK3α/β ser21/9 (pGSK3α/β; rabbit; 1:1000; Cell Signaling Technology), total GSK3α/β (t-GSK3α/β; mouse;
1:250; Santa Cruz Biotechnology), phosphorylated AktSer473 (p-AktSer473; rabbit; 1:1000;
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Cell Signaling Technology), phosphorylated AktThr308 (p-AktThr308; rabbit; 1:750; Cell
Signaling Technology), total Akt (t-Akt; mouse; 1:1000; Cell Signaling Technology),
phosphorylated ERK1/2 (p-ERK; rabbit; 1:1000; Cell Signalling Technology), total ERK1/2 (tERK; mouse; 1:2000; Cell Signalling Technology), phosphorylated JNK (p-JNK; rabbit; 1:1000;
Cell Signalling Technology), total JNK (t-JNK; rabbit; 1:1000; Cell Signalling Technology).
Membranes were finally probed with species appropriate fluorophore-conjugated
secondary antibodies (LI-COR IRDye 680RD and IRDye 800CW; Thermo Scientific) at a
dilution of 1:10000. LI-COR Odyssey Infrared Imaging System and Image Studio analysis
software were then used to scan and obtain densitometry measurements respectively,
normalizing the intensity of each sample’s target protein band to its respective α-tubulin band
intensity.

2.7 Histology
Rat subjects were euthanized, with their brains extracted and sliced as previously
mentioned in section 2.6. Following tissue extraction procedures as described in section 2.6
regarding western blotting, slides with PFC and NAcSh coronal sections were then stained with
cresyl violet dye as detailed by Loureiro et al. (2015). Sections with visible cannula tip sites
viewed under a microscope were photographed and correlated with their respective locations as
according to the rat brain atlas by Paxinos and Watson (2005) for placement accuracy.

2.8 Statistical Analyses
All statistical analyses were performed using SPSS (IBM SPSS Statistical Package
Version 26). Preliminary analyses for normal distribution were conducted for both behavioral
and molecular data (normalized densitometry measurements) using the Kolmogorov-Smirnov
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test, followed by either Two-way t-tests or One-way ANOVA analyses where appropriate; posthoc analyses were conducted utilizing Fischer’s LSD test. All statistical significances were
denoted by p < 0.05, with a 95% confidence interval.
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3. Results: Behavioral Assays
3.1 Baseline Cohort Behavioral Results
3.1.1 Open Field Test
The open field test was conducted primarily to assess potential alterations in locomotor
activity, and secondarily as an open-space anxiety measure (Figure 6). One-way ANOVA tests
demonstrated that there were no significant differences in total distance travelled between
treatment groups in the baseline cohort (F(5, 57) = 1.332, p = 0.264; figure 6B) ultimately
suggesting no significant differences in locomotor ability between treatment groups in their
respective test analyses.
In summary, these baseline cohort results from the open field test demonstrated that no
significant locomotor abnormalities resulted from treatment interventions in the cohort—
effectively eliminating the potential of locomotor abnormalities confounding the results of all
subsequent behavioral assays which inherently involve locomotion to some degree.
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3.1.2 Light Dark Box Test
The light dark box test was used to assess bright-space anxiety exhibited by treatment
groups. As shown in figure 7, when measuring total time spent in the light compartment, both
L200-CBD and L2000-CBD presented significantly increased time spent exploring the light
chamber compared to all other treatment groups (p ≤ 0.01 for all group comparisons except when
comparing L200-CBD with L2000-CBD) in the baseline cohort (F(5, 56) = 6.752, p ≤ 0.001; figure
7B).
The secondary assessment of bright-space anxiety, the total number of transitions made
by test subjects, also differed significantly between treatment groups in the baseline cohort (F(5,
56) =

5.775, p ≤ 0.001; figure 7C). Interestingly, while the L2000-CBD treatment group exhibited

significantly higher number of transitions between compartments compared to all other groups (p
≤ 0.05) except L200-CBD (p = 0.074), the L200-CBD treatment group only exhibited
significantly higher number of transitions when compared to the VAirVPBS and VAirVCBD groups
(p ≤ 0.05). In addition, the L2000-VCBD group presented significantly higher total number of
compartmental transitions compared to the VAirVPBS group (p = 0.016).
These LDB test results strongly suggest the presence of an Entourage Effect (EE)
between CBD and linalool which was supra-additive in its anxiolytic effects relative to subthreshold doses of either alone, given that the L2000-CBD group exhibited significantly reduced
bright-space anxiety compared to the VAirVPBS group, as well as its component vehicle groups
VAirCBD and L2000-VPBS in both anxiety assessment measures (total time in light, total number
of transitions). Results also suggest that this EE-potentiated bright-space anxiolysis is present in
a lesser degree following L200-CBD treatment, as the L200-CBD group exhibited significantly
reduced bright-space anxiety compared to the VAirVPBS group, VAirCBD and L200-VPBS groups
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in the primary anxiety measure (total time in light) but not the secondary anxiety measure (total
number of transitions).
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3.1.4 Social Motivation and Recognition Test
To assess sociability and social recognition memory as a pre-clinical model of social
anxiety disorder, the social motivation and recognition test was employed with results as shown
in figure 8. Sociability and social recognition memory were respectively quantified as social
motivation index (SMI) and social recognition index (SRI) values. SMI values were expressed as
the normalized absolute difference of time spent sniffing the two cages in stage 2 (social
motivation), while SRI values were expressed as the normalized absolute difference of time
spent sniffing the two cages in stage 3 (social recognition).
Ultimately, significant differences in stage 2 social motivation index and stage 3 social
recognition index values were not found between groups in the overall ANOVA analysis of the
baseline cohort (stages 2 and 3 respectively: F(5, 44) = 1.127, p = 0.360 [figure 8B]; F(5, 44) =
0.714, p = 0.616 [figure 8C])
Taken together, these SMI and SRI findings of non-significance in the baseline cohort
suggest respectively that there are no significant differences in social novelty preference and
social recognition memory between treatment groups—and consequently that the combination
treatments of linalool and cannabidiol do not elicit an EE-potentiated change in social cognition,
at least in the baseline cohort. This result is not particularly surprising however as previous
studies in our lab have demonstrated that social anxiety induced cognitive alterations generally
only occur following chronic stress exposure or other neurodevelopmental toxic insults (e.g.
Renard et al., 2017).
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3.1.3 Elevated Plus Maze Test
The open space anxiety of test subjects was assessed using the Elevated Plus Maze
behavioral assay. Regarding the time spent in open arms which represents the primary measure
of open space anxiety in this test, as shown in figure 9, one-way ANOVA analysis revealed no
significant differences between groups in the baseline cohort (F(5, 53) = 1.690, p = 0.153; figure
9B).
Within the secondary open space anxiety measure of total arm transitions, no significant
differences in transition counts between open and closed arms were discovered between groups
in the baseline cohort (F(5, 53) = 0.386, p = 0.856; figure 9C).
Taking into account the findings of non-significance in both the EPM assessments of
total in open arms and total arm transitions in the baseline cohort, this suggests that there were no
differences between groups in the perception of open-space anxiety in the more sensitive EPM
apparatus (as compared to the OFT apparatus); consequently, these findings present the lack of
EE-potentiated open-space anxiety within the context of the EPM test paradigm following
combination treatments of linalool and cannabidiol.
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3.1.5 Context-Dependent Fear Conditioning
The context-dependent fear conditioning (CFC) behavioral assay assessed contextdependent anxiety observed through freezing time presentation. As demonstrated in figure 10, in
the context of the CFC-Acquisition (as previously described), significant differences in freezing
time were found in the baseline cohort (F(5, 47) = 3.195, p = 0.015; figure 10B). The L200-CBD
group exhibited significantly lower freezing time when compared to solely the VAirVPBS and
L200-VPBS groups (p ≤ 0.05); the L2000-CBD group however demonstrated significantly lower
freezing time compared to all treatment groups (p ≤ 0.05) except its lower dose L200-CBD
counterpart (p = 0.668).
Significant differences were also found between groups in the baseline cohort when
assessing CFC-Recall (F(3, 34) = 6.360, p = 0.002; figure 10C). The L2000-CBD group was found
to exhibit significantly lower freezing time compared to all other groups (p ≤ 0.05).
In summary, these CFC assay results demonstrate that the L2000-CBD treatment was
able to significantly reduce the context-dependent anxiety induced by the CFC apparatus in both
the CFC-Acquisition and CFC-Recall challenges. This in turn suggests that the EE-potentiated
anxiolysis induced by L2000-CBD in this behavioral assay is effective in attenuating both fear
memory formation and recall, as shown respectively by the results from the CFC-Acquisition
and CFC-Recall challenges, strongly suggesting a strong entourage effect for the combinatorial
effects of CBD and linalool, relative to either compound alone.
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3.2 Flumazenil Challenge Behavioral Results
In light of the results from the baseline cohort suggesting the presence of an EEpotentiated anxiolysis following L2000-CBD treatment, the flumazenil challenge—involving
groups that received intra-cranial flumazenil alongside L2000-CBD treatment—was conducted
to determine whether this EE-potentiation involved GABAAR activity modulation, given that
previous studies have shown that linalool and CBD may generate anxiolysis via GABAAR
mechanisms of action (Bakas et al., 2017; Harada et al., 2018; Lopes et al., 2012; Milanos et al.,
2017).
3.2.1 Open Field Test
The OFT was used to identify potential alterations in locomotor activity and secondarily
as an open-space anxiety measure in the flumazenil cohort (Figure 11). One-way ANOVA tests
demonstrated that there were no significant differences in total distance travelled between
treatment groups in the flumazenil challenge cohort (F(3, 26) = 0.339, p = 0.798; figure 11A),
ultimately suggesting no significant differences in locomotor ability between treatment groups.
When assessing thigmotaxis anxiety measures of center-to-total locomotion ratios
(expressed as a percentage), ANOVA analysis revealed significant differences between treatment
groups (flumazenil: F(3, 32) = 10.06, p ≤ 0.01; figure 11B); post hoc analyses showed that the
L2000-CBD treatment group exhibited significantly higher center/total locomotion (%)
compared to all other treatment groups (p ≤ 0.05).
These flumazenil challenge OFT results demonstrated that no significant locomotor
abnormalities resulted from treatment interventions in the cohort, removing concerns of
locomotor abnormalities confounding interpretations of results from subsequent behavioral
assays which all involve locomotion. Furthermore, the center/total locomotion (%) results
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suggest that intra-cranial flumazenil administration is effective in removing the EE-potentiated
open-space anxiolysis exhibited by L2000-CBD group, as demonstrated by the significantly
reduced center/total locomotion (%) value following co-administration of L2000-CBD and
flumazenil.
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3.2.2 Light Dark Box Test
The LDB test was used to assess bright-space anxiety exhibited by treatment groups
using the same primary and secondary anxiety measures assessed in the baseline cohort (total
time in light compartment, total compartmental transitions). Within the flumazenil challenge
cohort, significant differences in total time spent in the light compartment between groups was
discovered through one-way ANOVA analysis (F(3, 31) = 18.89, p ≤ 0.001; figure 12A), with the
L2000-CBD group presenting significantly greater time in the light compartment than all other
treatment groups (p ≤ 0.001).
Furthermore, one-way ANOVA analysis revealed significant differences in terms of total
transition counts between treatment groups in the flumazenil challenge cohort (F(3, 31) = 18.191, p
≤ 0.001; figure 12B). Specifically, post hoc analyses revealed the number of total transitions
made by the L2000-CBD to be significantly higher than all other treatment groups (p ≤ 0.001).
These flumazenil challenge LDB test results demonstrated that intra-cranial flumazenil
administration was able to effectively eliminate the EE-potentiated anxiolysis elicited following
L2000-CBD treatment, as shown with the significant reduction in both total time in the light
compartment and total compartmental transitions exhibited by the co-treated L2000CBD+flumazenil group.
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3.2.3 Context-Dependent Fear Conditioning (Recall)
Utilizing the same CFC test apparatus employed in baseline cohort testing, contextdependent anxiety (specifically with treatment given immediately prior to stage 2 testing)
observed through freezing time presentation was assessed in the flumazenil challenge cohort. As
shown through one-way ANOVA and subsequent post-hoc analyses in figure 13, the L2000CBD group also presented significantly lower freezing time compared to all other treatment
groups (F(3, 32) = 19.283, p ≤ 0.001).
Conversely, when taking account the non-significance in freezing time between the
L2000-CBD+flumazenil group and the two vehicle groups (VAirVPBS, VAir+Flumazenil) as well
as the significantly higher freezing time presented by the L2000-CBD+flumazenil group when
compared to the flumazenil-free L2000-CBD group (p ≤ 0.05), these results suggest that intracranial flumazenil administration is able to prevent the presentation of EE-potentiated fearmemory anxiolysis induced by L2000-CBD treatment in the CFC-Recall challenge condition.
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3.3 EPA Challenge Behavioral Results
Given that baseline cohorts indicated the presence of EE-potentiated anxiolysis following
L2000-CBD treatment, the EPA challenge—involving groups that received intra-cranial EPA
(ERK activator) alongside L2000-CB treatment—was carried out to determine whether this EEpotentiation involved ERK activity modulation, as previous studies have suggested that linalool
and CBD may yield anxiolysis through regulation of pERK activity (Caputo et al., 2016; 2017;
2018; Hudson et al., 2019).
3.3.1 Open Field Test
Employing the OFT assay used in the flumazenil challenge cohort, total distance
travelled and thigmotaxis activity of treatment groups were assessed to respectively determine
the presence of any differences in locomotion and open-space anxiety between treatment groups
in the EPA challenge cohort.
OFT results from the EPA challenge cohort demonstrated no significant differences
between treatment groups in the assessment of total locomotion (F(3, 34) = 0.993, p = 0.409;
figure 14A); however, significant differences between groups were found when assessing
center/total locomotion (%), with the L2000-CBD treatment exhibiting significantly increased
center/total locomotion (%) values (p ≤ 0.05) in comparison to all other groups (F(3, 34) = 10.688,
p ≤ 0.01; figure 14B).
These OFT findings presented by the EPA challenge cohort demonstrate that no
significant locomotor abnormalities resulted from treatment interventions in the cohort,
indicating that there were no locomotor abnormalities present that would potentially confound
interpretations of results from subsequent behavioral assays involving locomotion. In addition,
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the center/total locomotion (%) results suggest that intra-cranial EPA administration is effective
in removing the EE-potentiated open-space anxiolysis exhibited by L2000-CBD group, as shown
by the significantly reduced center/total locomotion (%) value following co-administration of
L2000-CBD and flumazenil in conjunction with the non-significance between the L2000CBD+flumazenil and the two vehicle groups (VAirVPBS, VAir+EPA).
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3.3.2 Light Dark Box Test
Utilizing the LDB test in the same manner as in the baseline and flumazenil challenge
cohorts, bright-space anxiety exhibited by EPA challenge treatment groups was assessed through
the primary measure of total time in the light compartment and secondarily through the measure
of total compartmental transitions.
Within the EPA challenge cohort, one-way ANOVA analysis revealed significant
differences in total time spent in the light compartment between treatment groups (F(3, 35) =
7.644, p = 0.001; figure 15A), with post hoc analyses demonstrating that the L2000-CBD group
presented significantly greater time spent in the light compartment compared to all other groups
(p ≤ 0.05). A similar trend was observed in regard to total compartmental transitions, with oneway ANOVA analysis demonstrating significant differences between treatment groups (F(3, 35) =
11.921, p ≤ 0.01; figure 15B) and post hoc analyses showing that the L2000-CBD group
exhibited a significantly increased amount of compartmental transitions compared to all other
groups (p ≤ 0.05).
The significantly decreased total time spent in the light compartment and compartmental
transitions exhibited by the L2000-CBD+EPA treatment group when compared to the EPA-free
L2000-CBD group, concurrent with non-significance when compared to the VAirVPBS and
VAir+EPA vehicle groups suggests that intra-cranial EPA administration is capable of preventing
the EE-potentiated bright-space anxiolysis induced by L2000-CBD treatment.
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3.3.3 Context-Dependent Fear Conditioning (Acquisition)
Employing the same CFC test apparatus used in previous cohort testing, contextdependent anxiety—specifically with treatment given prior to the stage 1 conditioning phase—
was observed through freezing time presentation was assessed in the EPA challenge cohort.
As demonstrated in figure 16, one-way ANOVA analysis revealed significant differences
between treatment groups in the assessment of freezing time (F(3, 34) = 5.548, p = 0.004; figure
16); post hoc analyses further showed that the L2000-CBD treatment group exhibited
significantly greater time spent frozen when compared to all other groups (p ≤ 0.05).
Notably, given that the L2000-CBD+EPA treatment group exhibited non-significant
differences in freezing time when compared to vehicle groups (VAirVPBS, VAir+EPA) and that it
presented significantly increased freezing time in comparison to its EPA-free L2000-CBD
treatment counterpart, these results suggest that intra-cranial EPA administration is effective in
preventing the presentation of EE-potentiated fear-memory anxiolysis elicited by L2000-CBD
treatment in the CFC-Acquisition challenge condition.
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3.4 Chronic Stress Behavioral Results
The previous studies explored the ability of CBD + linalool combinations to produce
acute anxiolytic effects in otherwise healthy rat cohorts. However, given that most chronic
anxiety disorders are experienced following prolonged exposure to environmental stressors, we
next explored the potential effects of CBD + linalool combinations in mitigating anxiogenic
effects induced by chronic stress exposure (see methods). Following the findings from the
baseline cohort suggesting that L2000-CBD treatment is capable of eliciting an EE-potentiated
anxiolysis in various contexts, chronic stress models were generated using the CUS protocol
employed in this study and incorporated into a chronic stress cohort to determine whether
L2000-CBD treatment was capable of reversing alterations induced by chronic stress—and
secondarily if such a reversal was potent enough to induce the originally observed Entourage
Effect seen in the baseline cohort.

3.4.1 Open Field Test
Utilizing the OFT assay employed in previous cohorts, the locomotion and center/total
locomotion (%) of chronic stress cohort treatment groups were assessed to respectively
determine if any significant differences in locomotor or open-space anxiety were present
between groups.
One-way ANOVA analysis of total locomotion (F(3, 29) = 0.833, p = 0.487; figure 17A)
and center/total locomotion (%) (F(3, 32) = 1.115, p = 0.359; figure 17B) revealed no significant
differences between treatment groups in the chronic stress cohort. In addition, a pre-planned twotailed t-test comparison between the VAirVPBS and CUS-VAirVPBS treatment groups revealed no
significant differences in center/total locomotion (%) (t(14) = 1.022, p = 0.325; figure 17B—not
visualized due to insignificance).
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Collectively, these results indicate that there were no significant locomotor differences
between groups that could confound the interpretation of results from subsequent behavioral
assays involving an element of locomotion. Furthermore, these findings suggest that the chronic
stress resulting from exposure to the 2-week CUS protocol employed in this study is not
effective in achieving significant stress-induced open-space anxiety in the OFT paradigm (as
shown by the non-significance between the VAirVPBS and CUS-VAirVPBS treatment groups).
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3.4.2 Spontaneous Alternation
The spontaneous alternation (SA) behavioral paradigm was used to assess potential
working memory deficiencies between treatment groups in the chronic stress condition, with
results as shown in figure 18B. When assessing normalized alternation counts (expressed as a
percentage value in relation to total entry counts), no significant differences were found between
groups (F(3, 29) = 1.986, p = 0.138; figure 18B). A pre-planned two-tailed t-test comparison
between the VAirVPBS and CUS-VAirVPBS treatment groups presented no significant differences
(t(14) = 1.627, p = 0.126; figure 18B—comparison not visualized due to non-significance).
The insignificance in normalized alternation counts (%) found between groups in the SA
test ultimately suggests that there is lack of comparable memory deficits between said treatment
groups. Furthermore, pre-planned comparison results between VAirVPBS and CUS-VAirVPBS
treatment groups suggests that the 2-week CUS protocol used in this study was not sufficient in
generating a chronic stress-induced model of cognitive impairment. Nevertheless, an important
implication from these results is that the combination of CBD + linalool (at doses which are
highly anxiolytic), did not produce any cognitive impairments in and of themselves, relative to
VEH controls, suggesting that the potential therapeutic properties of CBD + linalool are free of
negative cognitive side effects, which, as previously discussed, are serious clinical limitations to
most commonly used anxiolytic medications.
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3.4.3 Novel Object Recognition
Long-term memory capacity was assessed through observations of object discrimination
by test subjects from the chronic stress cohort in the novel object recognition assay.
Significant differences in the novelty preference score, which measured novelty
preference in relation to overall exploration time of assigned objects, were not found between
treatment groups in the chronic stress cohort following one-way ANOVA analysis (F(3, 26) =
0.693, p = 0.565; figure 19B). Furthermore, pre-planned two-tailed test comparisons between the
VAirVPBS and CUS-VAirVPBS treatment groups presented no significant differences (t(13) = 0.489, p
= 0.647; figure 19B—comparison not visualized due to non-significance).
This lack of significant differences observed in the NOR paradigm suggests that there
were no relative deficiencies in long-term memory cognition between treatment groups in the
chronic stress cohort. In addition, lack of significant differences between the VAirVPBS and CUSVAirVPBS treatment groups following pre-planned comparison analysis suggests that the 2-week
CUS protocol used in this study was not sufficient in generating a chronic stress-induced model
of cognitive impairment. Again, similar to results observed with spontaneous alternation, these
findings suggest that the potential therapeutic properties of CBD + linalool for anxiolysis are free
of negative cognitive side effects.
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3.4.4 Light Dark Box Test
The LDB assay was used to assess for differences in bright-space anxiety between
treatment groups within the chronic stress cohort, utilizing the same primary measure of total
time spent in the light compartment and secondary measure of total compartmental transitions
employed in previous cohorts.
One-way ANOVA and subsequent post hoc analysis of chronic stress cohort data
revealed significant differences between treatment groups, with both the CUS-L2000-CBD and
non-stressed L2000-CBD treatment groups exhibiting significantly increased exploration time in
the light compartment (p ≤ 0.05) compared to VAirVPBS and CUS-VAirVPBS (F(3, 27) = 5.824, p ≤
0.003; figure 20A). In addition, a pre-planned comparison (significance denoted in green)
between the VAirVPBS and CUS-VAirVPBS treatment groups used to assess the validity of the
chronic stress model in the context of bright-space anxiety demonstrated significant differences
between the two groups, with the VAirVPBS group found to spend significantly greater time in
light than its CUS-VAirVPBS counterpart (t(13) = 2.431, p = 0.030).
In regard to the secondary measure of bright-space anxiety, the number of total
transitions made by treatment groups differed significantly (F(3, 27) = 4.218, p ≤ 0.014; figure
20B), with the CUS-L2000-CBD group presenting significantly greater number of total
transitions than the CUS-exposed and non-stressed VAirVPBS groups (p ≤ 0.05), while the nonstressed L2000-CBD group presented only significantly higher total transition counts when
compared to the CUS-VAirVPBS treatment group (p ≤ 0.05).
Taken together, the significant reduction in anxiety symptoms presented by the CUSL2000-CBD group when compared to the CUS-VAirVPBS group suggests that L2000-CBD
administration is effective in attenuating bright-space anxiety induced by chronic stress.
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Furthermore, the non-significance between L2000-CBD and CUS-L2000-CBD groups and
significant difference between VAirVPBS and CUS-L2000-CBD groups suggests that the EEpotentiated bright-space anxiolysis observed in the baseline cohort is also achieved under chronic
stress conditions.
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3.4.5 Social Motivation and Recognition Test
Utilizing the same SMRT assay employed in the baseline cohort, the sociability and
social recognition memory of treatment groups in the chronic stress cohort were respectively
assessed through the previously used measures of SMI and SRI.
While one-way ANOVA analysis revealed no significant differences between treatment
groups in stage 2 SMI values (F(3, 26) = 1.631, p = 0.206; figure 21A), a pre-planned two-tailed ttest comparison conducted within the chronic stress cohort between the VAirVPBS and CUSVAirVPBS groups revealed the CUS-treated model to elicit significantly lower stage 2 SMI values
(t(12) = 2.441, p = 0.031; figure 21A—significance comparison shown in green).
In regard to stage 3 of the SMRT assay, treatment groups in the chronic stress cohort
demonstrated significantly different SRI values (F(3, 26) = 5.615, p = 0.004; figure 21B). Post hoc
analyses revealed that the SRI value exhibited by the stressed VAirVPBS group was significantly
lower when compared to all other treatment groups (p ≤ 0.05).
In summary, these SMRT assay results from the chronic stress cohort suggest that the
CUS protocol employed in this study was effective in generating chronic stress-induced social
cognition impairments, as exemplified by the pre-planned comparison in figure 21A and the oneway ANOVA analysis in figure 21B. Furthermore, stage 3 SRI value analysis suggests that
L2000-CBD treatment was effective in reversing the social recognition memory deficits induced
by chronic stress exposure, as demonstrated by the significantly higher SRI values of the CUSL2000-CBD group compared to the CUS-VAirVPBS group.
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3.4.6 Elevated Plus Maze
The EPM assay was utilized in the chronic stress cohort in the same manner as done
previously with the baseline cohort, assessing open-space anxiety through the primary measure
of time spent in open arms and the secondary measure of total arm transitions.
One-way ANOVA analysis revealed significant differences in open arm exploration time
between treatment groups in the chronic stress cohort (F(3, 28) = 3.391, p = 0.032; figure 22A),
with subsequent post hoc analysis showing that the L2000-CBD and CUS-L2000-CBD groups
exhibited significantly greater open arm exploration time in comparison to the CUS-VAirVPBS
group (p ≤ 0.05). A pre-planned comparison conducted between VAirVPBS and CUS-VAirVPBS
groups assessing open arm exploration time (in an attempt to investigate the ability of the CUS
protocol to generate chronic-stress induced open-space anxiety) yielded no significant
differences (t(14) = 1.872, p ≤ 0.082; figure 22A—significance comparison not visualized due to
non-significance). Nevertheless, there were strong trends towards the CUS inducing significant
anxiogenic effects relative to non-stressed controls.
With regards to the secondary measure of open-space anxiety in the EPM assay, one-way
ANOVA analysis demonstrated significant differences in arm transition counts between
treatment groups in the chronic stress cohort (F(3, 28) = 3.433, p = 0.030; figure 22B). Post hoc
analyses specifically revealed a significant increase in arm transitions committed by both the
L2000-CBD and CUS-L2000-CBD groups when compared to the CUS-VAirVPBS group (p ≤
0.05).
These EPM assay results from assessment of the chronic stress cohort ultimately suggest
that while the CUS protocol was ineffective in inducing significantly increased open-space
anxiety in the EPM behavioral paradigm, L2000-CBD treatment was nonetheless effective in
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reversing moderate open-space anxiety induced by chronic stress.
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4. Results: Molecular Assays (Baseline Cohort)
Within the context of the baseline cohort, the molecular biomarkers previously described
in the introduction (GSK-3β, Akt, ERK and JNK) were quantified to in an attempt to elucidate
potential mechanisms of action correlating with various degrees of anxiolytic efficiency
displayed in behavioral assays. Two sets of ANOVA analyses were conducted for each protein
quantified, with one focused on comparing linalool vehicle groups to the double-control group
(VAirVPBS) within the NAcSh region (referred to as the “control analysis”), while the other
focused on comparing both L200-CBD and L2000-CBD to VAirVPBS and VAirCBD in both the
NAcSh and PFC regions (referred to as the “experimental analysis”). Both analyses expressed
levels of protein in comparison to the control group (VAirVPBS) as percentage values.
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4.1 GSK-3β Protein Analysis
As demonstrated in figure 23, one-way ANOVA analysis revealed no significant
differences in the control analysis (p-GSK-3β: F(2, 10) = 2.173, p = 0.1646 [figure 23A]; T-GSK3β: F(2, 10) = 0.9494, p = 0.4193 [figure 23B]; p/T-GSK-3β: F(2, 11) = 0.274, p = 0.7654 [figure
23C]). Within the experimental analysis, significant differences were found in the NAcSh region
when assessing p/T-GSK-3β values (F(3, 20) = 4.526, p = 0.0141; figure 23F); analysis of
differences between groups in p-GSK-3β (F(3, 20) = 1.956, p = 0.1531; figure 23D) and T-GSK3β (F(3, 20) = 1.339, p = 0.29; figure 23E) demonstrated non-significance. Post hoc analysis of
p/T-GSK-3β values revealed that the VAirCBD group exhibited significantly increased levels in
comparison to both VAirVPBS and L2000-CBD groups (p ≤ 0.05). Significantly different levels of
GSK-3β were also exhibited by treatment groups in PFC samples when analyzing p/T-GSK-3β
(F(3, 27) = 3.642, p = 0.0251; figure 23I) and p-GSK-3β (F(3, 27) = 3.554, p = 0.0274; figure 23G)
values; no significance was found when assessing levels of T-GSK-3β (F(3, 27) = 0.3919, p =
0.7598; figure 23H). In both the post hoc assessments of p/T-GSK-3β and p-GSK-3β values, the
VAirCBD group exhibited significantly increased levels in comparison to both VAirVPBS and
L2000-CBD groups (p ≤ 0.05).
Collectively, given the non-significance observed between the L2000-CBD and VAirVPBS
treatment in all GSK3β molecular assays conducted in as shown in the experimental analyses,
these findings suggest that L2000-CBD achieves its EE-potentiated anxiolysis (observed in the
behavioral tests) without significant modulation of GSK3β activity from baseline levels.
Furthermore, the lack of effect present following linalool treatment in the control analysis
suggests that linalool likely does not modulate GSK3β activity on its own; importantly however,
in light of the significant reduction of p/T-GSK3β levels following L2000-CBD treatment
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(compared to VAirCBD) in both experimental analyses within the PFC and NAcSh regions, these
findings suggest that linalool is potentially involved in allosteric modulation of GSK3β activity
above a certain threshold level—and that this allosteric intervention may serve as a component
mechanism of action for previously observed EE-potentiated anxiolysis.
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4.2 Akt Protein Analysis
As shown in figure 14, no significant differences were found in the control analysis when
focusing on either the Ser473 or Thr308 sites following a one-way ANOVA test assessment (pAktSer473: F(2, 12) = 1.614, p = 0.2395 [figure 24A]; T-Akt: F(2, 12) = 3.802, p = 0.0526 [figure
24B]; p/T-AktSer473: F(2, 12) = 1.399, p = 0.2843 [figure 24C]; p-AktThr308: F(2, 12) = 0.8696, p
= 0.4439 [figure 24A]; T-Akt: F(2, 12) = 3.664, p = 0.0573 [figure 24B]; p/T-AktThr308: F(2, 12) =
1.862, p = 0.1975 [figure 24C]).
While no significant differences were found in the NAcSh region when assessing
AktThr308 sites (p-AktThr308: F(3, 20) = 1.56, p = 0.2302 [figure 24E]; T-Akt: F(3, 20) = 2.527, p
= 0.0865 [figure 24F]; p/T-AktThr308: F(3, 20) = 1.287, p = 0.3060 [figure 24G]), p-AktSer473
(F(3, 21) = 0.5449, p = 0.6570; figure 24E) or T-Akt in the context of AktSer473 quantification
(F(3, 21) = 0.5727, p = 0.6392; figure 24F), significantly different levels of p/T-AktSer473 were
present in the brain region (F(3, 22) = 5.19, p = 0.0073; figure 24G). Specifically, both the
VAirCBD group and L200-CBD groups exhibited significantly increased p/T-AktSer473 values
in comparison to the VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05).
Similar trends were found in the PFC region (figure 14I/J/K); while no significant
differences were present following ANOVA analysis of AktThr308 site quantifications (pAktThr308: F(3, 21) = 0.5868, p = 0.6304 [figure 24I]; T-Akt: F(3, 30) = 1.148, p = 0.3456 [figure
24J]; p/T-AktThr308: F(3, 21) = 0.3236, p = 0.8082 [figure 24K]) or the T-Akt assessment of the
AktSer473 cohort (F(3, 30) = 2.642, p = 0.0674; figure 24J), expression levels of p-AktSer473 and
p/T-AktSer473 were significantly different between groups (respectively: F(3, 30) = 12.2, p ≤
0.001 [figure 24I]; F(3, 30) = 4.536, p = 0.0098 [figure 24K]). With regards to the assessment
intra-PFC p-AktSer473 levels, the VAirCBD group demonstrated significantly higher levels than
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all other treatment groups (p ≤ 0.05); when assessing p/T-AktSer473 group comparisons, the
VAirCBD group exhibited significantly increased expression levels compared to VAirVPBS and
L2000-CBD treatment groups (p ≤ 0.05), while the L200-CBD group presented significantly
higher p/T-AktSer473 levels when compared to the VAirVPBS group (p ≤ 0.05).
Altogether, these Akt molecular assay findings suggest that the EE-potentiated anxiolysis
elicited following L2000-CBD treatment observed previously in behavioral paradigms likely
does not involve significant modulation of Akt activity from baseline levels (as evidenced by the
non-significance in p/T-AktSer473 and p/T-AktThr308 levels between L2000-CBD and VAirVPBS
treatment groups in both PFC and NAcSh experimental analyses). Furthermore, similar to the
previous GSK3β analysis, the lack of significant differences between treatment groups following
linalool administration in the control analysis suggests that linalool likely does not modulate Akt
activity on its own; however the significant reduction of p/T-Akt levels following L2000-CBD
treatment (compared to VAirCBD) in both PFC and NAcSh experimental analyses present the
notion that linalool is potentially involved in allosteric modulation of Akt activity above a certain
threshold level. Unlike the GSK3β assay however, L200-CBD treatment achieved significantly
higher p/T-AktSer473 levels in the NAcSh experimental analysis (as well as a moderate increase
in PFC regional analysis) when compared to the L2000-CBD group, suggesting that a dosedependent attenuation of p/T-AktSer473 levels induced through increasing dosages of linalool
olfactory exposure may be a component mechanism of action through which L2000-CBD
treatment achieves its EE-potentiated anxiolysis.
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4.3 ERK Protein Analysis
As exhibited in Figure 15, no significant differences were found in the control analysis
when assessing quantification measures for either the ERK1 isoform (p-ERK1: F(2, 12) = 1.922, p
= 0.1888 [figure 25A]; T-ERK1: F(2, 12) = 2.709, p = 0.1069 [figure 25B]; p/T-ERK1: F(2, 12) =
1.117, p = 0.3589 [figure 25C]) or ERK2 isoform (p-ERK2: F(2, 12) = 1.088, p = 0.3681 [figure
25A]; T- ERK2: F(2, 12) = 2.727, p = 0.1056 [figure 25B]; p/T- ERK2: F(2, 12) = 0.9841, p = 0.4020
[figure 25C]).
Within the context of the NAcSh region, while no significant differences were found in
T-ERK in either ERK1 (F(3, 19) = 1.884, p = 0.1666; figure 25E) or ERK2 (F(3, 19) = 1.138, p =
0.3589; figure 25E), there were significantly different intra-NAcSh levels of p-ERK1 (F(3, 19) =
3.561, p = 0.0337; figure 25D), p/T-ERK1 (F(3, 19) = 4.329, p = 0.0174; figure 25F), p-ERK2
(F(3, 19) = 4.298, p = 0.0179; figure 25D) and p/T-ERK2 (F(3, 19) = 4.09, p = 0.0213; figure 25F)
between groups. Post hoc analyses revealed similar trends between phosphorylated levels of
ERK isoforms versus control and phosphorylated/total levels of ERK isoforms versus control;
the VAirCBD group presented significantly increased p-ERK1, p-ERK2, p/T-ERK1 and p/TERK2 in comparison to VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05). In addition,
solely in regard to analysis of p/T-ERK1 and p/T-ERK2 levels, the L200-CBD treatment group
displayed significantly higher levels of protein ratios when compared to its higher dosage
counterpart L2000-CBD treatment group (p ≤ 0.05).
Similar to the NAcSh region, within the PFC region (Figure 15G/H/I) no significant
differences were found in regards to T-ERK in both ERK1 (F(3, 22) = 0.2756, p = 0.8424; figure
25H) and ERK2 (F(3, 22) = 0.564, p = 0.6445; figure 25H); however, significant differences
between treatment group quantifications of p-ERK1 (F(3, 22) = 8.194, p ≤ 0.001; figure 25G), p/T82

ERK1 (F(3, 22) = 4.073, p = 0.0192; figure 25I), p-ERK2 (F(3, 22) = 8.656, p ≤ 0.001; figure 25G)
and p/T-ERK2 (F(3, 22) = 5.549, p = 0.0054; figure 25I) were found. The same pattern of
significant differences between treatment groups was present in the PFC region, with the
VAirCBD demonstrating significantly increased p-ERK1, p-ERK2, p/T-ERK1 and p/T-ERK2
levels in comparison to all other treatment groups (p ≤ 0.05).
Taken together, these findings from the ERK molecular assay suggest that the EEpotentiated anxiolysis elicited following L2000-CBD treatment observed previously in
behavioral paradigms likely does not involve significant modulation of ERK activity from
baseline levels (as presented by the non-significance in p/T-ERK1/2 levels between L2000-CBD
and VAirVPBS treatment groups in both PFC and NAcSh experimental analyses). Furthermore,
similar to the previous GSK3β and Akt analyses, the lack of significant differences (albeit in the
presence of a trend) between treatment groups following linalool administration in the control
analysis suggests that linalool likely does not modulate ERK activity on its own; however the
significant reduction of p/T-ERK levels following L2000-CBD treatment (compared to
VAirCBD) in both PFC and NAcSh experimental analyses present the notion that linalool is
potentially involved in allosteric modulation of ERK activity above a certain threshold level. In
addition, the fact that L200-CBD treatment achieved significantly higher p/T-ERK1/2 levels in
the NAcSh experimental analysis suggests that a dose-dependent attenuation of intra-NAcSh
p/T-ERK1/2 levels resulting from olfactory exposure to increasing dosages of linalool may be a
mechanism of action through which L2000-CBD treatment elicits its EE-potentiated anxiolysis
observed previously in the behavioral assays.
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4.4 JNK Protein Analysis
In a similar manner to the GSK-3β, Akt, and ERK protein analyses, no significant
differences were found between treatment groups in the control analysis of either the JNK1
isoform (p- JNK1: F(2, 11) = 0.7413, p = 0.4989 [figure 26A]; T- JNK1: F(2, 10) = 3.133, p = 0.0878
[figure 26B]; p/T- JNK1: F(2, 10) = 0.1874, p = 0.8320; [figure 26C]) or JNK2 isoform (p- JNK2:
F(2, 11) = 0.3476, p = 0.7139 [figure 26A]; T- JNK2: F(2, 10) = 2.752, p = 0.1116 [figure 26B]; p/TJNK2: F(2, 10) = 0.1727, p = 0.8439 [figure 26C).
Interestingly, when observing experimental analysis results within the NAcSh region as
shown in figure 16D/E/F, significant differences between treatment groups were only found
within the quantification of p-JNK1 (F(3, 19) = 3.827, p = 0.0267; figure 26D) and not within any
other assessment of JNK1 protein levels (T- JNK1: F(3, 19) = 3.052, p = 0.0536 [figure 26E]; p/TJNK1: F(3, 19) = 2.899, p = 0.0618 [figure 26F]) or JNK2 protein levels (p- JNK2: F(3, 19) = 2.872,
p = 0.0634 [figure 26D]; T- JNK2: F(3, 19) = 2.779, p = 0.0693 [figure 26E]; p/T-JNK2: F(3, 19) =
1.569, p = 0.2298 [figure 26F]). Post hoc analyses of p-JNK1 quantification revealed
significantly increased expression levels by the VAirCBD group when compared to its respective
VAirVPBS and L2000-CBD treatment groups (p ≤ 0.05).
ANOVA analyses of PFC region JNK quantification revealed a stark contrast to NAcSh
region results (figure 16G/H/I). While non-significance was found between treatment groups
when assessing T-JNK1 (F(3, 29) = 0.7696, p = 0.5204; figure 26H) and T-JNK2 (F(3, 29) = 0.5617,
p = 0.6446; figure 26H), significant differences were found in the analysis of p-JNK1 (F(3, 29) =
5.746, p = 0.0033; figure 26G), p/T- JNK1 (F(3, 29) = 6.781, p = 0.0013; figure 26I), p-JNK2 (F(3,
29) =

4.885, p = 0.0072; figure 26G) and p/T-JNK2 levels (F(3, 29) = 3.824, p = 0.0201; figure 26I)

between treatment groups. In both p-JNK1 and p-JNK2 post hoc analyses, the VAirCBD group
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demonstrated significantly increased expression levels when compared to VAirVPBS and L2000CBD treatment groups (p ≤ 0.05); unlike p-JNK1 however, p-JNK2 analysis also demonstrated
the L200-CBD group to exhibit significantly higher quantification than the L2000-CBD group (p
≤ 0.05). Between p/T-JNK1 and p/T-JNK2 post hoc analyses however a pattern of significant
differences between groups was found, with both the VAirCBD and L200-CBD groups
expressing higher quantification levels compared to VAirVPBS and L2000-CBD treatment groups
in their respective cohorts of analysis (p ≤ 0.05).
Similar to previous molecular analyses, these findings from the JNK molecular assay
suggest that the EE-potentiated anxiolysis elicited following L2000-CBD treatment observed
previously in behavioral paradigms likely does not involve significant modulation of JNK
activity from baseline levels (as presented by the non-significance in p/T-JNK1/2 levels between
L2000-CBD and VAirVPBS treatment groups in both PFC and NAcSh experimental analyses).
Furthermore, the non-significance (albeit in the presence of a trend) between treatment groups
following linalool administration in all measures within the control analysis suggests that linalool
likely does not modulate JNK activity on its own. However, the significant reduction of intraPFC p-JNK1/2 levels (as well as intra-PFC p/T-JNK1/2 levels) following L2000-CBD treatment
(compared to VAirCBD) suggests the notion that linalool is likely involved in allosteric
modulation of JNK activity above a certain threshold level. In addition, similar to patterns found
in Akt and ERK molecular assays, the fact that L200-CBD treatment achieved significantly
higher p/T-JNK1/2 levels in the PFC experimental analysis suggests that a dose-dependent
attenuation of intra-PFC p/T-JNK1/2 levels resulting from olfactory exposure to increasing
dosages of linalool may serve to be a component mechanism of action through which L2000CBD treatment elicits its EE-potentiated anxiolysis (observed in the behavioral assays).
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Discussion
The findings of this thesis demonstrate for the first time the potential presence of the
Entourage Effect between linalool and CBD in establishing a greater anxiolytic effect than their
individual administrations. While previous studies had demonstrated the CBD and linalool’s
modes of action through positive allosteric modulation of GABAARs and p-ERK
downregulation, this study highlighted the importance of these mechanisms specifically
following administration within the Nucleus Accumbens Shell (NAcSh) region. In light of the
hypothesis set forth which proposed EE-potentiated anxiolytic effects present in both symptoms
and biomarkers, these findings which demonstrate that significantly increased anxiolytic effects
of the combinatorial treatment (linalool and CBD) observed in behavioral assays were negatively
correlated with GABAAR inhibition and p-ERK activation, suggests that the linalool-CBD
anxiolytic interaction dynamic likely involves a unique mediation of neuronal activity and
cellular MAPK pathways not achieved by their individual administrations.
Baseline Treatment Cohort: EE-Potentiated Anxiolytic Effects in Behavioral Assays
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Regarding bright-space and fear-memory related anxiety, the EE-potentiated anxiolytic
effect of linalool and CBD in comparison to their individual administrations was readily
apparent. Within the light dark box and contextual fear conditioning assays, the combined
2000µL linalool and 5ng/0.5µL CBD treatment yielded much greater decreases in anxiety
symptoms than did their individual administrations (2000µL linalool or 5ng/0.5µL CBD),
suggesting that the observed EE-potentiated anxiolysis is superiorly effective in alleviating
bright-space and fear memory-related anxiety. These findings are consistent with those published
currently in the literature surrounding the anxiolytic potential of individual cannabidiol (Fogaca
et al., 2014; Gomes et al., 2010; Lemos et al., 2010; Long et al., 2010; Resstel et al., 2006) and
linalool treatments (Coelho et al., 2018; Harada et al., 2018) in these test paradigms.
Furthermore, in the context of the CFC behavioral assay, this EE-potentiated anxiolysis exhibited
by the L2000-CBD treatment was present in both the acquisition and recall scenarios, suggesting
that the treatment is potentially effective in both the prevention of anxiety stemming from fear
memory consolidation and the recall of such fear-related memory events. When taking into
account the observation that locomotor differences between groups were absent as documented
by Linck et al. (2010) and Long et al. (2010) following acute linalool and CBD administrations
respectively, this in turn presents the notion that this EE profile may uniquely affect the limbic
region (known for affective processing) without altering motor cortex functionality (Ali et al.,
2015; Guimaraes, 2004).
Interestingly, while the L2000-CBD treatment presented EE-potentiated anxiolysis within
these behavioral test paradigms, the lesser linalool-CBD combination treatment of L200-CBD
did not elicit significantly different freezing time compared to either of its component vehicle
groups (VAirCBD or L200-VPBS) and only expressed significant differences to its VAirCBD
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vehicle counterpart in the secondary bright-space anxiety measure of total transitions. Yet,
despite this contrast in EE-potentiated anxiolysis between L200-CBD and L2000-CBD
treatments, no significant differences were found between the two groups in all test paradigms—
suggesting the lack of a conclusive dose-dependent response in the combinatorial administration
of linalool and CBD (with respect to comparisons between 200 μL and 2000 μL). These findings
of non-significance but increasing trends of anxiolytic efficiency with greater linalool dosage
administrations has been documented by Coelho et al. (2018), presenting the notion that there
may be a moderate dose-dependent curve in linalool anxiolytic efficiency.
The overall lack of significant differences between treatment groups when assessing
social cognition measures within the social motivation and recognition test suggests that there is
no EE-potentiation in social cognitive abilities or associated anxiety following linalool-CBD
dual treatment. Although this observation stands in contrast to the finding established by Linck et
al. (2010) whereby linalool induced greater social interaction time (equivalent to greater social
motivation values), these findings align with the non-significance found from administration of
CBD-alone treatments (Long et al., 2010; Malone et al., 2009). In addition, while an olfactory
administration of linalool was used in the context of this thesis, Linck et al had employed
intraperitoneal linalool administrations; given that Takahashi et al. (2011) had found linalool
acetate to be essential in eliciting anxiolytic effects observed in the EPM test paradigm, this
suggests that the interaction between linalool and its formed metabolites following systemic
metabolism of pure linalool may be responsible for this difference in observed social behaviors.
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Linalool-CBD combinations demonstrated anxiolysis in the EPM assay only following CUS
exposure
Although results from the chronic stress cohort demonstrated significant differences
between CUS-exposed VAirVPBS and L2000-CBD treatment groups in the EPM assay, this was
not the case in the baseline cohort. Indeed, while the LDB and CFC assays suggested the
presence of an EE-potentiated anxiolysis following L2000-CBD treatment, this phenomenon was
not found in the EPM test anxiety measures within the baseline cohort as currently observed in
the literature surrounding CBD and linalool’s individually observed anxiolytic effects (Bradley
et al., 2007; Campos and Guimarães, 2008; Harada et al., 2018). It should be noted, however,
that different modes of administration (intracranial versus intraperitoneal, dorsolateral
periaqueductal gray versus NAcSh) as well as duration of drug administration (acute versus
chronic) have been employed to achieve these results in the aforementioned studies; thus,
significant differences between observed results and literature findings may stem from
differences in testing methodologies. Furthermore, when taking into consideration studies
incorporating intracranial infusion of CBD into brain regions within the mesolimbocortical
pathway (PFC, hippocampus) and within closer anatomic proximity to the NAcSh (PFC), no
significant differences were found in anxiety measures assessed in the elevated plus maze test
and other open-space anxiety test assays (Hudson et al., 2019; Szkudlarek et al., 2019).
Another potential basis for these findings may be attributable to the notion that the EEpotentiated anxiolysis of L2000-CBD attenuates different forms of anxiety to differing degrees,
especially depending on the behavioral paradigm used; specifically, while this potentiated
anxiolysis may be present in the reduction of bright-space and fear- memory anxieties as
observed respectively in the LDB and CFC assays, it may not be as relevant in the context of
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open-space anxiety assessed in the EPM assay. This line of inquiry has been supported by
Miyakawa et al (2003), who found that rodent models expression of anxiety measures between
the LDB and EPM tests were not always consistent—suggesting either differences in
environmental conditions or measures of different forms of anxiety being the cause of this
observed phenomenon (Takao and Miyakawa, 2006). Furthermore, even in the consideration of
schizophrenic rodent models (C57BL/6J) where CBD treatment is proposed to have a significant
reduction in anxiety, the same anxiolytic profile was not observed between the two tests
following CBD treatment (Long et al., 2010; Schleicher et al., 2019).
Taking into account the fact that post hoc analyses of open-field thigmotaxis (via
center/total locomotion ratio assessments) conducted in the flumazenil and EPA challenge
cohorts revealed the L2000-CBD group to yield significantly reduced open-space anxiety when
compared to the VAirVPBS control group, this ultimately suggests that the non-significance within
baseline cohort assessments involving EPM anxiety measures is likely attributable to a
combination of differences in methodology and varying sensitivity between assays in assessing
specific forms of anxiety—and that these variations in environmental conditions or sensitivity to
such fluctuations which may play a role in the generation of non-significance essentially did not
influence CUS-exposed models in the same manner.
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GABAAR inactivation reversed EE-potentiated anxiolytic effects

Significant increases in LDB and CFC anxiety measures exhibited by L2000-CBD
subjects following co-administration of the GABAAR antagonist flumazenil suggests that
GABAAR activation is essential in the EE-potentiated anxiolysis induced through L2000-CBD
treatment. While assessment of L2000-CBD effects is a novel venture, the lack of significant
differences between control and flumazenil vehicle groups in these tested assays and flumazenil
attenuation of BDZ-site agonist-induced anxiolysis have been documented in the existing
literature (Clément et al., 2009; Herzog et al., 1996; Hussain et al., 2015; Rex et al., 1996). In
addition, the observed lack of locomotor differences between co-administrations of flumazenil
with L2000-CBD and L2000-CBD only treatments found here are in line with previous findings
in the baseline cohort—reinforcing the notion that L2000-CBD treatment likely does not impair
motor function, and thus flumazenil would not be expected to elicit any alternations in locomotor
activity. Interestingly however, the assessment of OFT open-space anxiety introduced in the
flumazenil challenge cohort demonstrated that while locomotor abilities of test subjects did not
significantly differ between treatment groups, L2000-CBD treatment generated significantly
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reduced open-space anxiety symptoms as evidenced by the significantly greater center/total
locomotion percentage ratios in comparison to the VAirVPBS group. In addition, the significantly
increased open-space anxiety exhibited by the L2000-CBD+flumazenil group when compared to
the flumazenil-free L2000-CBD group counterpart suggests that GABAAR antagonism plays a
key role in attenuating L2000-CBD induced open space anxiety in the OFT assay.
Delving further into the EE-potentiated anxiolysis presented in the LDB and CFC assays,
it is important to mention that given the absence of significant differences between control
vehicles and flumazenil treated control vehicles in conjunction with significantly increased
anxiety exhibited by the L2000-CBD+flumazenil group (in contrast to its L2000-CBD group
counterpart) in these two assays, this suggests that flumazenil attenuations of L2000-CBD
anxiolysis may stem from mostly antagonist-exogenous compound interactions rather than
antagonist-endogenous compound interactions. A plausible explanation for this phenomenon
includes the possibility that flumazenil competitive inhibition of GABAARs following intraNAcSh administration in control vehicles induces changes in neuronal activity that are not
significant enough to be translated to behavioral changes—but that in the presence of an
increased number of neuronal populations being hyperpolarized due to L2000-CBD treatment,
flumazenil antagonism of L2000-CBD induced molecular mechanisms is significant enough to
translate into a reversion of observed behavior in L2000-CBD treated subjects.
Given that the literature has documented the greatest change in GABA EC50 to be elicited
by CBD following allosteric modulation at α2 subunit configurations (Bakas et al., 2017) and
primarily for linalool at α1 subunit configurations (Kessler et al., 2014; Milanos et al., 2017), this
differential modulation of GABAAR subunits provides support for EE-potentiated anxiolysis of
L2000-CBD—and given that flumazenil has been found to primarily target α1/α2/α3/α5 subunit
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configurations (Huang et al., 1998; Wieland and Lueddens, 1994), its administration and
subsequent competitive inhibition at these sites would be expected to result in the behavioral
observations seen in this experimental challenge cohort. This hypothesized mechanism of action
would especially help explain the L2000-CBD induced reduced fear recall that was reversed by
flumazenil treatment, as Schmitz et al. (2017) had demonstrated decreased hippocampal GABA
levels to result in dysfunctional suppression of memory recall. Furthermore, in consideration of
the connections between the olfactory bulb, the entorhinal cortex and hippocampus as previously
mentioned (Christen-Zaech et al., 2003; Vanderwolf, 1992), this GABAAR-mediated anxiolytic
theory provides a potential explanation for downstream effects elicited by activation of the
olfactory system upon linalool inhalation.
Although promising, further in-vitro investigations assessing co-administrations of
linalool and CBD on GABA EC50 however are required to substantiate correlational claims
between potential synergism surrounding EE-potentiated GABA current induction and the
antagonistic effects elicited by flumazenil on the molecular and systems level.
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Activation of p-ERK reversed EE-potentiated anxiolytic effects

\

The attenuation of EE-potentiated anxiolytic effects following EPA coadministration
observed in the EPA challenge cohort suggests that p-ERK activation is a key regulator of
mechanistic pathways utilized by L2000-CBD treatment to elicit its observed anxiety reduction
in test subjects. Non-significance findings between control vehicles and EPA-treated vehicles in
these assays are representative of the currently established literature (Einat et al., 2003; SierraFonsecaet al., 2019). Furthermore, regarding interactions between p-ERK and CBD, Hudson et
al. (2019) had found (utilizing the same mode of acute EPA administration via intra-vHipp) that
EPA administration—and consequently, increased p-ERK expression—was able to significantly
attenuate the anxiolysis induced by the combinatorial administrations of THC and CBD within
the LDB and CFC [acquisition] assays. Lastly in line with previous test cohorts, no significant
differences in locomotion was detected between groups, suggesting the lack of locomotor
impairments as a result of EPA treatment and the confirmation of no potential confounder in
subsequent assays as a result of locomotor differences.
This finding of non-significance in locomotor differences is particularly interesting in
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light of the fact that co-treatment of intra-cranial EPA and L2000-CBD resulted in the
elimination of OFT open-space anxiolysis, which was found present following L2000-CBD
treatment as shown by stark contrasts in center/total locomotion (%) performance—
demonstrating a similar pattern of results to the OFT anxiety assessment conducted by Hudson et
al. (2019). Although Hudson and authors utilized group comparisons which are not directly
comparable with the results in this study (as THC+CBD and EPA+THC+CBD groups were used
as opposed to L2000-CBD and L2000-CBD+EPA groups), the significantly increased openspace anxiety observed following the addition of EPA to THC+CBD combination treatments is
especially notable due to the fact that it provides a comparative assessment p-ERK effects on
EE-potentiation; as despite these obvious differences in EE combination components (CBD &
THC versus CBD & linalool), the study provides at least a rudimentary foundation to refer to in
the pursuit of correlations between p-ERK levels and novel EE combinations, such as the one
between CBD and linalool explored in this thesis. In addition, while elevated p-ERK expression
is known to result in downstream gene expression alterations over a long-term basis, the acute
findings in this thesis and those made by Hudson et al. (2019) suggests that the observed
attenuations in anxiety likely stems from fast-acting targets downstream of increased p-ERK
activation. This aligns with observations made in a review conducted by Peng et al. (2010)
highlighting the correlation between increased p-ERK and two receptors involved in long term
potentiation (LTP) memory receptors, the NMDA and AMPA receptors. Given the results in the
CFC assay which involves fear memory formation and subsequent recall, the increased freezing
time exhibited by test subjects who received co-administrative L2000-CBD and EPA treatment
suggests that the observed EE-potentiated anxiolysis likely involves either inactivation or fastacting downregulation of these target receptors and their subsequent synaptic alterations.
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As previously mentioned, correlations between ERK activation and linalool have also
been studied by Caputo et al. (2016; 2017; 2018) who discovered through in-vitro assays that
linalool was able to inhibit ADCY1, p-ERK and PKA expression within the SH-SY5Y cell line.
PKA has been shown to be essential in a host of cellular activities, including the regulation of
NMDARs and stimulation of downstream CREB-dependent transcription, both of which are
implicated in memory formation (Impey et al., 1998). ADCY1, which catalyzes the formation of
cAMP and thus is innately involved in the subsequent activation of PKA, has been found
upregulated in the nucleus accumbens of subjects with fear memory and associated anxiety (Du
et al., 2019); even more relevant in its study is the discovery that the lack of ADCY1 has been
directly linked to lowered sustainability of contextual memories, such as those acquired in the
CFC assay (Shan et al., 2008). Given the imaging findings of ERK and PKA co-activation during
LTP structural changes by Tang and Yasuda (2017) as well as the fact that ERK-mediated
signaling is a downstream target of ADCY1 activation, artificial p-ERK activation via EPA
administration provides a plausible explanation for the loss of behavioral effects previously seen
following linalool administration.
While these initial findings suggest ERK phosphorylation levels to be vital in regulating
EE-potentiated anxiolysis induced by L2000-CBD, it should be mentioned that the effects
observed following EPA administration undoubtedly involves ERK interaction with other
proteins and their associated signaling pathways, such as the PI3K (phosphoinositide 3-kinase)
pathway known to be implicated in crosstalk activity as well as regulation of the MAPK/ERK
pathway (Steelman et al., 2011; Won et al., 2012). Thus, while these initial findings provide
insight into the gross relations between EPA administration and associated reductions in EEpotentiated anxiolytic efficiency, further investigations studying associated crosstalk proteins
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(alone and in tandem) are required to elucidate the exact molecular mechanisms underlying these
behavioral correlations.
Chronic Unpredictable Stress: EE-Potentiated effects in behavioral assays

Utilizing the novel chronic unpredictable stress (CUS) protocol established by former
laboratory researcher Dr. Justine Renard, no significant differences in locomotor activity were
found while significant differences were observed between treatment groups in the light dark box
and three-chamber social interaction test that suggest the presence of EE-potentiated effects.
Although employing different variants of the CUS protocol, various studies have reported similar
findings of relatively equal locomotor activity but increased perceived anxiety by CUS-exposed
subjects when compared to non-stressed controls (Kaufmann and Brennan, 2018; Monteiro et al.,
2015). Interestingly, the inability of L2000-CBD to reverse the observed anxiety in the CUS-
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VAirVPBS group stands in contrast to these literature findings and previous results of open-space
anxiolysis observed between L2000-CBD and VAirVPBS groups in the challenge cohorts. While
longer duration (4-8 weeks) and variations in CUS protocols, as well as use of mouse models
may explain the differences in OFT results between those found in the literature (Kaufmann and
Brennan, 2018; Monteiro et al., 2015) and this study, discrepancies concerning significant
differences comparing L2000-CBD and VAirVPBS vehicle groups between challenge cohorts and
the chronic stress cohort are very likely to be attributable to vast variations in animal handling
duration prior to testing. Specifically, the fact that the L2000-CBD and VAirVPBS groups
experienced increased handling durations (an extra 14 days prior to testing due to CUS protocol
procedures) compared to their equivalents in the challenge cohort likely resulted in a significant
reduction of baseline anxiety levels; combined with the fact that the OFT assay was also
conducted relatively early on in the testing timeline following minimally stressful behavioral
assays (SA and NOR), it is entirely plausible that the reduced baseline anxiety levels remained
present during open field testing—effectively attenuating significant differences in open-space
anxiety previously observed in the challenge cohorts between the L2000-CBD and VAirVPBS
groups.
Studies employing CUS protocol variants have also documented chronically stressed
rodent models exhibiting significant increases in anxiety symptoms compared to their nonstressed control counterparts within the light dark box (Beery et al., 2012; Cancela et al., 1995;
Nasca et al., 2015) and elevated plus maze behavioral assays (Kaufmann and Brennan, 2018;
Monteiro et al., 2015; Rudyk et al., 2019). These established literature findings are consistent
with the observed anxiety measures in the LDB test, where a pre-planned t-test comparison
between VAirVPBS and CUS-VAirVPBS groups revealed the non-stressed group to exhibit
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significantly greater exposure in the light compartment. Interestingly however, this correlation
between vehicle groups was only moderate in nature within the EPM assay (t(14) = 1.872, p =
0.082; data not shown); this reduction of stress model efficiency may be attributable to the fact
that the employed CUS protocol was shorter in nature (2 versus 3 weeks exposure to CUS in the
aforementioned studies) and that the EPM test was conducted 14 days after cessation of the CUS
protocol (designated last in the battery of tests) in comparison to the LDB test which was carried
out 7 days following protocol termination.
Despite this lag in testing, the L2000-CBD treatment was found to result in significantly
reduced anxiety within both the LDB and EPM assays, as was observed with the significantly
increased exploration in the light compartment and open arms exhibited by the CUS-L2000-CBD
group in comparison to its CUS-VAirVPBS counterpart—suggesting that in the context of chronic
stress conditions, L2000-CBD treatment may be effective in alleviating both augmented levels of
bright-space and open-space anxieties. When considering the establishment of EE-potentiated
anxiolysis between L2000-CBD and its vehicle counterparts (VAirVPBS, VAirCBD, L2000-VPBS)
in the baseline cohort as well as assessing the similarities in observed behavioral phenomenon
between chronic control and experimental groups, the inference of EE-potentiation within these
chronic stress behavioral assays stands to be of merit. While Campos et al. (2013) and
Saiyudthong et al. (2016) have demonstrated individual administrations of CBD or linalool to be
effective in reversing chronic stress-induced alterations observed in anxiety and depression
behavioral assays respectively, their use of daily intraperitoneal administrations starkly contrasts
the single pre-test intracranial drug infusions employed within this thesis. Thus, to date, the
persistence of conceivable EE-potentiated anxiolysis within chronic stress settings remains a
plausible line of inquiry.
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Although there were clear differences in the degree of anxiety symptoms presented
between CUS-exposed and non-stressed treatment groups in anxiety assessments, results from
pre-planned t-test comparisons (data not shown due to non-significance) and ANOVA analysis
of SA and NOR tests suggest that working and long-term memory were not impaired in
chronically stressed vehicle models. The non-significance found in these memory cognition tests
are consistent with findings from Sadowski et al. (2009), Bowman et al. (2006) and Foyet et al.
(2017), with the latter employing a CUS protocol most similar in nature to the one used in this
thesis. However, despite the lack of memory impairments in CUS rat models, CUS-VAirVPBS
subjects were found to exhibit significantly lower SMI and SRI values versus non-stressed
VAirVPBS in stages 2 and 3 respectively of the social motivation and recognition test. This
deficiency in both social motivation and recognition is consistent with the existing literature
assessing effects of chronic stress on equivalent social interaction measures between nonstressed and chronically stressed vehicle groups (Van der Kooij et al., 2014; 2014a; Zain et al.,
2019).
The fact that no apparent memory deficits were found between groups within the chronic
stress cohort suggests that the significant SMI and moderate SRI deficits presented by CUSexposed control subjects (in comparison to stress-free VAirVPBS subjects) likely stem from
affective processing dysfunction rather than diminished memory capabilities. This finding is
particularly interesting in light of the literature surrounding the impact of chronic stress on
different brain regions. For while the hippocampus, which is well-known for its involvement in
the recall of episodic memory (Ross et al., 2018), can endure several weeks of chronic stress
before undergoing structural alterations (Mcewen, 2004), atrophy of dendrites within the PFC
has been found to result after a one week duration of CUS or even a single exposure event to
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such stressful conditions (Brown et al., 2005; Izquierdo et al., 2006). Given that the PFC is one
of the key components within the mesolimbocortical pathway involved in affective processing
and executive decision making, structural atrophy of this region—and in particular, degradation
of its connections to the amygdala—would help explain the decreased sociability and social
novelty exhibited by CUS-treated vehicle groups, as the loss of PFC regulation over the
amygdala would provide a likely explanation for this observed phenomenon in the absence of
memory impairments (Liu et al., 2020).
Given that L2000-CBD treatment was able to reverse SMI and SRI deficits to a moderate
and significant degree respectively in CUS-treated subjects, this in turn suggests that the
consequentially inferred EE-potentiation likely involved altered activation of the PFC and
associated brain regions in eliciting the changes in observed behavioral phenomena. Taking into
consideration that CBD and linalool have both been well documented to act on 5-HT1A and
GABAA receptors which are essential in the regulation of neuronal activity, the fact that vast
numbers of these receptors reside within brain regions such as the PFC and amygdala lends
credence to potential mechanisms of action underlying observed EE-potentiated effects (Albert
et al., 2014; Ghosal et al., 2017; Liu et al., 2014). Ultimately however, further investigations will
need to be pursued to address this mechanistic line of inquiry pertaining to EE-potentiation and
brain region activation.
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Molecular Profiles underlying EE-potentiated Anxiolysis

When assessing the possibility of an EE-potentiated anxiolysis between CBD and linalool
(2000μL), it is important to not only observe effects on a systems behavioral level but also on the
molecular level to potentially determine any underlying mechanisms that may correlate between
the two phenomena. While certain trend patterns were observed, the lack of significant
differences in all p/T protein expressions between VAirVPBS and the linalool vehicles (L200-VPBS
and L2000-VPBS) suggests that odorous linalool administration on its own, whether at the 200 or
2000μL dosage, does not yield notably different protein activation profiles compared to vehicle
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conditions. Notably, this molecular observation correlates with the relative lack of significant
differences between linalool vehicles and the VAirVPBS treatment group found in the majority of
one-way ANOVA analyses evaluating behavioral assay results.
In contrast, while no significant differences in p/T protein expression were found
between the VAirVPBS and L2000-CBD groups, the VAirCBD group presented significantly
different protein levels compared to the L2000-CBD as shown in Figure 31B (these differences
are highlighted in red within the summary table). When considering the results from behavioral
assays conducted, this in turn suggests that linalool likely acts in a manner that either 1) interacts
with CBD at the receptor level via allosteric modulation or receptor-complex formation, 2) alters
the effects of downstream signaling originally induced by CBD, 3) targets proteins and their
associated pathways outside the scope of the current molecular investigations or 4) results in a
combination of all these potential mechanisms. While addressing these mechanistic potentials
however, the results of each protein will be discussed in relation to one another as these proteins
ultimately interact with one another in either a direct or indirect manner.
Through in-vivo investigations utilizing behavioral assays following the knockdown of
GSK3β, Crofton et al. (2017) demonstrated that decreased GSK3β expression was correlated
with reductions in anxiety-like behavior in rodent models. In relation to the thesis molecular
findings, this is particularly interesting given the fact that while there were no significant
differences found in p/T-GSK3β expression between the L2000-CBD or L2000-VPBS treatment
and the VAirVPBS group, the VAirCBD group exhibited significantly increased levels in
comparison to both the VAirVPBS group and L2000-CBD treatment groups. The increase in p/TGSK3β expression following VAirCBD administration and the subsequent decline in following
the introduction of linalool into CBD treatment formulations suggests that linalool likely acts in
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some manner as an inhibitor of GSK3β phosphorylation—in turn suggesting that L2000-CBD
treatment achieves behavioral anxiolysis by inducing molecular changes within both the PFC and
NAcSh that either utilize a GSK3β-independent pathway and/or target downstream GSK3β
effectors.
The results of the VAirCBD treatment group are supported by the current advancements in
literature, which document CBD to noticeably increase p-GSK3β expression (Fogaça et al.,
2014; Libro et al., 2016; Vallée et al., 2017); furthermore, Libro et al. (2016) and Renard et al.
(2016) had specifically noted correlations between Akt activation and observed p-GSK3β levels.
The findings of Libro et al. (2016), who utilized in-vitro assays of mesenchymal stem cells and
found CBD administration to result in increased expression of p-GSK3β and p-Akt, provide
greater support for the observed increases in these respective phosphorylated/total protein levels
following VAirCBD administration; unfortunately however, due to lack of specifications
regarding Ser- and Thr-residue phosphorylation, site-specific correlations cannot be referenced
to. Interestingly however, Renard et al. (2016), whom utilized the same intra-NAcSh delivery of
CBD employed in this thesis, discovered significantly decreased p/T-GSK3β levels concurrent
with significantly decreased p/T-Akt levels in CBD-treated versus vehicle-treated AMPHsensitized rats, further supporting the findings of Libro et al. (2016). This exception to the
classical antagonistic relationship between the two proteins has in fact been documented by
Beurel et al. (2015), who noted that Akt serine-phosphorylation does not result in absolute
inhibition of GSK3 activity—and that in some cases such as the combined inhibitory
phosphorylation of AMP-activated kinase (AMPK) by GSK3 and Akt, the two proteins can work
in a cooperative rather than antagonistic manner. While the AMPH-sensitization of rat models
used by Renard and authors does not provide an ideal comparison to the models utilized in this
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thesis, the combined findings of Libro et al. (2016), Renard et al. (2016) and Beurel et al. (2015)
nonetheless suggest that CBD may elicit its effects through a mechanism of action that bypasses
the Akt/GSK-3 signaling pathways, providing an interesting finding that contrasts traditional
associations of inversely-correlated protein activity between GSK3β and Akt (Sani et al., 2012),
as well as a potential component mechanism of action through which L2000-CBD elicits EEpotentiated anxiolysis.
In contrast to the documented increase in inhibition of GSK3β following CBD treatment,
the molecular literature surrounding linalool focuses on Akt, and thus in extension, its
downstream regulation of GSK3β. An in-vitro study conducted by Pan and Zhang (2019)
observed in a clear-cut manner that linalool exposure (μM range) resulted in a dose-dependent
decrease in both phosphorylated PI3K and Akt, while expression of non-phosphorylated PI3K
and Akt remained unchanged. Although no significant differences between linalool-vehicles and
the control condition were observed in-vivo in this thesis when assessing either p/T-GSK3β or
p/T-Akt, the results of Pan and Zhang help to explain the significant reduction in both protein
expressions observed in the L2000-CBD treatment group (when compared to the VAirCBD
group)—ultimately suggesting that linalool may antagonize CBD-mediated effects on GSK3β
and Akt through inhibition of the PI3K/Akt pathway. Interestingly however, Rodenak-Kladniew
et al. (2018) had found that when employing a higher concentration of linalool in-vitro (in the
range of mM rather than μM), there was a negative correlation between phosphorylated Akt
levels and linalool concentration trending towards non-significance between the vehicle and 2.0
mM (highest dosage) linalool exposure groups; nonetheless, 1.0 and 1.5 μM of linalool
concentration exposures were sufficient to elicit significant declines in phosphorylated Akt levels
compared to control conditions. While this discrepancy in findings between the two in-vitro
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studies may be attributable to differences in the cell line utilized (OECM-1 vs. HEPG2
respectively), it potentially proposes the fascinating concept of a biphasic effect profile for
linalool on the molecular level that presents at specific dosages and via particular administration
routes. Consequently, given that these referenced studies involved direct contact of pure linalool
with cell cultures, further investigation utilizing intraperitoneal injections of linalool with rat
animal models can help clarify whether this dose-dependent response is replicable within in-vivo
models and in turn confirm whether there are significant differences in molecular activity
profiles between odorous and intraperitoneal exposures to linalool.
When analyzing the potential mechanistic pathways through which these proteins elicit
their effects, it is important to consider the duration of treatment administration (which was
acute, or at most arguably sub-chronic in nature). Thus, while alterations in GSK3β and Akt
activity are known to induce long-term changes through nuclear localization of downstream
target effectors and subsequent changes in mRNA production (Steelman et al., 2011), short-term
changes are crucial to consider in the context of acute/sub-chronic treatment protocols. A
relatively acute mode of action to consider is the ability of GSK3β to inhibit NMDAR-dependent
LTP and induce NMDAR-dependent LTD (long-term depression) as demonstrated by Peineau et
al. (2007); Peineau and authors had found in particular that inhibition of GSK3β during LTP via
activation of the PI3K-Akt pathway prevented synapses from undergoing LTD for up to 1 hour.
In addition, Leibrock et al. (2013) had found that while Akt2 knockout mice displayed increased
anxiety, they did not present cognitive impairments. Taking these two findings together into
consideration, it is plausible that reduced Akt activation—and consequently increased GSK3β
and LTD processes—observed in the L2000-CBD group resulted in decreased NMDAR activity
and associated NMDAR-dependent LTP that disrupted the formation of synaptic strengthening
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that would otherwise augment the consolidation of anxiety-related affections and associated
memories in anxiety assays (most notably the CFC test). This hypothesized, fast-acting
NMDAR-dependent mode of action itself is substantiated by studies demonstrating both
decreased depression and anxiety following NMDAR antagonism (Holubova et al., 2014; Vose
and Stanton, 2017). Given the roles of PFC and the NAcSh in working memory and associated
affective processing respectively, these observed findings of reduced p/T-GSK3β and p/T-Akt
levels elicited by L2000-CBD treatment in comparison its vehicle counterparts present a case for
acute resilience to environmental stressors, providing in turn an interesting line of inquiry to
pursue in further investigations assessing mechanisms underlying EE-potentiated anxiolysis
induced through L2000-CBD treatment.
In addition to GSK3β and Akt expression levels, ERK and JNK proteins have been found
to be integral in the modulation of affective processing; specifically, their increased activation
has been associated with increased anxiety-like behavior (Ailing et al., 2008; Hollos et al., 2018;
Mohammad et al., 2018; Pucilowska et al., 2015; Xiang et al., 2017; Zhao et al., 2017). When it
comes to the individual EE-components, CBD exposure (20μM) to in-vitro cultures involving
glioblastoma cells has been documented by Ivanov et al. (2017) to result in significantly
upregulated levels of p-JNK1/2, while downregulating p-ERK1/2 and p-Akt expression;
however, these p-ERK molecular results stand in contrast to the findings of McAllister et al.
(2011) who observed CBD treatment (1.5μM) to significantly increase p-ERK expression while
not affecting T-ERK expression in in-vitro cultures of human breast cancer cells (MDAMB231). While this contrast in findings may be explained by the differing nature of the cells
used, the change from upregulation to downregulation of p-ERK1/2 following an increase from
1.5 to 10 μM CBD exposure can potentially be attributed to the biphasic effects of CBD
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observed by Gallily et al. (2015) following intraperitoneal administration. Specifically, the
discovery that this biphasic effect was found present in serum TNFα levels (u-curve correlation
between increased CBD dosage and serum TNFα expression) provides support for this potential
mechanism of action, as TNFα is capable of activating ERK and JNK kinases (which would in
turn phosphorylate ERK and JNK to their active forms) (Sabio and Davis, 2014). Furthermore,
this may not only help explain the discrepancy in molecular activation profiles between the
studies conducted by McAllister et al. (2011) and Ivanov et al. (2017), but could also provide a
basis for differences in p-ERK activation following bilateral intracranial infusions utilized in this
thesis and by Hudson et al. (2019)—as Hudson and authors had documented no significant
differences in p-ERK expression between control and CBD treatment groups following 100
ng/0.5 μL CBD administration (in comparison to the 5 ng/0.5 μL used in this thesis).
Collectively, these findings not only highlight the potential for biphasic effects on the molecular
level following CBD administration but also bring to the forefront possible considerations of
TNFα being a key component in CBD’s modulatory effects on affective processing.
Contrasting the observed increase in p-ERK and p-JNK following VAirCBD
administration, the addition of linalool to CBD formulations was shown to elicit a moderate
dose-dependent decrease in p-ERK and p-JNK, with a significant reduction being observed
following the addition of 2000μL linalool as represented by the L2000-CBD treatment group.
These reductions in p-ERK and p-JNK are consistent with the current advancements in literature
regarding the molecular effects of linalool administration (Caputo et al., 2018; Gunaseelan et al.,
2017). Closer examination reveals that Gunaseelan et al. (2017) recorded in particular the
inhibition by linalool of UVB-induced (ultraviolet B rays) ROS formation and associated UVBinduced phosphorylation of ERK and JNK proteins, whilst also inhibiting the formation of
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biomarkers including TNFα (presenting TNFα-mediated inhibition of ERK and JNK pathways as
a combined target for linalool + CBD treatment). While UVB-induced ROS was evidently not
employed in this thesis, the key cellular event of ROS formation that leads to increased levels of
p-ERK and p-JNK has been observed to occur in animal models following acute (≤ 1 hour) or
chronic stress exposure (Huber et al., 2017; Nadeem et al., 2006; Zafir and Banu, 2009). As a
result, these findings correlating ROS activity and decreased p-ERK and p-JNK expression
following linalool exposure are arguably applicable to the thesis molecular observations, as these
protein analyses were ultimately conducted following acute/sub-chronic stress exposures of
rodent models.
Expanding on the work of Caputo and authors, in addition to inhibitions of p-ERK in the
SH-SY5Y neuroblastoma cell line, studies conducted (2016; 2017; 2018) had shown that
ADCY1 and PKA expression were also reduced in SH-SY5Y cells following linalool
administration. Given that the activation cascade of ADCY1/cAMP/PKA leads to the initiation
and maintenance of CREB alterations on the genomic level that are instrumental in the prognosis
of mood disorders (Dwivedi and Pandey, 2008) as well as the fact that PKA activity has shown
to be crucial in initiating neurite extension (Sánchez et al., 2004), some of the contributory
effects of linalool towards EE-potentiated anxiolysis may be attributable to the previously
mentioned regulation of LTP/LTD events in affective formation and processing. The linaloolinduced downstream modulation of PKA activity is particularly interesting to note given that invitro studies conducted by Poisbeau et al. (1999) demonstrated that PKA activation in adult
hippocampal neurons decreased GABAAR current amplitudes, providing a correlation between
the findings of Caputo et al. (2016; 2017; 2018) and the significantly reduced anxiolysis
exhibited by the L2000-CBD+flumazenil in the flumazenil challenge cohort. Altogether, these
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studies highlight a mechanism of action unique to linalool that potentially differentiates the lack
of anxiolysis observed following VAirCBD treatment from the presence of EE-potentiated
anxiolysis following L2000-CBD treatment. It is interesting to note however that while
significant differences between treatment groups were present in regard to p/T-JNK1/2 and p/TERK1/2 levels, these differences were relatively region-specific. Increasing dosages of linalool
exposure beginning with the linalool-free VAirCBD treatment led first to reductions in PFC p/TJNK1/2 levels, with even greater dosage exposure of 2000 μL linalool yielding reductions in
both the PFC and NAcSh regions (when compared to VAirCBD group data); furthermore, p/TERK1/2 levels exhibited by VAirCBD and L200-CBD groups were only significantly higher than
those observed following L2000-CBD treatment in the PFC, and not the NAcSh region. Given
that the drug delivery methods did not include intra-PFC administrations, these unique patterns
of phosphorylation suggest a few inter-region mechanisms of interest including NAcSh-mediated
inhibition of PFC MAPK/ERK signaling and an associated PFC-mediated reciprocal inhibition
of NAcSh MAPK/ERK signaling at higher doses of linalool (2000 μL)—both of which are
reflective of the GABAergic and glutamatergic connections between the two structures of the
corticostriatal pathway.
Altogether, these studies assessing the individual effects of CBD and linalool on ERK
activity propose a variety of mechanisms which may underlie correlations between
phosphorylated ERK levels and the EE-potentiated anxiolysis observed in the baseline cohort,
including CBD’s attenuation of TNFα levels, linalool’s reduction of ROS formation and PKA
activation (Caputo et al., 2016; 2017; 2018; Gunaseelan et al., 2017; Sabio and Davis, 2014)—all
of which have been described to result in decreased ERK activation. In addition, studies have
demonstrated that GSK3β and ERK activity are inversely correlated, with ERK-mediated
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inhibition of GSK3β activity being noted to particularly involve Akt activation (Pal et al., 2017;
Wang et al., 2006). This inverse correlation between the two proteins helps to further explain the
significant differences in molecular activation between the VAirVPBS and L2000-CBD baseline
cohort groups, as the latter has been documented to uniquely involve the inhibition of ERK, and
consequently non-inhibition of GSK3β through direct upstream PKA modulation in a linalooldependent manner whilst antagonizing CBD-mediated effects on GSK3β and Akt through
PI3K/Akt pathway inhibition as described previously (Caputo et al., 2016; 2017; 2018; Pan and
Zhang, 2019). Although western blot analysis of EPA challenge cohort data is required to
confirm this interpretation, when considering these literature findings in conjunction with the
results of reduced THC+CBD treatment anxiolysis following EPA co-administration in the study
conducted by Hudson et al. (2019) and the attenuation of L2000-CBD anxiolytic efficacy when
concurrently administered with EPA found in this study, the combined results of baseline cohort
molecular analysis and EPA challenge behavioral analysis ultimately suggests that ERK protein
activation serves as a likely antagonist of L2000-CBD mechanistic interactions that result in EEpotentiated anxiolysis.
While these proposed individual and concerted mechanisms of action for GSK3β, Akt,
ERK and JNK provide insight into the generation of EE-potentiated anxiolysis, it is also
important to consider the influence of these proteins on cell-surface receptor targets—in
particular the GABA-A receptor, to address potential correlations between systems-level,
receptor-level and intracellular activity present in the flumazenil challenge cohort data.
Interestingly, GABAAR activity has been found to be negatively correlated to GSK3β activity
through a D2-receptor mediated suppression mechanism (Beurel et al., 2015; Li et al., 2012).
Furthermore, this suppression mechanism appears to be a product of a larger signaling cascade
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involving Akt, termed the Akt/GSK3β signaling cascade (Beaulieu et al., 2007; Li et al., 2012).
Although these literature findings documenting the collective inhibitory regulation of Akt and
GSK3β on GABAAR activity correlate with p/T-Akt data following L2000-CBD treatment
observed in this thesis, there exists lack of a significant increase in p/T-GSK3β following L2000CBD treatment. While this prevents a complete correlation from being established between these
literature findings and the molecular data observed in this thesis, the exact mechanisms of action
through which the Akt/GSK3β cascade modulates GABAAR activity—whether it be through
direct modulation of phosphorylation sites or downstream effectors—remains unclear. In light of
this complexity and the research conducted by Beurel et al. (2015) detailing that certain GSK3β
protein complexes may be unaffected by inhibitory serine-phosphorylation, while the effects of
the Akt/GSK3β signaling cascade may not be directly correlated to observed thesis data, the
cascade mechanism presents nonetheless an interesting line of inquiry to pursue in investigating
the relationship between these proteins, the GABAA receptor and the EE-potentiated anxiolysis
found following L2000-CBD treatment in the baseline cohort.
In addition to Akt and GSK3β, the two MAPK proteins—ERK and JNK—have also been
found to impact GABAAR activity. Through in-vitro investigations using the HEK293 cell line,
Bell-Horner et al. (2006) demonstrated that an ERK phosphorylation site (T375) on the GABAA
receptor was essential in facilitating ERK-mediated inhibition of GABAAR activity; furthermore,
administration of UO126 (inhibitor of MEK1/2, which is an upstream activator of ERK) resulted
in the reduction of ERK phosphorylation/activation and consequently yielded increased
GABAAR peak current amplitudes. Supporting this finding is the in-vitro research published by
Brady et al. (2018), where enhancement of GABAAR activity via application of the GABAAR
agonist muscimol resulted in delayed ERK activation. Interestingly, GABAAR agonism via
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muscimol administration was also found to affect JNK pathway activity (Ma et al., 2016); a
deeper investigation specifically revealed that increased GABAAR activity as a result of GABA
or muscimol treatment resulted in significantly reduced JNK1/2 signaling activity compared to
controls and that subsequent inhibition of GABAAR activity restored JNK1/2 activity.
Collectively, these in-vitro studies (Bell-Horner et al., 2006; Brady et al., 2018; Ma et la.,
2016) demonstrate an opposing relationship between GABAAR activity and the two MAPK
proteins, ERK and JNK, which help to explain the significant decrease in p/T-ERK and p/T-JNK
levels exhibited by the L2000-CBD group when compared to the VAirVPBS group in the baseline
cohort and the corresponding differences in anxiolysis achieved by the two treatments. Lastly,
although western blot analysis of the flumazenil challenge cohort is required to substantiate these
interpretations, the correlation in findings between GABAAR activity, molecular profiles
supported by the literature and anxiolytic differences between the L2000-CBD and control
treatment groups suggests that flumazenil—which effectively attenuated the anxiolytic efficiency
of the L2000-CBD treatment to vehicle levels—and consequently GABAAR antagonism are able
to effectively reverse EE-potentiated anxiolysis elicited by L2000-CBD treatment.
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While these collections of studies help to elucidate the EE-potentiated mechanism of
CBD-linalool treatments, conclusive interpretations remain relatively difficult to establish
without further investigation. A primary concern is that although these fascinating results and
associated mechanisms may show merit, the current thesis findings and supporting studies
discussed can only at best establish a correlational impact between olfactory nervous system
activation and downstream effects on the entorhinal cortex and hippocampus (and thus episodic
memory formation). For while the literature reports that lavender oil has been shown to modulate
autonomic nerve activity and relevant signaling pathways in the CNS (Koulivand et al., 2013),
without electrophysiological investigations assessing hippocampal activity following linalool
administration, only assumptions can be made between behavioral phenomena, biomarker levels
and associated brain activity.
There also remain systems-level and molecular-level complexities to consider in the
analysis of behavioral and molecular observations following L2000-CBD treatment. On the
systems-level, given that the NAcSh forms an integral component of the greater
mesolimbocortical pathway and that the interactions between the PFC, amygdala and nucleus
accumbens as a result of their circuit connections have been deemed essential in affective
processing (Jackson and Moghaddam, 2001), this suggests that the observed molecular profiles
within the PFC region played a key role in producing the behavioral outcomes recorded
following treatment exposures. However, the manner in which mesocorticolimbic regions such
as the PFC and VTA respond to molecular changes and subsequent reciprocal regulation of
associated brain regions—notably in conjunction to the NAcSh—following L2000-CBD
administration remains unclear. As mentioned in section 1.2.3, this consideration of associated
mesocorticolimbic regions is especially important when it comes to the VTA, as there exists a
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prominent feedback system between the NAcSh and VTA that regulates dopaminergic activation
of the NAc (and associated structures) as described previously; in addition, VTA glutamatergic
inputs have shown to play a regulatory role of intra-NAc GABAergic interneurons, which
subsequently in turn modulate the inhibitory projections/ability of the NAc (Qi et al., 2016).
On the molecular level, an important complexity to consider is that significant differences
in Akt protein expression were solely found in relation to the Ser473—and not Thr308—site of
Akt. This is particularly interesting since Thr308 site-specific phosphorylation was originally
thought to be conclusive evidence of Akt activation—and yet emerging evidence suggests that
not only can the two sites regulate one another, but that downstream effects differ depending on
site-specific phosphorylation and that both sites are required to be phosphorylated for full
activation of Akt (Vadlakonda et al., 2013; Yung et al., 2011). Ultimately, further investigations
incorporating the use of electrophysiology, as well as specifically disconnection studies between
NAcSh and these associated brain regions following the use of protein-specific inhibitors
(including phosphorylation site-specific activators/inhibitors in the case of Akt) may help to
elucidate the correlation between molecular alterations and neuronal activity both within these
regions, and in relation to the NAcSh.
Last but not least, there exists the fact that within this thesis there existed a lack of
significant differences between the VAirVPBS control and L2000-CBD treatment groups on the
molecular level which did not correlate with differences observed in behavioral assays. While
this may appear as an obstacle in understanding the observed EE-potentiated anxiolysis on the
behavioral level, this interesting phenomenon can be explained by unique molecular interactions
outside of the scope of this thesis investigation as well as the possibility that there may exist
unique molecular profiles exhibited in other mesocorticolimbic associated regions (such as the
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amygdala, hippocampus) induced by L2000-CBD treatment that are different in nature when
compared to VAirVPBS treatments. Subsequently, these differences in molecular profiles may be
associated with unique modulations of neuronal activity within the mesocorticolimbic system
that can help elucidate the contrasting degrees of anxiolysis observed following the two
treatment administrations.
Nonetheless, despite these mysteries which remain unanswered and the endless molecular
interactions which potentially underlie the observed molecular profiles following treatment
administration, this exploratory thesis ultimately establishes a case for the presence of the
entourage effect between cannabidiol and linalool that augments their collective anxiolytic
potential.

Conclusions and Future Directions
As mainstream adoption of cannabis and cannabis-related products grow, there exists a
growing need for information surrounding the properties and associated mechanisms of cannabis
to ensure safe usage, whether recreational or medicinal. Furthermore, recent advances in the past
two decades regarding cannabis research has characterized the existence of various
phytocannabinoids such as CBD and THC, as well as a multitude of terpenes which have
demonstrated therapeutic properties when administered in an isolated manner. Increasingly
however, explorations are being made in the field regarding combinatorial formulations of
phytocannabinoid-phytocannabinoid and the potential for a superior therapeutic effect not
elicited by either component substance alone; this effect, known as the Entourage Effect, has yet
to be thoroughly explored in regard to phytocannabinoid-terpene formulations.
This thesis explored the potential presence of an Entourage Effect between linalool and
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cannabidiol, demonstrating for the first time using behavioral assays that a combinatorial
administration of these two compounds can yield EE-potentiated bright-space and fear-memory
induced anxiolysis in acute treatment and chronic stress settings, as well as a significant
reduction in open-space anxiety within specific contexts. In addition, this Entourage Effect was
found to be critically modulated by GABAAR regulation and ERK activation, highlighting two
potential mechanisms underlying the observed EE-potentiated anxiolysis following concurrent
administration of odorous 2000 μL linalool and intra-NAcSh 5 ng/0.5μL cannabidiol treatment.
While the lower dosage combination treatment involving 200 μL linalool and 5 ng/0.5μL
cannabidiol resulted in some instances of EE-potentiated anxiolysis, the presence of the
Entourage Effect was not as consistent as the higher linalool dosage combinatorial treatment; in
conjunction with the absence of significant differences between these two treatments, dosedependent effects cannot be concluded at this time.
Observations of molecular profiles demonstrated differential activations of GSK3β, Akt,
ERK and JNK across treatment groups when standardized against control group expression
levels. While the lack of significant differences in protein expression between VAirVPBS and
L2000-CBD groups strongly suggests there exists other associated proteins and brain regions
involved in characterizing the molecular profile elicited following L2000-CBD exposure, the
preliminary findings of this thesis suggest that the EE-potentiated anxiolysis exhibited by this
treatment group involves a unique interaction between the studied proteins and their associated
pathways not observed in either component group alone.
Although questions ultimately remain regarding the underlying mechanisms of the
observed EE-potentiated anxiolysis induced by L2000-CBD treatment, the establishment of the
Entourage Effect between the two compounds and their associated dosages opens up a new
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chapter in the therapeutic potential of cannabis and cannabis-related products—as in addition to
linalool, there exists several more terpenes with anxiolytic profiles theorized to yield EEpotentiated effects that have yet to be explored. Given the relatively safe profile of these natural
compounds when compared to conventional medications and their associated side effects, these
natural medicines present a potential complimentary treatment, or even replacement in the
treatment of anxiety and anxiety-related disorders. Furthermore, this thesis helps support
emerging evidence suggesting that the NAcSh plays an integral role in affective memory
formation and processing, thus giving greater credence to the brain region as a potential target
for treatments towards mood disorders. Thus, while future investigations involving
electrophysiological analysis, disconnection studies and associated brain regions in the
mesocorticolimbic pathway are required to further substantiate any correlations between
molecular and behavioral observations, this thesis nonetheless demonstrates the untapped
therapeutic potential of cannabis—effectively laying the groundwork for future innovations in
cannabis-related medical alternatives.

123

References
Adams, T., & Taylor, S. (2010). Safety Evaluation of Essential Oils: A Constituent-Based
Approach. In K.H. Baser & G. Buchbauer (Eds.), Handbook of Essential Oils (pp. 185-208).
Taylor & Francis Group.
Ailing, F., Fan, L., Li, S., & Manji, S. (2008). Role of extracellular signal-regulated kinase signal
transduction pathway in anxiety. Journal of psychiatric research, 43(1), 55–63.
https://doi.org/10.1016/j.jpsychires.2008.01.018
Akimova, E., Lanzenberger, R., & Kasper, S. (2009). The Serotonin-1A Receptor in Anxiety
Disorders. Biological Psychiatry, 66(7), 627-635. doi:10.1016/j.biopsych.2009.03.012
Albert, P. R., Vahid-Ansari, F., & Luckhart, C. (2014). Serotonin-prefrontal cortical circuitry in
anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor
expression. Frontiers in behavioral neuroscience, 8, 199.
https://doi.org/10.3389/fnbeh.2014.00199
Ali, B., Al-Wabel, N. A., Shams, S., Ahamad, A., Khan, S. A., & Anwar, F. (2015). Essential
oils used in aromatherapy: A systemic review. Asian Pacific Journal of Tropical Biomedicine,
5(8), 601–611. doi: 10.1016/j.apjtb.2015.05.007
Anjos, P. J., Lima, A. O., Cunha, P. S., De Sousa, D. P., Onofre, A. S., Ribeiro, T. P., Medeiros,
I. A., Antoniolli, A. R., Quintans-Júnior, L. J., & Santosa, M. R. (2013). Cardiovascular effects
induced by linalool in normotensive and hypertensive rats. Zeitschrift fur Naturforschung. C,
Journal of biosciences, 68(5-6), 181–190.
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib,
M. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors.
Pharmacological research, 119, 358–370. https://doi.org/10.1016/j.phrs.2017.02.022
Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century.
Dialogues in clinical neuroscience, 17(3), 327–335.
Bandelow, B., Sagebiel, A., Belz, M., Görlich, Y., Michaelis, S., & Wedekind, D. (2018).
Enduring effects of psychological treatments for anxiety disorders: Meta-analysis of follow-up
studies. The British Journal of Psychiatry, 212(6), 333-338. doi:10.1192/bjp.2018.49
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force On
Treatment Guide. (2008). World Federation of Societies of Biological Psychiatry (WFSBP)
Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and PostTraumatic Stress Disorders – First Revision. The World Journal of Biological Psychiatry, 9(4),
248-312. doi:10.1080/15622970802465807
Barker, M. (2004). Persistence of cognitive effects after withdrawal from long-term
benzodiazepine use: A meta-analysis. Archives of Clinical Neuropsychology, 19(3), 437-454.
doi:10.1016/s0887-6177(03)00096-9
124

Beaulieu, J. M., Gainetdinov, R. R., & Caron, M. G. (2007). The Akt-GSK-3 signaling cascade
in the actions of dopamine. Trends in pharmacological sciences, 28(4), 166–172.
https://doi.org/10.1016/j.tips.2007.02.006
Bedwell, S. A., Billett, E. E., Crofts, J. J., Macdonald, D. M., & Tinsley, C. J. (2015). The
topology of connections between rat prefrontal and temporal cortices. Frontiers in Systems
Neuroscience, 9. doi:10.3389/fnsys.2015.00080
Beery, A. K., Lin, J., Biddle, J. S., Francis, D. D., Blackburn, E. H., & Epel, E. S. (2012).
Chronic stress elevates telomerase activity in rats. Biology Letters, 8(6), 1063–1066. doi:
10.1098/rsbl.2012.0747
Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., . . . Tsichlis, P.
(1998). Akt activation by growth factors is a multiple-step process: The role of the PH domain.
Oncogene, 17(3), 313-325. doi:10.1038/sj.onc.1201947
Bell-Horner, C. L., Dohi, A., Nguyen, Q., Dillon, G. H., & Singh, M. (2006). ERK/MAPK
pathway regulates GABAA receptors. Journal of neurobiology, 66(13), 1467–1474.
https://doi.org/10.1002/neu.20327
Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M. H., Vogel Z., et al. (1998). An
entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol
cannabinoid activity. Eur. J. Pharmacol. 353, 23–31. 10.1016/S0014-2999(98)00392-6
Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S.,
Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J.
E., Zuardi, A. W., & Crippa, J. A. (2011). Cannabidiol reduces the anxiety induced by simulated
public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology: official
publication of the American College of Neuropsychopharmacology, 36(6), 1219–1226.
https://doi.org/10.1038/npp.2011.6
Beurel, E., Grieco, S. F., & Jope, R. S. (2015). Glycogen synthase kinase-3 (GSK3): regulation,
actions, and diseases. Pharmacology & therapeutics, 148, 114–131.
https://doi.org/10.1016/j.pharmthera.2014.11.016
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., WintonBrown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., Mehta, M. A., Stone, J. M.,
Tunstall, N., Giampietro, V., Kapur, S., Murray, R. M., Zuardi, A. W., Crippa, J. A., Atakan, Z.,
& McGuire, P. K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on
human brain function and psychopathology. Neuropsychopharmacology: official publication of
the American College of Neuropsychopharmacology, 35(3), 764–774.
https://doi.org/10.1038/npp.2009.184
Blacktop, J. M., Vranjkovic, O., Mayer, M., Van Hoof, M., Baker, D. A., & Mantsch, J. R.
(2016). Antagonism of GABA-B but not GABA-A receptors in the VTA prevents stress- and
intra-VTA CRF-induced reinstatement of extinguished cocaine seeking in rats.
Neuropharmacology, 102, 197–206. https://doi.org/10.1016/j.neuropharm.2015.11.013
125

Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017). Clinical
and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9Tetrahydrocannabinol. Neuropsychopharmacology, 43(1), 142-154. doi:10.1038/npp.2017.209
Bowman, R. E., Maclusky, N. J., Diaz, S. E., Zrull, M. C., & Luine, V. N. (2006). Aged rats: Sex
differences and responses to chronic stress. Brain Research, 1126(1), 156–166. doi:
10.1016/j.brainres.2006.07.047
Bradley, B., Starkey, N., Brown, S., & Lea, R. (2007). Anxiolytic effects of Lavandula
angustifolia odour on the Mongolian gerbil elevated plus maze. Journal of Ethnopharmacology,
111(3), 517–525. doi: 10.1016/j.jep.2006.12.021
Brady, M. L., Pilli, J., Lorenz-Guertin, J. M., Das, S., Moon, C. E., Graff, N., & Jacob, T. C.
(2018). Depolarizing, inhibitory GABA type A receptor activity regulates GABAergic synapse
plasticity via ERK and BDNF signaling. Neuropharmacology, 128, 324–339.
https://doi.org/10.1016/j.neuropharm.2017.10.022
Brown, S. M., Henning, S., & Wellman, C. L. (2005). Mild, Short-term Stress Alters Dendritic
Morphology in Rat Medial Prefrontal Cortex. Cerebral Cortex, 15(11), 1714–1722. doi:
10.1093/cercor/bhi048
Brum, L. F., Elisabetsky, E., & Souza, D. (2001). Effects of linalool on [(3)H]MK801 and [(3)H]
muscimol binding in mouse cortical membranes. Phytotherapy research: PTR, 15(5), 422–425.
https://doi.org/10.1002/ptr.973
Buchta, W. C., Mahler, S. V., Harlan, B., Aston-Jones, G. S., & Riegel, A. C. (2017). Dopamine
terminals from the ventral tegmental area gate intrinsic inhibition in the prefrontal cortex.
Physiological reports, 5(6), e13198. https://doi.org/10.14814/phy2.13198
Burkhouse, K. L., Jagan Jimmy, Defelice, N., Klumpp, H., Ajilore, O., Hosseini, B., Fitzgerald,
K. D., Monk, C. S., & Phan, K. L. (2020). Nucleus accumbens volume as a predictor of anxiety
symptom improvement following CBT and SSRI treatment in two independent samples.
Neuropsychopharmacology: official publication of the American College of
Neuropsychopharmacology, 45(3), 561–569. https://doi.org/10.1038/s41386-019-0575-5
Callaway, J. C. (2004). Hempseed as a nutritional resource: An overview. Euphytica, 140(1-2),
65-72. doi:10.1007/s10681-004-4811-6
Campos, A. C., & Guimarães, F. S. (2008). Involvement of 5HT1A receptors in the anxiolyticlike effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats.
Psychopharmacology, 199(2), 223–230. https://doi.org/10.1007/s00213-008-1168-x
Campos, A. C., Moreira, F. A., Gomes, F. V., Bel, E. A., & Guimarães, F. S. (2012). Multiple
mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric
disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607),
3364-3378. doi:10.1098/rstb.2011.0389
Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., …
126

Guimarães, F. S. (2013). The anxiolytic effect of cannabidiol on chronically stressed mice
depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
International Journal of Neuropsychopharmacology, 16(6), 1407–1419. doi:
10.1017/s1461145712001502
Cancela, L., Bregonzio, C., & Molina, V. (1995). Anxiolytic-like effect induced by chronic stress
is reversed by naloxone pretreatment. Brain Research Bulletin, 36(3), 209–213. doi:
10.1016/0361-9230(94)00185-4
Caputo, L., Nazzaro, F., Souza, L. F., Aliberti, L., De Martino, L., Fratianni, F., Coppola, R., &
De Feo, V. (2017). Laurus nobilis: Composition of Essential Oil and Its Biological Activities.
Molecules (Basel, Switzerland), 22(6), 930. https://doi.org/10.3390/molecules22060930
Caputo, L., Reguilon, M., Mińarro, J., Feo, V. D., & Rodriguez-Arias, M. (2018). Lavandula
angustifolia Essential Oil and Linalool Counteract Social Aversion Induced by Social Defeat.
Molecules, 23(10), 2694. doi: 10.3390/molecules23102694
Caputo, L., Souza, L. F., Alloisio, S., Cornara, L., & De Feo, V. (2016). Coriandrum sativum and
Lavandula angustifolia Essential Oils: Chemical Composition and Activity on Central Nervous
System. International journal of molecular sciences, 17(12), 1999.
https://doi.org/10.3390/ijms17121999
Castro, D. C., & Bruchas, M. R. (2019). A Motivational and Neuropeptidergic Hub: Anatomical
and Functional Diversity within the Nucleus Accumbens Shell. Neuron, 102(3), 529-552.
doi:10.1016/j.neuron.2019.03.003
Cha, J., Carlson, J. M., Dedora, D. J., Greenberg, T., Proudfit, G. H., & Mujica-Parodi, L. R.
(2014). Hyper-reactive human ventral tegmental area and aberrant mesocorticolimbic
connectivity in overgeneralization of fear in generalized anxiety disorder. The Journal of
neuroscience: the official journal of the Society for Neuroscience, 34(17), 5855–5860.
https://doi.org/10.1523/JNEUROSCI.4868-13.2014
Charlson, F., Ommeren, M. V., Flaxman, A., Cornett, J., Whiteford, H., & Saxena, S. (2019).
New WHO prevalence estimates of mental disorders in conflict settings: A systematic review
and meta-analysis. The Lancet, 394(10194), 240-248. doi:10.1016/s0140-6736(19)30934-1
Christen-Zaech, S., Kraftsik, R., Pillevuit, O., Kiraly, M., Martins, R., Khalili, K., & Miklossy, J.
(2003). Early Olfactory Involvement in Alzheimer’s Disease. Canadian Journal of Neurological
Sciences / Journal Canadien Des Sciences Neurologiques, 30(1), 20-25.
doi:10.1017/S0317167100002389
Clément, Y., Guisquet, A.-M. L., Venault, P., Chapouthier, G., & Belzung, C. (2009).
Pharmacological Alterations of Anxious Behaviour in Mice Depending on Both Strain and the
Behavioural Situation. PLoS ONE, 4(11). doi: 10.1371/journal.pone.0007745
Coelho, L. S., Correa-Netto, N. F., Masukawa, M. Y., Lima, A. C., Maluf, S., Linardi, A., &
Santos-Junior, J. G. (2018). Inhaled Lavandula angustifolia essential oil inhibits consolidation of
contextual- but not tone-fear conditioning in rats. Journal of ethnopharmacology, 215, 34–41.
127

https://doi.org/10.1016/j.jep.2017.12.038
Coque, L., Mukherjee, S., Cao, J. L., Spencer, S., Marvin, M., Falcon, E., Sidor, M. M.,
Birnbaum, S. G., Graham, A., Neve, R. L., Gordon, E., Ozburn, A. R., Goldberg, M. S., Han, M.
H., Cooper, D. C., & McClung, C. A. (2011). Specific role of VTA dopamine neuronal firing
rates and morphology in the reversal of anxiety-related, but not depression-related behavior in
the ClockΔ19 mouse model of mania. Neuropsychopharmacology: official publication of the
American College of Neuropsychopharmacology, 36(7), 1478–1488.
https://doi.org/10.1038/npp.2011.33
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational
Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers
in immunology, 9, 2009. https://doi.org/10.3389/fimmu.2018.02009
Crofton, E. J., Nenov, M. N., Zhang, Y., Scala, F., Page, S. A., McCue, D. L., Li, D., Hommel, J.
D., Laezza, F., & Green, T. A. (2017). Glycogen synthase kinase 3 beta alters anxiety-,
depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens
shell. Neuropharmacology, 117, 49–60. https://doi.org/10.1016/j.neuropharm.2017.01.020
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995). Inhibition
of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378(6559), 785789. doi:10.1038/378785a0
Da Cunha, C., Roozendaal, B., Vazdarjanova, A., & McGaugh, J. L. (1999). Microinfusions of
flumazenil into the basolateral but not the central nucleus of the amygdala enhance memory
consolidation in rats. Neurobiology of learning and memory, 72(1), 1–7.
https://doi.org/10.1006/nlme.1999.3912
Davies, C., & Bhattacharyya, S. (2019). Cannabidiol as a potential treatment for psychosis.
Therapeutic advances in psychopharmacology, 9, 2045125319881916.
https://doi.org/10.1177/2045125319881916
Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D.,
Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain
constituent that binds to the cannabinoid receptor. Science (New York, N.Y.), 258(5090), 1946–
1949. https://doi.org/10.1126/science.1470919
Donovan, M. R., Glue, P., Kolluri, S., Emir, B. (2010). Comparative efficacy of antidepressants
in preventing relapse in anxiety disorders — A meta-analysis. Journal of Affective Disorders,
123(1-3), 9-16. doi:10.1016/j.jad.2009.06.021
dos Reis, L. M., & Canto-de-Souza, A. (2008). Intra-periaqueductal gray matter injections of
midazolam fail to alter anxiety in plus-maze experienced mice. Brain research, 1231, 93–102.
https://doi.org/10.1016/j.brainres.2008.06.042
Durham, R., Chambers, J., Power, K., Sharp, D., Macdonald, R., Major, K., . . . Gumley, A.
(2005). Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland.
Health Technology Assessment, 9(42). doi:10.3310/hta9420
128

D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., .
. . Krystal, J. H. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for
cognition, psychosis, and addiction. Biological Psychiatry, 57(6), 594-608.
doi:10.1016/j.biopsych.2004.12.006
Du, K., Lu, W., Sun, Y., Feng, J., & Wang, J.-H. (2019). mRNA and miRNA profiles in the
nucleus accumbens are related to fear memory and anxiety induced by physical or psychological
stress. Journal of Psychiatric Research, 118, 44–65. doi: 10.1016/j.jpsychires.2019.08.013
Dwivedi, Y., & Pandey, G. N. (2008). Adenylyl cyclase-cyclicAMP signaling in mood disorders:
role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatric disease and
treatment, 4(1), 161–176. https://doi.org/10.2147/ndt.s2380
Einat, H., Yuan, P., Gould, T. D., Li, J., Du, J., Zhang, L., … Chen, G. (2003). The Role of the
Extracellular Signal-Regulated Kinase Signaling Pathway in Mood Modulation. The Journal of
Neuroscience, 23(19), 7311–7316. doi: 10.1523/jneurosci.23-19-07311.2003
Elisabetsky, E., Marschner, J., & Souza, D. O. (1995). Effects of linalool on glutamatergic
system in the rat cerebral cortex. Neurochemical Research, 20(4), 461-465.
doi:10.1007/bf00973103
Elisabetsky, E., Brum, L. F., & Souza, D. O. (1999). Anticonvulsant properties of linalool in
glutamate-related seizure models. Phytomedicine: international journal of phytotherapy and
phytopharmacology, 6(2), 107–113. https://doi.org/10.1016/s0944-7113(99)80044-0
Ellwood, I. T., Patel, T., Wadia, V., Lee, A. T., Liptak, A. T., Bender, K. J., & Sohal, V. S.
(2017). Tonic or Phasic Stimulation of Dopaminergic Projections to Prefrontal Cortex Causes
Mice to Maintain or Deviate from Previously Learned Behavioral Strategies. The Journal of
neuroscience: the official journal of the Society for Neuroscience, 37(35), 8315–8329.
https://doi.org/10.1523/JNEUROSCI.1221-17.2017
Engeli, L., Delahaye, M., Borgwardt, S., Gallinat, J., Müller, D., Walter, M., Lang, U.E., &
Beck, J. (2014). Akt2 Gene is Associated with Anxiety and Neuroticism in Humans. Journal of
Vascular Medicine & Surgery, 2(3), 1-4. doi: 10.4172/2329-6925.1000141
Etkin, A., Prater, K. E., Hoeft, F., Menon, V., & Schatzberg, A. F. (2010). Failure of Anterior
Cingulate Activation and Connectivity with the Amygdala During Implicit Regulation of
Emotional Processing in Generalized Anxiety Disorder. American Journal of Psychiatry, 167(5),
545-554. doi:10.1176/appi.ajp.2009.09070931
Everitt, B. J., & Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction:
From actions to habits to compulsion. Nature Neuroscience, 8(11), 1481-1489.
doi:10.1038/nn1579
Fogaça, M., Reis, F., Campos, A., & Guimarães, F. (2014). Effects of intra-prelimbic prefrontal
cortex injection of cannabidiol on anxiety-like behavior: Involvement of 5HT1A receptors and
previous stressful experience. European Neuropsychopharmacology, 24(3), 410-419.
doi:10.1016/j.euroneuro.2013.10.012
129

Foyet, H. S., Deffo, S. T., Yewo, P. K., Antioch, I., Zingue, S., Asongalem, E. A., … Ciobica, A.
(2017). Ficus sycomorus extract reversed behavioral impairment and brain oxidative stress
induced by unpredictable chronic mild stress in rats. BMC Complementary and Alternative
Medicine, 17(1). doi: 10.1186/s12906-017-2012-9
Franck, L. S., Naughton, I., & Winter, I. (2004). Opioid and benzodiazepine withdrawal
symptoms in paediatric intensive care patients. Intensive and Critical Care Nursing, 20(6), 344351. doi:10.1016/j.iccn.2004.07.008
Funahashi S. (2017). Working Memory in the Prefrontal Cortex. Brain sciences, 7(5), 49.
https://doi.org/10.3390/brainsci7050049
Gallily R., Yekhtin Z., Hanus L. (2015). Overcoming the bell-shaped dose-response of
cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacology & Pharmacy, 6,
75–85. doi: 10.4236/pp.2015.62010
Gaoni, Y., & Mechoulam, R. (1966). Cannabichromene, a new active principle in hashish.
Chemical Communications (London), (1), 20-21. doi:10.1039/c19660000020
Garcia-Garcia, A. L., Newman-Tancredi, A., & Leonardo, E. D. (2014). 5-HT(1A) [corrected]
receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.
Psychopharmacology, 231(4), 623–636. doi: 10.1007/s00213-013-3389-x
Gartside, S. E., Umbers, V., Hajós, M., & Sharp, T. (1995). Interaction between a selective 5HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5HT. British journal of pharmacology, 115(6), 1064–1070. doi: 10.1111/j.14765381.1995.tb15919.x
Ghosal, S., Hare, B., & Duman, R. S. (2017). Prefrontal Cortex GABAergic Deficits and Circuit
Dysfunction in the Pathophysiology and Treatment of Chronic Stress and Depression. Current
opinion in behavioral sciences, 14, 1–8. doi: 10.1016/j.cobeha.2016.09.012
Godsil, B. P., Kiss, J. P., Spedding, M., & Jay, T. M. (2013). The hippocampal–prefrontal
pathway: The weak link in psychiatric disorders? European Neuropsychopharmacology, 23(10),
1165-1181. doi: 10.1016/j.euroneuro.2012.10.018
Gomes, F. V., Reis, D. G., Alves, F. H., Corrêa, F. M., Guimarães, F. S., & Resstel, L. B. (2012).
Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of
contextual fear conditioning via 5-HT1A receptors. Journal of psychopharmacology (Oxford,
England), 26(1), 104–113. doi: 10.1177/0269881110389095
Gordon, J. A., & Hen, R. (2004). The Serotonergic System and Anxiety. NeuroMolecular
Medicine, 5(1), 027-040. doi: 10.1385/nmm:5:1:027
Groenewegen, H. J., & Russchen, F. T. (1984). Organization of the efferent projections of the
nucleus accumbens to pallidal, hypothalamic, and mesencephalic structures: A tracing and
immunohistochemical study in the cat. The Journal of Comparative Neurology, 223(3), 347-367.
doi: 10.1002/cne.902230303
130

Guimaraes, V. (2004). Cannabidiol increases Fos expression in the nucleus accumbens but not in
the dorsal striatum. Life Sciences, 75(5), 633–638. doi: 10.1016/j.lfs.2004.01.015
Gunaseelan, S., Balupillai, A., Govindasamy, K., Ramasamy, K., Muthusamy, G., Shanmugam,
M., Thangaiyan, R., Robert, B. M., Prasad Nagarajan, R., Ponniresan, V. K., & Rathinaraj, P.
(2017). Linalool prevents oxidative stress activated protein kinases in single UVB-exposed
human skin cells. PloS one, 12(5), e0176699. https://doi.org/10.1371/journal.pone.0176699
Hahn B. (2018). The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset
Psychosis. Schizophrenia bulletin, 44(1), 46–53. https://doi.org/10.1093/schbul/sbx105
Hamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012).
Functional Neuroimaging of Major Depressive Disorder: A Meta-Analysis and New Integration
of Baseline Activation and Neural Response Data. American Journal of Psychiatry, 169(7), 693703. doi:10.1176/appi.ajp.2012.11071105
Harada, H., Kashiwadani, H., Kanmura, Y., & Kuwaki, T. (2018). Linalool Odor-Induced
Anxiolytic Effects in Mice. Frontiers in behavioral neuroscience, 12, 241. doi:
10.3389/fnbeh.2018.00241
Hare, B. D., & Duman, R. S. (2020). Prefrontal cortex circuits in depression and anxiety:
contribution of discrete neuronal populations and target regions. Molecular psychiatry,
10.1038/s41380-020-0685-9. Advance online publication. doi: 10.1038/s41380-020-0685-9
Heimer, L., Zahm, D., Churchill, L., Kalivas, P., & Wohltmann, C. (1991). Specificity in the
projection patterns of accumbal core and shell in the rat. Neuroscience, 41(1), 89-125. doi:
10.1016/0306-4522(91)90202-y
Helbing, C., Brocka, M., Scherf, T., Lippert, M. T., & Angenstein, F. (2016). The role of the
mesolimbic dopamine system in the formation of blood-oxygen-level dependent responses in the
medial prefrontal/anterior cingulate cortex during high-frequency stimulation of the rat perforant
pathway. Journal of Cerebral Blood Flow & Metabolism, 36(12), 2177-2193.
doi:10.1177/0271678x15615535
Herzog, C. D., Stackman, R. W., & Walsh, T. J. (1996). Intraseptal Flumazenil Enhances, while
Diazepam Binding Inhibitor Impairs, Performance in a Working Memory Task. Neurobiology of
Learning and Memory, 66(3), 341–352. doi: 10.1006/nlme.1996.0074
Hollos, P., Marchisella, F., & Coffey, E. T. (2018). JNK Regulation of Depression and Anxiety.
Brain plasticity (Amsterdam, Netherlands), 3(2), 145–155. doi: 10.3233/BPL-170062
Holubova, K., Nekovarova, T., Pistovcakova, J., Sulcova, A., Stuchlík, A., & Vales, K. (2014).
Pregnanolone Glutamate, a Novel Use-Dependent NMDA Receptor Inhibitor, Exerts
Antidepressant-Like Properties in Animal Models. Frontiers in behavioral neuroscience, 8, 130.
https://doi.org/10.3389/fnbeh.2014.00130
Huber, N., Fusani, L., Ferretti, A., Mahr, K., & Canoine, V. (2017). Measuring short-term stress
in birds: Comparing different endpoints of the endocrine-immune interface. Physiology &
131

Behavior, 182, 46–53. doi: 10.1016/j.physbeh.2017.09.017
Huang, Q., Liu, R., Zhang, P., He, X., Mckernan, R., Gan, T., … Cook, J. M. (1998). Predictive
Models for GABAA/Benzodiazepine Receptor Subtypes: Studies of Quantitative
Structure−Activity Relationships for Imidazobenzodiazepines at Five Recombinant
GABAA/Benzodiazepine Receptor Subtypes [αxβ3γ2 (x= 1−3, 5, and 6)] via Comparative
Molecular Field Analysis. Journal of Medicinal Chemistry, 41(21), 4130–4142. doi:
10.1021/jm980317y
Hudson, R., Renard, J., Norris, C., Rushlow, W. J., & Laviolette, S. R. (2019). Cannabidiol
Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral
Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation. The Journal of
neuroscience: the official journal of the Society for Neuroscience, 39(44), 8762–8777.
https://doi.org/10.1523/JNEUROSCI.0708-19.2019
Huo, M., Cui, X., Xue, J., Chi, G., Gao, R., Deng, X., Guan, S., Wei, J., Soromou, L. W., Feng,
H., & Wang, D. (2013). Anti-inflammatory effects of linalool in RAW 264.7 macrophages and
lipopolysaccharide-induced lung injury model. The Journal of surgical research, 180(1), e47–
e54. https://doi.org/10.1016/j.jss.2012.10.050
Hussain, S.M., & Farhana, S.A. (2015). Exploring the Possible Mode of Anxiolytic Action of a
Polyherbal Formulation in Animal Models of Anxiety. Asian Journal of Biomedical and
Pharmaceutical Sciences, 5, 12-16.
Ikemoto S. (2010). Brain reward circuitry beyond the mesolimbic dopamine system: a
neurobiological theory. Neuroscience and biobehavioral reviews, 35(2), 129–150.
https://doi.org/10.1016/j.neubiorev.2010.02.001
Impey, S., Obrietan, K., Wong, S. T., Poser, S., Yano, S., Wayman, G., … Storm, D. R. (1998).
Cross Talk between ERK and PKA Is Required for Ca2 Stimulation of CREB-Dependent
Transcription and ERK Nuclear Translocation. Neuron, 21(4), 869–883. doi: 10.1016/s08966273(00)80602-9
Ironside, M., Browning, M., Ansari, T. L., Harvey, C. J., Sekyi-Djan, M. N., Bishop, S. J., . . .
O'shea, J. (2019). Effect of Prefrontal Cortex Stimulation on Regulation of Amygdala Response
to Threat in Individuals With Trait Anxiety. JAMA Psychiatry, 76(1), 71.
doi:10.1001/jamapsychiatry.2018.2172
Ivanov, V. N., Wu, J., & Hei, T. K. (2017). Regulation of human glioblastoma cell death by
combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling
pathways. Oncotarget, 8(43), 74068–74095. doi: 10.18632/oncotarget.18240
Izquierdo, A., Wellman, C. L., & Holmes, A. (2006). Brief uncontrollable stress causes dendritic
retraction in infralimbic cortex and resistance to fear extinction in mice. The Journal of
neuroscience: the official journal of the Society for Neuroscience, 26(21), 5733–5738.
https://doi.org/10.1523/JNEUROSCI.0474-06.2006
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009). Non-psychotropic
132

plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends in
Pharmacological Sciences, 30(10), 515-527. doi:10.1016/j.tips.2009.07.006
Jackson, M. E., & Moghaddam, B. (2001). Amygdala Regulation of Nucleus Accumbens
Dopamine Output is Governed by the Prefrontal Cortex. The Journal of Neuroscience, 21(2),
676–681. doi: 10.1523/jneurosci.21-02-00676.2001
Jardim, M. C., & Guimarães, F. S. (2001). GABAergic and glutamatergic modulation of
exploratory behavior in the dorsomedial hypothalamus. Pharmacology, biochemistry, and
behavior, 69(3-4), 579–584. https://doi.org/10.1016/s0091-3057(01)00560-3
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M.
T. (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the
efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with
intractable cancer-related pain. Journal of pain and symptom management, 39(2), 167–179.
https://doi.org/10.1016/j.jpainsymman.2009.06.008
Jope, R. S., & Roh, M. S. (2006). Glycogen synthase kinase-3 (GSK3) in psychiatric diseases
and therapeutic interventions. Current drug targets, 7(11), 1421–1434.
https://doi.org/10.2174/1389450110607011421
Kagan, E. R., Frank, H. E., Norris, L. A., Palitz, S. A., Chiappini, E. A., Knepley, M. J., Crane,
M. E., Phillips, K. E., Ginsburg, G. S., Keeton, C., Albano, A. M., Piacentini, J., Peris, T.,
Compton, S., Sakolsky, D., Birmaher, B., & Kendall, P. C. (2020). Antidepressant Use in a 3- to
12-Year Follow-up of Anxious Youth: Results from the CAMELS Trial. Child psychiatry and
human development, 10.1007/s10578-020-00983-w. Advance online publication. doi:
10.1007/s10578-020-00983-w
Kalin, N. H., Shelton, S. E., Fox, A. S., Oakes, T. R., & Davidson, R. J. (2005). Brain regions
associated with the expression and contextual regulation of anxiety in primates. Biological
psychiatry, 58(10), 796–804. doi: 10.1016/j.biopsych.2005.05.021
Kaufmann, D., & Brennan, K. C. (2018). The Effects of Chronic Stress on Migraine Relevant
Phenotypes in Male Mice. Frontiers in cellular neuroscience, 12, 294. doi:
10.3389/fncel.2018.00294
Kazdin, A. E. (2000). Encyclopedia of psychology, Vol 3. American Psychological Association.
Kessler, A., Sahin-Nadeem, H., Lummis, S. C., Weigel, I., Pischetsrieder, M., Buettner, A., &
Villmann, C. (2014). GABA(A) receptor modulation by terpenoids from Sideritis extracts.
Molecular nutrition & food research, 58(4), 851–862. https://doi.org/10.1002/mnfr.201300420
Kessler, A., Villmann, C., Sahin-Nadeem, H., Pischetsrieder, M., & Buettner, A. (2012).
GABAA receptor modulation by the volatile fractions of Sideritis species used as ‘Greek’ or
‘Turkish’ mountain tea. Flavour and Fragrance Journal, 27(4), 297-303. doi:10.1002/ffj.3099
Koulivand, P. H., Khaleghi Ghadiri, M., & Gorji, A. (2013). Lavender and the nervous system.
Evidence-based complementary and alternative medicine: eCAM, 2013, 681304. doi:
133

10.1155/2013/681304
Lago, T., Davis, A., Grillon, C., & Ernst, M. (2017). Striatum on the anxiety map: Small detours
into adolescence. Brain research, 1654(Pt B), 177–184. doi: 10.1016/j.brainres.2016.06.006
Laprairie, R. B., Bagher, A. M., Kelly, M. E., & Denovan-Wright, E. M. (2015). Cannabidiol is a
negative allosteric modulator of the cannabinoid CB1 receptor. British journal of pharmacology,
172(20), 4790–4805. doi: 10.1111/bph.13250
Lara, A. H., & Wallis, J. D. (2015). The Role of Prefrontal Cortex in Working Memory: A Mini
Review. Frontiers in systems neuroscience, 9, 173. doi: 10.3389/fnsys.2015.00173
Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. New York: Springer.
Ledoux, J. E. (2000). Emotion Circuits in the Brain. Annual Review of Neuroscience, 23(1), 155184. doi: 10.1146/annurev.neuro.23.1.155
Lee, A. T., Vogt, D., Rubenstein, J. L., & Sohal, V. S. (2014). A class of GABAergic neurons in
the prefrontal cortex sends long-range projections to the nucleus accumbens and elicits acute
avoidance behavior. The Journal of neuroscience: the official journal of the Society for
Neuroscience, 34(35), 11519–11525. doi: 10.1523/JNEUROSCI.1157-14.2014
Leibrock, C., Ackermann, T. F., Hierlmeier, M., Lang, F., Borgwardt, S., & Lang, U. E. (2013).
Akt2 deficiency is associated with anxiety and depressive behavior in mice. Cellular physiology
and biochemistry: international journal of experimental cellular physiology, biochemistry, and
pharmacology, 32(3), 766–777. doi: 10.1159/000354478
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010). Involvement of the prelimbic prefrontal
cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behavioural
Brain Research, 207(1), 105–111. doi: 10.1016/j.bbr.2009.09.045
Lesch, K. P., & Gutknecht, L. (2004). Focus on the 5-HT1A receptor: Emerging role of a gene
regulatory variant in psychopathology and pharmacogenetics. The International Journal of
Neuropsychopharmacology, 7(4), 381-385. doi: 10.1017/s1461145704004845
Levita, L., Hoskin, R., & Champi, S. (2012). Avoidance of harm and anxiety: a role for the
nucleus accumbens. NeuroImage, 62(1), 189–198. doi: 10.1016/j.neuroimage.2012.04.059
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J.,
Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates
psychotic symptoms of schizophrenia. Translational psychiatry, 2(3), e94. doi:
10.1038/tp.2012.15
Li, Y. C., Wang, M. J., & Gao, W. J. (2012). Hyperdopaminergic modulation of inhibitory
transmission is dependent on GSK-3β signaling-mediated trafficking of GABAA receptors.
Journal of neurochemistry, 122(2), 308–320. doi: 10.1111/j.1471-4159.2012.07790.x
Libro, R., Diomede, F., Scionti, D., Piattelli, A., Grassi, G., Pollastro, F., Bramanti, P., Mazzon,
E., & Trubiani, O. (2016). Cannabidiol Modulates the Expression of Alzheimer's Disease134

Related Genes in Mesenchymal Stem Cells. International journal of molecular sciences, 18(1),
26. doi: 10.3390/ijms18010026
Linck, V., Silva, A. D., Figueiró, M., Caramão, E., Moreno, P., & Elisabetsky, E. (2010). Effects
of inhaled Linalool in anxiety, social interaction and aggressive behavior in mice.
Phytomedicine, 17(8-9), 679-683. doi :10.1016/j.phymed.2009.10.002
Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., &
Díaz, Á. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances
cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology, 103,
16–26. doi: 10.1016/j.neuropharm.2015.12.017
Liu, Z.-P., Song, C., Wang, M., He, Y., Xu, X.-B., Pan, H.-Q., … Pan, B.-X. (2014). Chronic
stress impairs GABAergic control of amygdala through suppressing the tonic GABAA receptor
currents. Molecular Brain, 7(1), 32. doi: 10.1186/1756-6606-7-32
Liu, W.-Z., Zhang, W.-H., Zheng, Z.-H., Zou, J.-X., Liu, X.-X., Huang, S.-H., … Pan, B.-X.
(2020). Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced
anxiety. Nature Communications, 11(1). doi: 10.1038/s41467-020-15920-7
Long, L. E., Chesworth, R., Huang, X.-F., Mcgregor, I. S., Arnold, J. C., & Karl, T. (2010). A
behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in
C57BL/6JArc mice. The International Journal of Neuropsychopharmacology, 13(07), 861–876.
doi: 10.1017/s1461145709990605
Lopes, A. P. F., Ganzer, L., Borges, A. C., Kochenborger, L., Januário, A. C., Faria, M. S., …
Paschoalini, M. A. (2012). Effects of GABA ligands injected into the nucleus accumbens shell
on fear/anxiety-like and feeding behaviours in food-deprived rats. Pharmacology Biochemistry
and Behavior, 101(1), 41–48. doi: 10.1016/j.pbb.2011.11.013
Loureiro, M., Renard, J., Zunder, J., & Laviolette, S. R. (2015). Hippocampal cannabinoid
transmission modulates dopamine neuron activity: impact on rewarding memory formation and
social interaction. Neuropsychopharmacology: official publication of the American College of
Neuropsychopharmacology, 40(6), 1436–1447. doi: 10.1038/npp.2014.329
Lyons, D., de Jaeger, X., Rosen, L. G., Ahmad, T., Lauzon, N. M., Zunder, J., Coolen, L. M.,
Rushlow, W., & Laviolette, S. R. (2013). Opiate exposure and withdrawal induces a molecular
memory switch in the basolateral amygdala between ERK1/2 and CaMKIIα-dependent signaling
substrates. The Journal of neuroscience: the official journal of the Society for Neuroscience,
33(37), 14693–14704. doi: 10.1523/JNEUROSCI.1226-13.2013
Ma, J., Zhang, Y., Wang, J., Zhao, T., Ji, P., Song, J. ... Luo, W. (2016). Proliferative effects of
gamma-amino butyric acid on oral squamous cell carcinoma cells are associated with mitogenactivated protein kinase signaling pathways. International Journal of Molecular Medicine, 38,
305-311. doi: 10.3892/ijmm.2016.2597
Madonna, D., Delvecchio, G., Soares, J. C., & Brambilla, P. (2019). Structural and functional
neuroimaging studies in generalized anxiety disorder: A systematic review. Brazilian Journal of
135

Psychiatry, 41(4), 336-362. doi: 10.1590/1516-4446-2018-0108
Malcolm, B. J., & Tallian, K. (2018). Essential oil of lavender in anxiety disorders: Ready for
prime time?. The mental health clinician, 7(4), 147–155. doi: 10.9740/mhc.2017.07.147
Mallet, N., Le Moine, C., Charpier, S., & Gonon, F. (2005). Feedforward inhibition of projection
neurons by fast-spiking GABA interneurons in the rat striatum in vivo. The Journal of
neuroscience: the official journal of the Society for Neuroscience, 25(15), 3857–3869. doi:
10.1523/JNEUROSCI.5027-04.2005
Malone, D. T., Jongejan, D., & Taylor, D. A. (2009). Cannabidiol reverses the reduction in social
interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. Pharmacology,
biochemistry, and behavior, 93(2), 91–96. doi: 10.1016/j.pbb.2009.04.010
Mannella, F., Gurney, K., & Baldassarre, G. (2013). The nucleus accumbens as a nexus between
values and goals in goal-directed behavior: A review and a new hypothesis. Frontiers in
Behavioral Neuroscience, 7. doi: 10.3389/fnbeh.2013.00135
Marín-Burgin, A., Mongiat, L. A., Pardi, M. B., & Schinder, A. F. (2012). Unique processing
during a period of high excitation/inhibition balance in adult-born neurons. Science (New York,
N.Y.), 335(6073), 1238–1242. doi: 10.1126/science.1214956
Maroun, M., Kavushansky, A., Holmes, A., Wellman, C., & Motanis, H. (2012). Enhanced
Extinction of Aversive Memories by High-Frequency Stimulation of the Rat Infralimbic Cortex.
PLoS ONE, 7(5). doi: 10.1371/journal.pone.0035853
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., .
. . Franco, R. (2017). Binding and Signaling Studies Disclose a Potential Allosteric Site for
Cannabidiol in Cannabinoid CB2 Receptors. Frontiers in Pharmacology, 8. doi:
10.3389/fphar.2017.00744
McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C.,
Pakdel, A., Lee, J., Limbad, C., Liu, Y., Debs, R. J., Moore, D. H., & Desprez, P. Y. (2011).
Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation,
invasion, and metastasis. Breast cancer research and treatment, 129(1), 37–47. doi:
10.1007/s10549-010-1177-4
Mcewen, B. S. (2004). Protection and Damage from Acute and Chronic Stress: Allostasis and
Allostatic Overload and Relevance to the Pathophysiology of Psychiatric Disorders. Annals of
the New York Academy of Sciences, 1032(1), 1–7. doi: 10.1196/annals.1314.001
Mechoulam, R. (1986). The Pharmacohistory of Cannabis sativa. In: Mechoulam, R. (ed.).
Cannabinoids as Therapeutic Agents. CRC Press: Boca Raton, FL, pp. 1–19.
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R.,
Gopher, A., Almog, S., Martin, B. R., & Compton, D. R. (1995). Identification of an endogenous
2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical
pharmacology, 50(1), 83–90. doi: 10.1016/0006-2952(95)00109-d
136

Mechoulam R., Ben-Shabat S. (1999). From gan-zi-gun-nu to anandamide and 2arachidonoylglycerol: the ongoing story of cannabis. Nat. Prod. Rep., 16, 131–143. doi:
10.1039/a703973e
Mechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some
pharmacological aspects. Journal of clinical pharmacology, 42(S1), 11S–19S. doi:
10.1002/j.1552-4604.2002.tb05998.x
Miyakawa, T., Leiter, L. M., Gerber, D. J., Gainetdinov, R. R., Sotnikova, T. D., Zeng, H.,
Caron, M. G., & Tonegawa, S. (2003). Conditional calcineurin knockout mice exhibit multiple
abnormal behaviors related to schizophrenia. Proceedings of the National Academy of Sciences
of the United States of America, 100(15), 8987–8992. doi: 10.1073/pnas.1432926100
Milanos, S., Elsharif, S. A., Janzen, D., Buettner, A., & Villmann, C. (2017). Metabolic Products
of Linalool and Modulation of GABAA Receptors. Frontiers in chemistry, 5, 46. doi:
10.3389/fchem.2017.00046
Millar, S. A., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O'Sullivan, S. E.
(2019). A systematic review of cannabidiol dosing in clinical populations. British journal of
clinical pharmacology, 85(9), 1888–1900. doi: 10.1111/bcp.14038
Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E., & Jope, R. S. (2010). GSK3 influences
social preference and anxiety-related behaviors during social interaction in a mouse model of
fragile X syndrome and autism. PloS one, 5(3), e9706. doi: 10.1371/journal.pone.0009706
Mohammad, H., Marchisella, F., Ortega-Martinez, S., Hollos, P., Eerola, K., Komulainen, E.,
Kulesskaya, N., Freemantle, E., Fagerholm, V., Savontaus, E., Rauvala, H., Peterson, B. D., van
Praag, H., & Coffey, E. T. (2018). JNK1 controls adult hippocampal neurogenesis and imposes
cell-autonomous control of anxiety behaviour from the neurogenic niche. Molecular psychiatry,
23(2), 362–374. doi: 10.1038/mp.2016.203
Mohlman, J., Price, R. B., Eldreth, D. A., Chazin, D., Glover, D. M., & Kates, W. R. (2009). The
relation of worry to prefrontal cortex volume in older adults with and without generalized
anxiety disorder. Psychiatry research, 173(2), 121–127. doi: 10.1016/j.pscychresns.2008.09.010
Montero-Oleas, N., Arevalo-Rodriguez, I., Nuñez-González, S., Viteri-García, A., & SimancasRacines, D. (2020). Therapeutic use of cannabis and cannabinoids: an evidence mapping and
appraisal of systematic reviews. BMC complementary medicine and therapies, 20(1), 12. doi:
10.1186/s12906-019-2803-2
Monteiro, S., Roque, S., de Sá-Calçada, D., Sousa, N., Correia-Neves, M., & Cerqueira, J. J.
(2015). An efficient chronic unpredictable stress protocol to induce stress-related responses in
C57BL/6 mice. Frontiers in psychiatry, 6, 6. doi: 10.3389/fpsyt.2015.00006
Morales, P., Goya, P., Jagerovic, N., & Hernandez-Folgado, L. (2016). Allosteric Modulators of
the CB1 Cannabinoid Receptor: A Structural Update Review. Cannabis and Cannabinoid
Research, 1(1), 22-30. doi: 10.1089/can.2015.0005
137

Morano, A., Cifelli, P., Nencini, P., Antonilli, L., Fattouch, J., Ruffolo, G., Roseti, C., Aronica,
E., Limatola, C., Di Bonaventura, C., Palma, E., & Giallonardo, A. T. (2016). Cannabis in
epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
Epilepsia open, 1(3-4), 145–151. doi: 10.1002/epi4.12015
Morgan, M. A., Romanski, L. M., & Ledoux, J. E. (1993). Extinction of emotional learning:
Contribution of medial prefrontal cortex. Neuroscience Letters, 163(1), 109-113. doi:
10.1016/0304-3940(93)90241-c
Muller, J., Corodimas, K. P., Fridel, Z., & Ledoux, J. E. (1997). Functional inactivation of the
lateral and basal nuclei of the amygdala by muscimol infusion prevents fear conditioning to an
explicit conditioned stimulus and to contextual stimuli. Behavioral Neuroscience, 111(4), 683691. doi: 10.1037/0735-7044.111.4.683
Murkar, A., Kent, P., Cayer, C., James, J., Durst, T., & Merali, Z. (2019). Cannabidiol and the
Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear
Memory Reconsolidation. Frontiers in Behavioral Neuroscience, 13. doi:
10.3389/fnbeh.2019.00174
Nadeem, A., Masood, A., Masood, N., Gilani, R. A., & Shah, Z. A. (2006). Immobilization stress
causes extra-cellular oxidant–antioxidant imbalance in rats: Restoration by L-NAME and
vitamin E. European Neuropsychopharmacology, 16(4), 260–267. doi:
10.1016/j.euroneuro.2005.08.001
Nasca, C., Zelli, D., Bigio, B., Piccinin, S., Scaccianoce, S., Nisticò, R., & Mcewen, B. S.
(2015). Stress dynamically regulates behavior and glutamatergic gene expression in
hippocampus by opening a window of epigenetic plasticity. Proceedings of the National
Academy of Sciences, 112(48), 14960–14965. doi: 10.1073/pnas.1516016112
Nauta, W., Smith, G., Faull, R., & Domesick, V. B. (1978). Efferent connections and nigral
afferents of the nucleus accumbens septi in the rat. Neuroscience, 3(4-5), 385-401. doi:
10.1016/0306-4522(78)90041-6
Nicola, S. M., Surmeier, D. J., & Malenka, R. C. (2000). Dopaminergic Modulation of Neuronal
Excitability in the Striatum and Nucleus Accumbens. Annual Review of Neuroscience, 23(1),
185-215. doi: 10.1146/annurev.neuro.23.1.185
Norris, C., Loureiro, M., Kramar, C., Zunder, J., Renard, J., Rushlow, W., & Laviolette, S. R.
(2016). Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic
Transmission in the Mesolimbic System. Neuropsychopharmacology: official publication of the
American College of Neuropsychopharmacology, 41(12), 2839–2850. doi: 10.1038/npp.2016.93
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C.,
Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A.,
Montalban, X., Klimek, A., Davies, P., & Sativex Spasticity Study Group (2011). A randomized,
double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols*
(Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple
138

sclerosis. European journal of neurology, 18(9), 1122–1131. doi: 10.1111/j.14681331.2010.03328.x
Owen, R. T., & Tyrer, P. (1983). Benzodiazepine dependence. A review of the evidence. Drugs,
25(4), 385–398. doi: 10.2165/00003495-198325040-00003
Pal, R., Bondar, V. V., Adamski, C. J., Rodney, G. G., & Sardiello, M. (2017). Inhibition of
ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous
Sclerosis. Scientific reports, 7(1), 4174. doi: 10.1038/s41598-017-04528-5
Pan, W., & Zhang, G. (2019). Linalool monoterpene exerts potent antitumor effects in OECM 1
human oral cancer cells by inducing sub-G1 cell cycle arrest, loss of mitochondrial membrane
potential and inhibition of PI3K/AKT biochemical pathway. Journal of B.U.ON.: official journal
of the Balkan Union of Oncology, 24 1, 323-328.
Paxinos, G. and Watson, C. (2005). The Rat Brain in Stereotaxic Coordinates. Compact 5th
Edition. Academic Press.
Peana, A. T., Rubattu, P., Piga, G. G., Fumagalli, S., Boatto, G., Pippia, P., & Montis, M. G.
(2006). Involvement of adenosine A1 and A2A receptors in (−)-linalool-induced antinociception.
Life Sciences, 78(21), 2471-2474. doi: 10.1016/j.lfs.2005.10.025
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., … Collingridge, G. L.
(2007). LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β. Neuron, 53(5), 703–
717. doi: 10.1016/j.neuron.2007.01.029
Pelz, M. C., Schoolcraft, K. D., Larson, C., Spring, M. G., & López, H. H. (2017). Assessing the
role of serotonergic receptors in cannabidiol's anticonvulsant efficacy. Epilepsy & behavior:
E&B, 73, 111–118. doi: 10.1016/j.yebeh.2017.04.045
Peng, S., Zhang, Y., Zhang, J., Wang, H., & Ren, B. (2010). ERK in learning and memory: a
review of recent research. International journal of molecular sciences, 11(1), 222–232. doi:
10.3390/ijms11010222
Pertwee, R. G., Ross, R. A., Craib, S. J., & Thomas, A. (2002). (-)-Cannabidiol antagonizes
cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. European journal of
pharmacology, 456(1-3), 99–106. doi: 10.1016/s0014-2999(02)02624-9
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant
cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British
Journal of Pharmacology, 153(2), 199-215. doi: 10.1038/sj.bjp.0707442
Petrocellis, L. D., & Marzo, V. D. (2009). Non-CB1, Non-CB2 Receptors for Endocannabinoids,
Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and
Transient Receptor Potential Channels. Journal of Neuroimmune Pharmacology, 5(1), 103-121.
doi: 10.1007/s11481-009-9177-z.
Pitman, R. K., Rasmusson, A. M., Koenen, K. C., Shin, L. M., Orr, S. P., Gilbertson, M. W.,
Milad, M. R., & Liberzon, I. (2012). Biological studies of post-traumatic stress disorder. Nature
139

reviews. Neuroscience, 13(11), 769–787. doi: 10.1038/nrn3339
Poisbeau, P., Cheney, M. C., Browning, M. D., & Mody, I. (1999). Modulation of synaptic
GABAA receptor function by PKA and PKC in adult hippocampal neurons. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 19(2), 674–683. doi:
10.1523/JNEUROSCI.19-02-00674.1999
Pucilowska, J., Vithayathil, J., Tavares, E. J., Kelly, C., Karlo, J. C., & Landreth, G. E. (2015).
The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation
and brain cytoarchitecture linked to the ERK MAPK pathway. The Journal of neuroscience: the
official journal of the Society for Neuroscience, 35(7), 3190–3200. doi:
10.1523/JNEUROSCI.4864-13.2015
Qi, J., Zhang, S., Wang, H.-L., Barker, D. J., Miranda-Barrientos, J., & Morales, M. (2016).
VTA glutamatergic inputs to nucleus accumbens drive aversion by acting on GABAergic
interneurons. Nature Neuroscience, 19(5), 725–733. doi: 10.1038/nn.4281
Qiao, X., Gai, H., Su, R., Deji, C., Cui, J., Lai, J., & Zhu, Y. (2018). PI3K-AKT-GSK3β-CREB
signaling pathway regulates anxiety-like behavior in rats following alcohol withdrawal. Journal
of Affective Disorders, 235, 96–104. doi: 10.1016/j.jad.2018.04.039
Rauch, S. L., Whalen, P. J., Shin, L. M., Mcinerney, S. C., Macklin, M. L., Lasko, N. B., . . .
Pitman, R. K. (2000). Exaggerated amygdala response to masked facial stimuli in posttraumatic
stress disorder: A functional MRI study. Biological Psychiatry, 47(9), 769-776. doi:
10.1016/s0006-3223(00)00828-3
Read, J., & Williams, J. (2018). Adverse Effects of Antidepressants Reported by a Large
International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. Current drug
safety, 13(3), 176–186. doi: 10.2174/1574886313666180605095130
Renard, J., Loureiro, M., Rosen, L. G., Zunder, J., Oliveira, C. D., Schmid, S., … Laviolette, S.
R. (2016). Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral
Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase
Signaling Pathway. The Journal of Neuroscience, 36(18), 5160–5169. doi:
10.1523/jneurosci.3387-15.2016
Resstel, L. B., Joca, S. R., Moreira, F. A., Corrêa, F. M., & Guimarães, F. S. (2006). Effects of
cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual
conditioned fear in rats. Behavioural brain research, 172(2), 294–298. doi:
10.1016/j.bbr.2006.05.016
Resstel, L. B., Tavares, R. F., Lisboa, S. F., Joca, S. R., Corrêa, F. M., & Guimarães, F. S.
(2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural
and cardiovascular responses to acute restraint stress in rats. British journal of pharmacology,
156(1), 181–188. doi: 10.1111/j.1476-5381.2008.00046.x
Rex, A. (1996). “Anxiolytic” action of diazepam and abecarnil in a modified open field test.
Pharmacology Biochemistry and Behavior, 53(4), 1005–1011. doi: 10.1016/0091140

3057(95)02121-3
Rodenak-Kladniew, B., Castro, A., Stärkel, P., De Saeger, C., García de Bravo, M., & Crespo, R.
(2018). Linalool induces cell cycle arrest and apoptosis in HepG2 cells through oxidative stress
generation and modulation of Ras/MAPK and Akt/mTOR pathways. Life sciences, 199, 48–59.
doi: 10.1016/j.lfs.2018.03.006
Ross, D. A., Sadil, P., Wilson, D. M., & Cowell, R. A. (2018). Hippocampal Engagement During
Recall Depends on Memory Content. Cerebral Cortex, 29(4), 1699–1699. doi:
10.1093/cercor/bhy182
Rudyk, C., Dwyer, Z., Mcneill, J., Salmaso, N., Farmer, K., Prowse, N., & Hayley, S. (2019).
Chronic unpredictable stress influenced the behavioral but not the neurodegenerative impact of
paraquat. Neurobiology of Stress, 11, 100179. doi: 10.1016/j.ynstr.2019.100179
Ruffolo, G., Cifelli, P., Roseti, C., Thom, M., van Vliet, E. A., Limatola, C., Aronica, E., &
Palma, E. (2018). A novel GABAergic dysfunction in human Dravet syndrome. Epilepsia,
59(11), 2106–2117. doi: 10.1111/epi.14574
Russo, E. B. (2001). Handbook of psychotropic herbs: A scientific analysis of herbal remedies
for psychiatric conditions. New York: Routledge.
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at
5-HT1a receptors. Neurochemical research, 30(8), 1037–1043. doi: 10.1007/s11064-005-6978-1
Russo E. B. (2007). History of cannabis and its preparations in saga, science, and sobriquet.
Chemistry & biodiversity, 4(8), 1614–1648. doi: 10.1002/cbdv.200790144
Russo, E. B., Jiang, H. E., Li, X., Sutton, A., Carboni, A., del Bianco, F., Mandolino, G., Potter,
D. J., Zhao, Y. X., Bera, S., Zhang, Y. B., Lü, E. G., Ferguson, D. K., Hueber, F., Zhao, L. C.,
Liu, C. J., Wang, Y. F., & Li, C. S. (2008). Phytochemical and genetic analyses of ancient
cannabis from Central Asia. Journal of experimental botany, 59(15), 4171–4182. doi:
10.1093/jxb/ern260
Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid
entourage effects. British Journal of Pharmacology, 163(7), 1344-1364. doi: 10.1111/j.14765381.2011.01238.x
Russo, S. J., & Nestler, E. J. (2013). The brain reward circuitry in mood disorders. Nature
reviews. Neuroscience, 14(9), 609–625. doi: 10.1038/nrn3381
Sabio, G., & Davis, R. J. (2014). TNF and MAP kinase signalling pathways. Seminars in
immunology, 26(3), 237–245. doi: 10.1016/j.smim.2014.02.009
Sadowski, R. N., Jackson, G. R., Wieczorek, L., & Gold, P. E. (2009). Effects of stress,
corticosterone, and epinephrine administration on learning in place and response tasks.
Behavioural Brain Research, 205(1), 19–25. doi: 10.1016/j.bbr.2009.06.027
Saiyudthong, S., Mekseepralard, C., & Srijittapong, D. (2016). PS120. Effects of linalool on
141

chronic stress-induced depressive-like behaviour and BDNF protein in the hippocampus of rats.
International Journal of Neuropsychopharmacology, 19(Suppl 1), 40–41. doi:
10.1093/ijnp/pyw043.120
Sánchez, S., Jiménez, C., Carrera, A., Diaz-Nido, J., Avila, J., & Wandosell, F. (2004). A cAMPactivated pathway, including PKA and PI3K, regulates neuronal differentiation. Neurochemistry
International, 44(4), 231–242. doi: 10.1016/s0197-0186(03)00150-5
Sani, G., Napoletano, F., Forte, A. M., Kotzalidis, G. D., Panaccione, I., Porfiri, G. M.,
Simonetti, A., Caloro, M., Girardi, N., Telesforo, C. L., Serra, G., Romano, S., Manfredi, G.,
Savoja, V., Tamorri, S. M., Koukopoulos, A. E., Serata, D., Rapinesi, C., Del Casale, A.,
Nicoletti, F., … Girardi, P. (2012). The wnt pathway in mood disorders. Current
neuropharmacology, 10(3), 239–253. doi: 10.2174/157015912803217279
Schmitz, T. W., Correia, M. M., Ferreira, C. S., Prescot, A. P., & Anderson, M. C. (2017).
Hippocampal GABA enables inhibitory control over unwanted thoughts. Nature
Communications, 8(1). doi: 10.1038/s41467-017-00956-z
Schleicher, E. M., Ott, F. W., Müller, M., Silcher, B., Sichler, M. E., Löw, M. J., … Bouter, Y.
(2019). Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor
Performance and Anxiety in C57BL/6J Mice. Frontiers in Behavioral Neuroscience, 13. doi:
10.3389/fnbeh.2019.00094
Schulz, R., Runge, C. G., Bönstrup, M., Cheng, B., Gerloff, C., Thomalla, G., & Hummel, F. C.
(2019). Prefrontal-Premotor Pathways and Motor Output in Well-Recovered Stroke Patients.
Frontiers in Neurology, 10. doi:10.3389/fneur.2019.00105
Seo, D., Funderburk, S. C., Bhatti, D. L., Motard, L. E., Newbold, D., Girven, K. S., . . .
Bruchas, M. R. (2016). A GABAergic Projection from the Centromedial Nuclei of the Amygdala
to Ventromedial Prefrontal Cortex Modulates Reward Behavior. The Journal of Neuroscience,
36(42), 10831-10842. doi:10.1523/jneurosci.1164-16.2016
Sesack, S. R., & Grace, A. A. (2009). Cortico-Basal Ganglia Reward Network: Microcircuitry.
Neuropsychopharmacology, 35(1), 27-47. doi: 10.1038/npp.2009.93
Shan, Q., Chan, G. C., & Storm, D. R. (2008). Type 1 adenylyl cyclase is essential for
maintenance of remote contextual fear memory. The Journal of neuroscience: the official journal
of the Society for Neuroscience, 28(48), 12864–12867. doi: 10.1523/JNEUROSCI.2413-08.2008
Sierra-Fonseca, J. A., Parise, L. F., Flores-Ramirez, F. J., Robles, E. H., Garcia-Carachure, I., &
Iñiguez, S. D. (2019). Dorsal Hippocampus ERK2 Signaling Mediates Anxiolytic-Related
Behavior in Male Rats. Chronic stress (Thousand Oaks, Calif.), 3, 10.1177/2470547019897030.
doi: 10.1177/2470547019897030
Somogyi, P., Bolam, J., Totterdell, S., & Smith, A. (1981). Monosynaptic input from the nucleus
accumbens-ventral striatum region to retrogradely labelled nigrostriatal neurones. Brain
Research, 217(2), 245-263. doi: 10.1016/0006-8993(81)90002-0
142

Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, R. C., Long, J., Laidler, P., Mijatovic,
S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., Donia, M., Fagone, P., Malaponte, G.,
Nicoletti, F., Libra, M., Milella, M., Tafuri, A., Bonati, A., Bäsecke, J., Cocco, L., … McCubrey,
J. A. (2011). Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling
growth and sensitivity to therapy-implications for cancer and aging. Aging, 3(3), 192–222. doi:
10.18632/aging.100296
Straiker, A., Dvorakova, M., Zimmowitch, A., & Mackie, K. (2018). Cannabidiol Inhibits
Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Molecular pharmacology, 94(1),
743–748. doi: 10.1124/mol.118.111864
Strasser, A., Xin, L., Gruetter, R., & Sandi, C. (2019). Nucleus accumbens neurochemistry in
human anxiety: A 7 T 1H-MRS study. European neuropsychopharmacology: the journal of the
European College of Neuropsychopharmacology, 29(3), 365–375. doi:
10.1016/j.euroneuro.2018.12.015
Strobel, A., Gutknecht, L., Rothe, C., Reif, A., Mössner, R., Zeng, Y., Brocke, B., & Lesch, K.
P. (2003). Allelic variation in 5-HT1A receptor expression is associated with anxiety- and
depression-related personality traits. Journal of neural transmission (Vienna, Austria : 1996),
110(12), 1445–1453. doi: 10.1007/s00702-003-0072-0
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., &
Waku, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in
brain. Biochemical and biophysical research communications, 215(1), 89–97. doi:
10.1006/bbrc.1995.2437
Szkudlarek, H. J., Desai, S. J., Renard, J., Pereira, B., Norris, C., Jobson, C., Rajakumar, N.,
Allman, B. L., & Laviolette, S. R. (2019). Δ-9-Tetrahydrocannabinol and Cannabidiol produce
dissociable effects on prefrontal cortical executive function and regulation of affective behaviors.
Neuropsychopharmacology: official publication of the American College of
Neuropsychopharmacology, 44(4), 817–825. doi: 10.1038/s41386-018-0282-7
Takahashi, M., Satou, T., Ohashi, M., Hayashi, S., Sadamoto, K., & Koike, K. (2011).
Interspecies comparison of chemical composition and anxiolytic-like effects of lavender oils
upon inhalation. Natural product communications, 6(11), 1769–1774.
Takao, K., Miyakawa, T. Light/dark Transition Test for Mice. J. Vis. Exp. (1), e104, doi:
10.3791/104 (2006).
Tang, S., & Yasuda, R. (2017). Imaging ERK and PKA Activation in Single Dendritic Spines
during Structural Plasticity. Neuron, 93(6), 1315–1324.e3. doi: 10.1016/j.neuron.2017.02.032
Tepper, J. M., Wilson, C. J., & Koós, T. (2008). Feedforward and feedback inhibition in
neostriatal GABAergic spiny neurons. Brain research reviews, 58(2), 272–281. doi:
10.1016/j.brainresrev.2007.10.008
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007).
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor
143

agonists in vitro. British journal of pharmacology, 150(5), 613–623. doi: 10.1038/sj.bjp.0707133
Torregrossa, M. M., Tang, X. C., & Kalivas, P. W. (2008). The glutamatergic projection from
the prefrontal cortex to the nucleus accumbens core is required for cocaine-induced decreases in
ventral pallidal GABA. Neuroscience letters, 438(2), 142–145. doi:
10.1016/j.neulet.2008.04.016
Ujváry, I., & Hanuš, L. (2016). Human Metabolites of Cannabidiol: A Review on Their
Formation, Biological Activity, and Relevance in Therapy. Cannabis and cannabinoid research,
1(1), 90–101. doi: 10.1089/can.2015.0012
Vadlakonda, L., Dash, A., Pasupuleti, M., Kumar, K. A., & Reddanna, P. (2013). The Paradox of
Akt-mTOR Interactions. Frontiers in Oncology, 3. doi: 10.3389/fonc.2013.00165
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017). Effects of cannabidiol
interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation
in Alzheimers disease. Acta Biochimica Et Biophysica Sinica, 49(10), 853–866. doi:
10.1093/abbs/gmx073
Van Bockstaele, E. J., Chan, J., & Pickel, V. M. (1996). Pre- and postsynaptic sites for serotonin
modulation of GABA-containing neurons in the shell region of the rat nucleus accumbens. The
Journal of comparative neurology, 371(1), 116–128. doi: 10.1002/(SICI)10969861(19960715)371:1<116::AID-CNE7>3.0.CO;2-6
van der Kooij, M. A., Fantin, M., Rejmak, E., Grosse, J., Zanoletti, O., Fournier, C., Ganguly,
K., Kalita, K., Kaczmarek, L., & Sandi, C. (2014). Role for MMP-9 in stress-induced
downregulation of nectin-3 in hippocampal CA1 and associated behavioural alterations. Nature
communications, 5, 4995. doi: 10.1038/ncomms5995
van der Kooij, M. A., Fantin, M., Kraev, I., Korshunova, I., Grosse, J., Zanoletti, O., Guirado, R.,
Garcia-Mompó, C., Nacher, J., Stewart, M. G., Berezin, V., & Sandi, C. (2014). Impaired
hippocampal neuroligin-2 function by chronic stress or synthetic peptide treatment is linked to
social deficits and increased aggression. Neuropsychopharmacology: official publication of the
American College of Neuropsychopharmacology, 39(5), 1148–1158. doi: 0.1038/npp.2013.315
van der Kooij, M. A., Hollis, F., Lozano, L., Zalachoras, I., Abad, S., Zanoletti, O., Grosse, J.,
Guillot de Suduiraut, I., Canto, C., & Sandi, C. (2018). Diazepam actions in the VTA enhance
social dominance and mitochondrial function in the nucleus accumbens by activation of
dopamine D1 receptors. Molecular psychiatry, 23(3), 569–578. doi: 10.1038/mp.2017.135
Vanderwolf, C. (1992). Hippocampal activity, olfaction, and sniffing: an olfactory input to the
dentate gyrus. Brain Research, 593(2), 197–208. doi: 10.1016/0006-8993(92)91308-2
Vose, L. R., & Stanton, P. K. (2017). Synaptic Plasticity, Metaplasticity and Depression. Current
neuropharmacology, 15(1), 71–86. doi: 10.2174/1570159x14666160202121111
Wagner, H., & Ulrich-Merzenich, G. (2009). Synergy research: approaching a new generation of
phytopharmaceuticals. Phytomedicine: international journal of phytotherapy and
144

phytopharmacology, 16(2-3), 97–110. doi: 10.1016/j.phymed.2008.12.018
Wanchoo, S. J., Swann, A. C., & Dafny, N. (2009). Descending glutamatergic pathways of PFC
are involved in acute and chronic action of methylphenidate. Brain research, 1301, 68–79. doi:
10.1016/j.brainres.2009.08.095
Wang, Q., Zhou, Y., Wang, X., & Evers, B. M. (2006). Glycogen synthase kinase-3 is a negative
regulator of extracellular signal-regulated kinase. Oncogene, 25(1), 43–50. doi:
10.1038/sj.onc.1209004
Wieland, H. A., & Lueddens, H. (1994). Four amino acid exchanges convert a diazepaminsensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA
receptor. Journal of Medicinal Chemistry, 37(26), 4576–4580. doi: 10.1021/jm00052a019
Willock, C. D., Berdux, N. C., Franke, T. F. (2016). Modeling the Role of Impaired Akt Kinase
Signaling in the Susceptibility to Stress. The FASEB Journal, 30(1), 1119.20-1119.20. doi:
10.1096/fasebj.30.1_supplement.1119.20
Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews Neuroscience, 5(6),
483-494. doi: 10.1038/nrn1406
Won, J.-K., Yang, H. W., Shin, S.-Y., Lee, J. H., Heo, W. D., & Cho, K.-H. (2012). The
crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy
of MEK inhibitor. Journal of Molecular Cell Biology, 4(3), 153–163. doi: 10.1093/jmcb/mjs021
Xiang, M., Jiang, Y., Hu, Z., Yang, Y., Botchway, B. O., & Fang, M. (2017). Stimulation of
Anxiety-Like Behavior via ERK Pathway by Competitive Serotonin Receptors 2A and 1A in
Post-Traumatic Stress Disordered Mice. Neurosignals, 25(1), 39–53. doi: 10.1159/000481791
Yamaguchi, T., Wang, H., Li, X., Ng, T. H., & Morales, M. (2011). Mesocorticolimbic
Glutamatergic Pathway. Journal of Neuroscience, 31(23), 8476-8490. doi:
10.1523/jneurosci.1598-11.2011
Yang, H., Jong, J. W., Tak, Y., Peck, J., Bateup, H. S., & Lammel, S. (2018). Nucleus
Accumbens Subnuclei Regulate Motivated Behavior via Direct Inhibition and Disinhibition of
VTA Dopamine Subpopulations. Neuron, 97(2). doi :10.1016/j.neuron.2017.12.022
Yung, H. W., Charnock-Jones, D. S., & Burton, G. J. (2011). Regulation of AKT
phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate
specificity in a severity dependent manner. PloS one, 6(3), e17894. doi:
10.1371/journal.pone.0017894
Zafir, A., & Banu, N. (2009). Modulation of in vivo oxidative status by exogenous corticosterone
and restraint stress in rats. Stress, 12(2), 167–177. doi: 10.1080/10253890802234168
Zahm D. S. (2000). An integrative neuroanatomical perspective on some subcortical substrates
of adaptive responding with emphasis on the nucleus accumbens. Neuroscience and
biobehavioral reviews, 24(1), 85–105. doi: 10.1016/s0149-7634(99)00065-2
145

Zahm, D. S., & Heimer, L. (1993). Specificity in the efferent projections of the nucleus
accumbens in the rat: Comparison of the rostral pole projection patterns with those of the core
and shell. The Journal of Comparative Neurology, 327(2), 220-232. doi: 10.1002/cne.903270205
Zain, M. A., Pandy, V., Majeed, A., Wong, W. F., & Mohamed, Z. (2019). Chronic restraint
stress impairs sociability but not social recognition and spatial memoryin C57BL/6J mice.
Experimental animals, 68(1), 113–124. doi: 10.1538/expanim.18-0078
Zamora-Martinez, E. R., & Edwards, S. (2014). Neuronal extracellular signal-regulated kinase
(ERK) activity as marker and mediator of alcohol and opioid dependence. Frontiers in
Integrative Neuroscience, 8. doi: 10.3389/fnint.2014.00024
Zeke, A., Misheva, M., Reményi, A., & Bogoyevitch, M. A. (2016). JNK Signaling: Regulation
and Functions Based on Complex Protein-Protein Partnerships. Microbiology and molecular
biology reviews: MMBR, 80(3), 793–835. doi: 10.1128/MMBR.00043-14
Zhang, N., Zhang, L., Feng, L., & Yao, L. (2016). The anxiolytic effect of essential oil of
Cananga odorata exposure on mice and determination of its major active constituents.
Phytomedicine, 23(14), 1727–1734. doi: 10.1016/j.phymed.2016.10.017
Zhao, H.-B., Jiang, Y.-M., Li, X.-J., Liu, Y.-Y., Bai, X.-H., Li, N., … Zhao, F.-Z. (2017). Xiao
Yao San Improves the Anxiety-Like Behaviors of Rats Induced by Chronic Immobilization
Stress: The Involvement of the JNK Signaling Pathway in the Hippocampus. Biological &
Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin, 40(2), 187–194. doi:
10.1248/bpb.b16-00694

146

Curriculum Vitae
Name:

Richard Leu

Post-secondary
Education and
Degrees:

Western University
London, Ontario, Canada
2018-2020 MSc.
Western University
London, Ontario, Canada
2014-2018 BMSc.

Honours and
Awards:

Natural Sciences and Engineering Research Council of Canada
(NSERC) – Alexander Graham Bell Canada Graduate Scholarship
2019-2020
Dean’s Honor List
2014, 2016, 2017
Western University Four Year Continuing Admission Scholarship
2014, 2015, 2017

Related Work
Experience:

Teaching Assistant
Western University
2018-2020
Clinical Research Assistant
St. Michael’s Hospital
2016, 2018
Clinical Researcher
University Health Network
2014-2015

Publications:

Butt, D.A., Alharty, R., Leu, R. & Cheung, A.M. (2015).
Hypertension, Antihypertensive Drugs and the Risk of Fractures.
Clinic Rev Bone Miner Metab, 13, 160-172. doi: 10.1007/s12018-0159191-z
Hwang, J.K., Leu, R. & Butt, D.A. (2015). Hypertension,
Antihypertensive Drugs, and Bone Mineral Density. Clinic Rev Bone
Miner Metab, 13, 149–159. doi: 10.1007/s12018-015-9193-x
147

